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ABSTRACT
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that binds
pollutants, therapeutic drugs and endogenous ligands. AHR is of particular interest in cancer and
has been shown to play roles in both tumor progression and tumor suppression. As a result, it has
received growing attention as a possible chemotherapeutic target. AHR is expressed in all breast
cancer subtypes and can promote or inhibit breast cancer depending on the ligand it binds. The
Notch signaling pathway is a highly conserved evolutionary pathway that plays extremely vital
roles during development by regulating cell fate and differentiation. Notch signaling has
increasingly attracted attention as a therapeutic target for cancer treatments and ligand-induced
Notch activation has been reported to promote the progression of several cancers including
breast cancer. Jagged 1 (JAG1) is a Notch receptor ligand that is overexpressed in all breast
cancer subtypes, including triple negative breast cancer (TNBC). JAG1 promotes various vital
functions of cancer biology including cancer stem cell maintenance, drug-resistance, epithelialmesenchymal transition (EMT), and metastasis. The regulation of JAG1 by AHR in breast
cancer cells via two AHR ligands, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 2-(1’Hindole-3’-carbonyl)-thiazole-4-carboxylic acid methylester (ITE), were investigated for this
dissertation. TCDD is the prototype AHR ligand, and ITE is a non-toxic endogenous AHR ligand
with anti-cancer activity. Our laboratory has discovered that ligand-activated AHR inhibits the
expression and activity of the JAG1-Notch pathway in human breast cancer cells, which in turn
decreases breast cancer cell invasion. By conducting ribonucleic acid (RNA)-sequencing and
analyzing the data via Ingenuity Pathway Analysis (IPA), we identified a significant association
between TCDD-regulated genes (TRGs) and cell movement. We found that silencing AHR
expression by short-interfering RNA (siRNA) or antagonizing its activity with the AHR

xvii

antagonist CH-223191 in breast cancer cells restored JAG1 expression, which established that
ligand-activated AHR is an inhibitor of the JAG1-Notch pathway in breast cancer cells. AHR
was also found to be necessary for suppressing the expression of the EMT regulator Snail, a
crucial protein required for promoting cancer metastasis. Finally, we have shown that other nontoxic AHR agonists such as tranilast also decreases JAG1 expression in TNBC cells.
Collectively, my work is the first to show that ITE is a tumor-suppressing AHR ligand in breast
cancer cells in part because it reduces JAG1 expression. The findings presented in this
dissertation suggest targeting the JAG1-Notch pathway with non-toxic AHR ligands could be a
new mechanism to suppress the invasive activity of TNBC, which is a breast cancer subtype for
which there are no targeting therapies.
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CHAPTER 1
OVERVIEW OF CURRENT KNOWLEDGE IN BREAST CANCER
1.1. Survival Rates and Subtypes
There are more than 3.5 million women with breast cancer in the United States
(American Cancer Society, 2016). Breast cancer is a heterogeneous disease that has been
clinically organized into four subtypes (Figure 1) based on certain molecular markers: 1)
Luminal A (Estrogen Receptor (ER)+/Progesterone Receptor (PR)+/Human Epidermal Growth
Factor Receptor 2 (HER2)-) makes up ~40-50% of breast cancers, 2) Luminal B
(ER+/PR+/HER2+) makes up ~15-20% of breast cancers, 3) HER2-enriched (ER-/PR-/HER2+)
makes up ~8-10% of breast cancers and 4) triple negative breast cancer (TNBC) (ER-/PR/HER2-) makes up ~15-20% of breast cancers (Keegan, DeRouen, Press, Kurian, & Clarke,
2012). Women with Luminal A tumors have the best 10-year survival rates (70%), compared
with women with Luminal B (54%), HER2-enriched (48%), and TNBC (53%) tumors
(Kennecke, et al., 2010). Women with Luminal A and B, and HER2-enriched subtypes can be
treated with anti-estrogen or HER2 targeting therapy, respectively. However, TNBC lacks
molecular targets for specific cancer targeting. Currently, women with TNBC are treated with
chemotherapy and endure the associated toxicities of these non-specific drugs.
Recent studies have identified a small subpopulation of cells within breast tumors that
exhibit stem-cell like characteristics that confer these cells with heightened tumorigenic activity,
drug resistance (Gottesman, Fojo, & Bates, 2002; Ma & Allan, 2011), tumor recurrence (Yi,
Kabha, Papadopoulos, & Wagner, 2014; Bosukonda & Carlson, 2017) and metastatic activity
(Xie, et al., 2012; Uchino, et al., 2010). This small subpopulation of cells has been termed cancer
stem cells (CSCs) and they are driven by signaling pathways that are triggered by
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Figure 1. Subtypes of Breast Cancer Tumors
Each subtype has a different prognosis and treatment response. For ER+/PR+ group, because ER
is a therapeutic target, the Luminal A and Luminal B subtypes are amenable to hormone therapy.
Similarly, the HER2 groups are potential candidates for trastuzumab therapy. For the ER-/PRgroup, in the current absence of expression of a recognized therapeutic target, basal tumors are
difficult to treat, more biologically aggressive and often have a poor prognosis. This is because
the basal phenotype is characterized by the lack of expression of ER, PR and HER2 and is
sometimes referred to as triple negative breast cancer. TNBC = Triple Negative Breast Cancer,
ER = Estrogen Receptor, PR = Progesterone Receptor, HER2 = Human Epidermal Growth
Factor Receptor 2.
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extracellular signals, mutations, and epigenetic control (Hartwig, et al., 2014). In this section, the
subtypes of breast cancer, breast cancer therapies and breast cancer stem cells (BCSCs) will be
discussed.
1.2. Breast Cancer Subtype Characteristics and Current Treatment Strategies
1.2.1. Luminal A and B Subtype
The Luminal A and B subtypes are highly associated with proliferation/cell cycle-related
pathways and luminal/hormone-regulated cell processes (Prat, et al., 2015). The ER is expressed
in the Luminal A and Luminal B breast cancer subtypes. The five and ten-year survival rates for
Luminal B breast cancer are worse than for Luminal A breast cancer, irrespective of therapy.
Compared with Luminal A breast cancer, Luminal B breast cancer exhibits higher expression of
proliferation/cell cycle-related genes and proteins as well as lower expression of several genes
that link with luminal breast cells, including the PR (Prat, et al., 2013). The analysis of mutation
rates has demonstrated that Luminal A breast cancer exhibits fewer mutations than Luminal B
breast cancer. The Luminal A subtype has a lower percentage of gene amplification events such
as lower rates of cyclin D1 (CCND1) gene amplification, fewer tumor protein 53 (TP53)
mutations (12% vs. 29%), and a higher rate of phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha (PIK3CA) (45% vs. 29%) and mitogen-activated protein kinase kinase
kinase 1 (MAP3K1) mutations (13% versus 5%) compared to Luminal B tumors (Cancer
Genome Atlas Network, 2012). The differences in these particular molecular markers (i.e., PR,
CCND1, TP53, PIK3CA and MAP3K1) are used to distinguish Luminal A breast cancer from
Luminal B breast cancer.
Luminal A and Luminal B breast cancers are responsive to chemotherapy in a
neoadjuvant setting in which treatment is given as a first step to shrink a tumor before surgery.
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Although surgery is the frontline therapy, Luminal A and Luminal B breast cancers are also
treated with chemotherapy, radiation therapy, and hormone therapy. A clinical study was
conducted on 208 women with Luminal A or Luminal B breast cancer that were treated with
anthracycline/taxane-based chemotherapy. According to the pathologic complete response (pCR)
data, which is the absence of residual invasive disease in the breast and in the auxiliary lymph
nodes at the completion of the neoadjuvant treatment, the pCR rates in patients with Luminal A
and Luminal B subtypes were 3% and 16%, respectively (Prat, Parker, & Fan, 2012). The results
from a study comparing Luminal A to Luminal B breast cancer identified that women with lowproliferating Luminal A breast tumors were more responsive to paclitaxel compared with women
that had high-proliferating Luminal B tumors (Martín, et al., 2013).
The use of drugs that specifically target estrogen signaling in Luminal A or Luminal B
breast cancer has been in clinical practice for nearly fifty years (Lumachi, Santeufemia, & Basso,
2015). The estrogen targeting drugs target several different aspects of estrogen signaling in
breast cancer (Figure 2). For instance, aromatase converts androgen into estrogen
(Brueggemeier, Hackett, & Diaz-Cruz, 2005). The aromatase inhibitors (AIs), anastrozel and
letrozol, bind to aromatase and block its activity, which reduces estrogen production. AIs are
approved for the treatment of ER positive breast cancer in postmenopausal, but not
premenopausal, women. Aromatase inhibition is ineffective in premenopausal women with
functionally active ovaries, because reducing estrogen levels in these women with AIs induces a
compensatory increase in the secretion of luteinizing hormone (LH) and follicle stimulating
hormone (FSH), which in turn increases aromatase activity leading to increases in estrogen levels
(Ma, Reinert, Chmielewska, & Ellis, 2015). The selective estrogen receptor modulators (SERMs)
include tamoxifen, raloxifen and toremifine. The SERMs bind to the ER and have tissue-specific
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Figure 2. Current Strategies for Endocrine Therapies in Breast Cancer
Estrogen activates nuclear ER (genomic pathway) and ER in or near the membrane (nongenomic pathway). Membrane associated ER binds to growth factor signaling components such
as PI3K. Estrogen then activates growth factor signaling, activating key molecules such as Akt or
RAS, and downstream molecules such as mTOR and MAPK, which promote cell proliferation
and survival. (A) AIs assist in decreasing the synthesis of estrogen as an approach for reducing
growth-stimulatory effects. (B) SERDs function as high affinity competitive antagonists and
induce a conformational change that is incompatible with co-regulator interactions and target the
receptor for proteasomal degradation. (C) Humanized monoclonal antibodies target different
growth factor receptors that promote cancer growth by blocking their activation. (D) Smallmolecule TKIs bind the intracellular domains of growth factor receptors to block activation of
their downstream signaling pathways. (E) SERMs act as a competitive receptor inhibitor in the
breast tissue by selectively blocking ER signaling and inhibiting the proliferation of tumor cells.
ER = Estrogen Receptor, EGFR = Epidermal Growth Factor Receptor, HER2 = Human
Epidermal Growth Factor Receptor 2, MAPK = Mitogen-activated Protein Kinase, mTOR =
Mechanistic Target of Rapamycin, PI3K = Phosphoinositide 3-kinase, SERDs = Selective
Estrogen Receptor Down Regulators, TKIs = Tyrosine Kinase Inhibitors, SERMs = Selective
Estrogen Receptor Modulators, RAS = Rat Sarcoma Viral Proto-Oncogene, Akt = Serinethreonine Protein Kinase.
5

effects. For instance, tamoxifen acts as a partial nonsteroidal agonist in some tissues such as the
liver, uterus, and bone. However, tamoxifen is a competitive ER inhibitor in breast and brain.
Hence, the SERMs are categorized as being “modulators” rather than “down-regulators” of ER
or estrogen signaling (Powles, Ashley, Tidy, Smith, & Dowsett, 2007).
Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes into active
metabolites endoxifen and 4-hydroxytamoxifen (4-HT), which then bind to ER and suppress the
proliferation of ER-positive breast cancer cells (Lumachi, Brunello, Maruzzo, Basso, & Basso,
2013; Wu, X. et al., 2009). The SERMs, such as tamoxifen, are extensively used to treat ER
expressing breast cancer in both pre- and post-menopausal women (Lumachi, et al., 2013). The
selective estrogen receptor down-regulators (SERDs) are different from SERMs, because they
function as ER antagonists in all tissues (Yeh, et al., 2013; Lumachi, et al., 2011). Fulvestrant is
the only Food and Drug Administration (FDA) approved SERD to treat breast cancer and
competes with estrogen for the ligand-binding pocket in the ER, which induces proteolytic
downregulation of the ER in breast cancer cells. The affinity of fulvestrant for the ER is 100
times stronger than the affinity of tamoxifen (Wardell, Marks, & McDonnell, 2011). Fulvestrant
is efficacious in treating tamoxifen resistant breast cancer, and it is combined with an AI when
treating metastatic ER-positive breast cancer (Ikeda, et al., 2011; Jiang, et al., 2014).
1.2.2. HER2-enriched Subtype
The breast cancer subtype with HER2 gene amplification is termed HER2-enriched
breast cancer (Prat, et al., 2015). Because HER2-enriched breast cancer has aggressive biological
behavior and a poor clinical outcome, its overall survival rate is worse than Luminal A and
Luminal B breast cancer subtypes (Burstein, 2005). The HER2 gene encodes a transmembrane
protein that plays a vital role in the regulation of cell growth, survival, and differentiation

6

(Wahler & Suh, 2015; Ménard, Pupa, Campiglio, & Tagliabue, 2003). HER2-enriched tumors
have a higher frequency of mutations across the genome compared with Luminal A and Luminal
B breast cancer (Neve, Lane, & Hynes, 2001); 72% and 39% of HER2 breast cancers exhibit
mutations in TP53 and PIK3CA, respectively (Prat, et al., 2015). The overexpression of HER2 in
breast cancer promotes metastatic properties of tumor cells and increases the chances for drug
resistance in response to chemotherapy and endocrine therapy (Prat & Baselga, 2008). There are
four anti-HER2 drug categories that are used to treat HER2 positive breast cancer; they include
1) monoclonal antibodies (mAbs), 2) small molecule tyrosine kinase inhibitors (TKIs), 3)
antibody-drug conjugates (ADCs), and 4) new emerging therapies such as heat shock protein 90
(HSP90) inhibitors.
The epidermal growth factor receptor (EGFR) family of proteins is a group of
transmembrane receptor tyrosine kinases that includes HER2, human epidermal growth factor
receptor 3 (HER3), and human epidermal growth factor receptor 4 (HER4) (Lv, et al., 2016). The
ligands that bind these receptors include epidermal growth factor (EGF), heregulin, and tumor
growth factor a (TGFa). Upon activation, HER2 will form a heterodimer with another member
of the EGFR family of receptors and induce phosphorylation-mediated signaling pathways that
promote breast cancer progression (Tzahar, et al., 1996) (Figure 2). The HER2 monoclonal
antibodies trastuzumab and pertuzumab inhibit HER2 signaling by preventing the
homodimerization or heterodimerization of HER2 receptor complexes, which inhibits HER2mediated signaling in breast cancer cells (Hudis, 2007). Trastuzumab has also been shown to
induce endocytosis of HER2, leading to its degradation and increases in cellular apoptosis
(Hudis, 2007). Even though trastuzumab has extended survival in patients with breast tumors
that overexpress HER2, resistance occurs through alterations of HER2-regulated downstream
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signaling pathways that are induced by other tyrosine kinase receptors and or shedding of HER2
receptors (Wong & Lee, 2012; Rexer & Arteaga, 2012) (Figure 2).
Small molecule TKIs were developed to overcome HER2 resistance (Figure 2). TKIs
bind to the intracellular tyrosine kinase domain of HER2 to prevent the phosphorylation of
tyrosine kinase, which inhibits the activation of signaling pathways that are downstream of
HER2 signaling (Lv, et al., 2016). One example is lapatinib, the second FDA approved antiHER2 targeting agent. Lapatinib is an orally active, dual small molecular inhibitor of HER2 and
human epidermal growth factor receptor 1 (HER1) that induces prolonged inhibition of tyrosine
phosphorylation in tumor cells (Johnston & Leary, 2006; Nahta, Yu, Hung, Hortobagyi, &
Esteva, 2006). A previous study found that lapatinib had a high efficacy in halting the
progression of HER2 expressing breast cancer when used as a first line therapy, where 24% of
patients demonstrated an increase in overall response and progression-free survival rate (Gomez,
et al., 2008). The mechanism of action for lapatinib has not been determined; however, there are
several hypotheses to explain how the drug suppresses HER1 and HER2 (Tai, Mahato, & Cheng,
2010). The first hypothesis is that lapatinib specifically targets the tyrosine kinase domain of
HER2 and HER1 to inhibit downstream signaling (Xia, et al., 2002). The second hypothesis
proposes that lapatinib perturbs the activity of signaling proteins that sit downstream of HER2
(Xia, et al., 2002). The third hypothesis is that lapatinib induces breast cancer cell apoptosis by
inhibiting insulin-like growth factor-1 receptor (IGF-1R). Lapatinib, in combination with HER2
monoclonal antibodies has been shown to induce a synergistic effect in the treatment of HER2enriched breast cancer (Konecny, et al., 2006; Xia, et al., 2005). The observed synergistic effect
of combining lapatinib with a HER2 blocking antibody has been attributed to differences in the
mechanism by which lapatinib and HER2 blocking antibodies target HER2 (Xia, et al., 2005).
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ADCs are a newer class of HER2-targeting agents, where the monoclonal antibody is
conjugated with a cytotoxic agent through a thioester linker. Ado-trastuzumab emtansine (TDM1) is an ADC that was FDA approved in 2013 (Amiri-Kordestani, et al., 2014). The
mechanism of action has been postulated to initially start with trastuzumab binding specifically
to the extracellular portion of HER2. Binding between trastuzumab and HER2 is postulated to
induce a form of passive endocytosis of HER2-trastuzumab complexes. These HER2-drug
complexes enter the cytoplasm, followed by their degradation by the lysosome, which then
releases the emtansine (DM1) component from the complex via cleavage of the thioester linker
and allows DM1 to exert its cytotoxicity by inhibiting microtubule formation, inducing cell cycle
arrest and promoting apoptosis (Martínez, et al., 2016; Lewis Phillips, et al., 2008).
Other emerging HER2 targeting agents include HSP90 inhibitors. The stability and
function of several cellular proteins is dependent on the molecular chaperon function of HSP90
(Chen, Singh, & Perdew, 1997). Consequently, HSP90 inhibitors will induce the degradation of
various cytosolic transcription factors but is postulated to be very effective at inhibiting breast
cancer progression because breast cancer cells exhibit high levels of HSP90 (Solit, et al., 2002;
Pick, et al., 2007). HER2 stability is dependent on HSP90. Therefore, the inhibition of HSP90
reduces the stability of HER2, which in turn reduces the survival of HER2 positive breast cancer
cells (Huszno & Nowara, 2016; Munagala, Agil, & Gupta, 2011). The first generation HSP90
inhibitor tanespinmycin, has reported anti-tumor activity in HER2-enriched breast cancer and is
currently undergoing clinical trials in combination with trastuzumab (Tsang & Finn, 2012).
1.2.3. Triple Negative Subtype
TNBC is an aggressive breast cancer subtype that lacks the expression of the ER, PR, and
HER2 receptors. Because there are no specific molecular targets for the treatment of TNBC,
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women with this disease have high rates of metastatic breast cancer and breast cancer recurrence
(Zhang, Liu, Wang, & Zhang, 2016; Ismail-Khan & Bui, 2010). The only option for women with
TNBC is systemic chemotherapy that comes with inherent toxicities (Figure 3). TNBC is
correlated with a high risk for relapse and poor overall survival compared to the other breast
cancer subtypes. The high rate of TNBC relapse is postulated to be attributed to the lack of drugs
that are specific for TNBC (Zhang, Liu, Wang, & Zhang, 2016). Clinical studies, however, have
demonstrated that TNBC is initially responsive to chemotherapy. Indeed, a meta-analysis of five
adjuvant trials was conducted to compare anthracycline-containing regimens which include:
cyclophosphamide, methotrexate, and fluorouracil (CMF). The results of the study showed that
anthracycline-containing regimens were superior to CMF for the treatment of TNBC (Di Leo, et
al., 2010). Therefore, anthracycline/taxane-based adjuvant regimens are currently the most
rational therapy for women with TNBC. Although TNBC is initially responsive to
chemotherapy, prolonged therapy with these drugs usually leads to drug-resistance. Despite
initial responses to anthracycline/taxane-based regimens, women with TNBC often relapse and
tumors return more drug resistant and aggressive. Therefore, the identification of TNBC
molecular targets will be important for improving the survival of women with this disease.
To find a solution for TNBC relapse and drug-resistance, Burstein et al. identified 4
stable characterized subgroups of TNBC to help identify any potential molecular targets and
novel treatment strategies (Table 1): 1) Luminal/Androgen Receptor (LAR), 2) Mesenchymal
(MES), 3) Basal-like Immune Suppressed (BLIS) and 4) Basal-like Immune Activated (BLIA)
(Burstein, et al., 2015). The identification of novel molecular targets is critical for improving
patient survival with TNBC and must be fundamentally different than what is currently being
used (Zhang, Liu, Wang, & Zhang, 2016). Novel agents for TNBC that are currently being
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Figure 3. Current Systemic Chemotherapy Agents that are Used in the Treatment of Triple
Negative Breast Cancer
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TNBC Subtype
Luminal/Androgen
Subtype
(LAR)

Prognostic Status
•
•
•

Mesenchymal Subtype
(MES)

•
•
•

Basal-like Immune
Suppressed
(BLIS)

•
•
•

Basal-like Immune
Activated
(BLIA)

•
•
•

Gene Expression Unique to TNBC Subtype

Gene expression exhibits ER, AR,
and HER4 signaling
Demonstrates expression of ER and
other ER-regulated genes
May respond to anti-estrogen and androgen therapies in conjunction
with chemotherapies

•

ER: Estrogen Receptor

•

CAXII: Carbonic Anhydrase 12

•

AR: Androgen Receptor

•

RET: Ret Proto-oncogene

Previously described as “stem-like”
or “claudin-low”
Expresses genes normally exclusive
to osteocytes and adipocytes
May respond to PPAR!-inhibitors
in conjunction with chemotherapies

•

ADH1β: Alcohol Dehydrogenase 1β

•

GHR: Growth Hormone Receptor

•

PPAR!: Peroxisome Proliferator-activated Receptor !

•

IL1R1: Interleukin 1 Receptor, Type I

Exhibits downregulation of
immune- and cytokine-regulation
pathways
Exhibits the worst clinical outcome
of TNBC subtypes
May respond to immunecheckpoint inhibitors in
conjunction with chemotherapies

•

VTCN1: V-set Domain Containing T-cell Activation
Inhibitor I

•

TUBB2B: Tubulin β, Class IIB

•

KIT: KIT Proto-oncogene Receptor Tyrosine Kinase

•

FGFR2: Fibroblast Growth Factor Receptor 2

Displays up-regulation of genes
controlling immune function
Exhibits the best clinical outcome
of TNBC subtypes
May respond to cytokine- or
immune-checkpoint inhibitors in
conjunction with chemotherapy

•

CXCL10: C-X-C Motif Chemokine Ligand 10

•

CTLA4: Cytotoxic T-lymphocyte-associated Protein 4

•

TOP2α: Topoisomerase 2α

•

LCK: Lymphocyte-specific Protein Tyrosine Kinase

Table 1. The Novel Subtypes of Triple Negative Breast Cancer
The novel subtypes of TNBC along with prognostic factors and some selected genes with
significant overexpression unique to each subtype that can serve as potential drug targets. 1)
LAR, 2) MES, 3) BLIS, and 4) BLIA. Using independent TNBC datasets, Burstein et al.
determined that BLIS and BLIA tumors have the worst and best prognoses, respectively
(independently of other known prognostic factors), compared to the other subtypes. Collectively,
RNA and DNA genomic studies identified stable, reproducible TNBC subtypes characterized by
specific RNA and DNA markers, which can help identify potential targets for more effective
treatments of TNBC cells. TNBC subtype classification is also based on molecules they do
express as opposed to molecules they do not express. All molecules shown in this table have the
potential to be targeted for treatment or are already undergoing clinical trials.
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studied include poly-(adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitors,
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors and androgen receptor (AR)
inhibitors (Burstein, et al., 2015).
PARPs are a large family of enzymes that are important for the repair of single-stranded
breaks in deoxyribonucleic acid (DNA) through the base excision repair pathway and were
identified to be a potential target for the treatment of the MES subtype in TNBC (Burstein, et al.,
2015; Hoeijmakers, 2001). When certain chemotherapies cause DNA damage, PARP repairs the
damage and this in turn promotes drug resistance (Figure 4). Because DNA contains various
lesions such as single-strand breaks, double-stranded breaks, and homologous recombination,
inhibiting PARP leads to the accumulation of double stranded breaks; resulting in genomic
instability and eventually cell death (Amé, Spenlehauer, & de Murcia, 2004). Therefore, PARP
inhibitors are postulated to increase the sensitivity and responsiveness of TNBC to
chemotherapy. Currently, there are several PARP inhibitors in clinical development. The
combination treatment of PARP inhibitors with chemotherapy in TNBC has been investigated in
phase I-III clinical trials, and this combination showed a favorable clinical response. One
example is a trial that showed the combination of carboplatin and PARP inhibitor, veliparib,
added to weekly paclitaxel and followed by doxorubicin and cyclophosphamide led to a doubling
of the complete response rate in patients with TNBC from 26% to 52% (Rugo, Olopade,
DeMichele, & Yau, 2016). However, long-term treatment with PARP inhibitors resulted in drug
resistance by increasing expression of P-glycoprotein (P-gp) efflux pumps (Rottenberg, et al.,
2008).
Prior reports have established that breast cancer cells are able to initiate an immune
response that increases the population of tumor infiltrating lymphocytes (TILs) into breast
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DNA
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NAD+

Cell Survival
Base-Excision Repair

Figure 4. PARP Mechanism and Inhibition
The PARPs have a particularly critical role in the base-excision repair pathway, binding to
single-strand breaks in DNA, modifying proteins in the vicinity, and ultimately leading to the
recruitment of DNA repair proteins to the sites of damage. PARP inhibitors block the activity of
the PARP enzymes by mimicking the nicotinamide moiety of NAD+ and binding to the PARP
catalytic site, which either directly blocks PARP enzymatic activity or causes PARP to
accumulate on DNA and promotes apoptosis. NAD+ = Nicotinamide Adenine Dinucleotide,
PARP = Poly-(ADP-ribose) Polymerase.
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tumors (Disis & Stanton, 2015). Increasing the number of TILs in breast tumors was correlated
with a favorable treatment outcome depending on the intensity of the tumor immune response
(Demaria, et al., 2001). CTLA4 is an immune checkpoint ligand found on the surface of T-cells
that modulates the generation and maintenance of immune responses (Gross & Jure-Kunkel,
2013). CTLA4 is critical for inhibiting T-cell immune response by regulating cell cycle
progression and maintains a favorable tumor microenvironment (Greenwald, et al., 2002). The
monoclonal antibody tremelimumab, which inhibits the CTLA4 pathway, was evaluated in
hormone-positive breast cancer and has shown to abrogate immunosuppressive activity (CiminoMathews, Foote, & Emens, 2015). Targeting CTLA4 effectively promotes T-cell activity,
thereby potentiating the antitumor immune response (Chawla, Philips, Alatrash, & Mittendorf,
2014). Therefore, immunomodulatory drugs can lay the foundation for immune-based therapies
in TNBC, especially for the BLIA subtype, which was identified to express higher levels of
CTLA4 compared to the other TNBC subtypes (Burstein, 2005).
It has also been shown that the LAR subtype of TNBC represented a unique type of
breast cancer with adverse clinical outcome. As a result, AR inhibition was regarded as a
potential endocrine therapy for patients with this particular subtype of TNBC (Choi, Kang, Lee,
& Bae, 2015). The LAR subtype characterized by AR expression was shown to be sensitive to
the AR antagonist bicalutamide alone or in combination with PI3K inhibitors (Lehmann, et al.,
2011; Burstein, 2005; Crumbaker, Khoja, & Joshua, 2017). These new findings suggest that
targeting the AR in TNBC could be beneficial.
1.2.4. Breast Cancer Stem Cells
The discovery of BCSCs came from a flow cytometry experiment that identified a small
subpopulation (<1% of the tumor population) of cancer cells which expressed higher cluster of
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differentiation 44 (CD44), lower cluster of differentiation 24 (CD24) and increased aldehyde
dehydrogenase 1 (ALDH1) phenotype (i.e. CD44+CD24low/-ALDH1+) (Pires, Amorim, Souza,
Rodrigues, & Mencalha, 2016). This CD44+CD24low/-ALDH1+ population of cells was highly
tumorigenic, because transplanting a few hundred of them into mice was sufficient to regenerate
a breast tumor (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003). Extensive
evidence shows that BCSCs are associated with tumor initiation, cancer progression, metastasis,
and resistance to chemotherapy. Furthermore, they are also associated with tumor relapse and
treatment failure (Al-Ejeh, et al., 2011). Therefore, a better understanding of how BCSCs
contribute to breast cancer progression may lead to better cancer therapies (Figure 5). Analogous
to normal stem cells, BCSCs are reliant on embryonic pathways to maintain their capacity for
pluripotency and self-renewal. The pathways that control these stem cell features include the
wingless-type MMTV integration site family (Wnt)/b-catenin, Hedgehog (Hh), and Notch (Pires,
Amorim, Souza, Rodrigues, & Mencalha, 2016). These signaling pathways not only maintain
cancer stem cell features, they also allow tumor cells to thrive in hypoxic environments (Figure
6). The roles of Wnt, Hedgehog and Notch pathways in breast cancer will be reviewed in the
following sections.
The Wnt/b-catenin signaling pathway plays a vital role in developmental processes that
determine cell patterning and cell fate determination (Howe & Brown, 2004). Wnt-protein
ligands are palmitoylated by porcupine, released from cells, and exert their cellular effects by
binding to cell surface Frizzled receptors that are complexed with low-density lipoprotein 5
(LRP5) and low-density lipoprotein 6 (LRP6) (Figure 6). The Wnt-Frizzled-LRP5-LRP6
receptor complex attracts axin and dishevelled (DVL) to the cell membrane, which triggers the
inhibition of glycogen synthase kinase-3b (GSK-3b). Inhibition of GSK-3b activity in response
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CSC-Targeted
Cancer Therapy

Cancer Stem Cells
Are Targeted in Tumor

Tumor Undergoes Traditional
Cancer Therapy Without
CSC Population

Tumor Loses Ability
To Regenerate Cells And
Greatly Decreases Chances
Of Tumor Reoccurrence

Cancer Stem Cells
Survive Treatment

Cancer Stem Cells
Replicate

Tumor Reoccurs
With Drug Resistance

Breast Cancer
Tumor

Traditional
Cancer Therapy
= Cancer Stem Cells
= Normal Tumor Cells
= Drug-Resistant Tumor Cells

Figure 5. The Strategy Behind Targeting the Breast Cancer Stem Cell Population in Breast
Tumors
Targeting the stem cell niche to eradicate BCSCs represents a new area of therapeutic
development. Understanding the biology of BCSCs and the mechanisms that support them in
breast cancer could help improve tumor treatment and prevent recurrence and metastasis. The
theory behind targeting CSCs in breast tumors is to prevent tumor recurrence and drug
resistance. BCSCs = Breast Cancer Stem Cells, CSCs = Cancer Stem Cells.
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Figure 6. The Activation of Developmental Signaling Pathways in Cancer Stem Cells
Notch, Wnt, and Hedgehog signaling pathways regulate normal and stem cell fate. (A) Notch
signaling. Upon binding of Notch ligands to the Notch receptor, the NICD translocates to the
nucleus where it binds with the CSL co-activator complex and MAML to induce transcription of
its target genes for stem cell dedifferentiation. (B) Wnt signaling. Canonical Wnt signaling
occurs through the stabilization and nuclear accumulation of β-catenin. Wnt ligands bind to the
Frizzled receptor and the LRP co-receptor, activates DVL and recruits the axin degradation
complex to the LRP receptor away from β-catenin, preventing its degradation. β-catenin is then
free to translocate to the nucleus and associate with the transcription factors TCF/LEF and CBP
to initiate transcription of target genes for mammary gland development and stem cell renewal.
(C) Hedgehog signaling. Hh is a secreted ligand that binds to its receptor, Patched. When
Patched is activated by Hh binding, inhibition of the SMO receptor is relieved, which allows
SMO to localize to the plasma membrane. SMO is then able to inhibit the phosphorylation and
cleavage of Gli which prevents the formation of Gli-R and instead promotes the formation of
Gli-A, which translocates into the nucleus and initiates transcription of target genes for stem cell
regulation. (D) In hypoxia, HIF-1α is not phosphorylated by PHD proteins and is stabilized in the
cytoplasm by NICD, where it is then translocated into the nucleus and induces gene expression
for maintaining undifferentiated cancer stem cells. JAG1 = Jagged1, DLL1 = Delta-like ligand 1,
ADAM = A-disintegrin and metalloproteinase, NICD = Notch Intracellular Domain, HIF-1α =
Hypoxia Inducible Factor 1α, RBP-Jk = Recombination Signal Binding Protein for
Immunoglobulin Kappa J Region, CSL = RBP-Jk/Suppressor of Hairless/ Lag-1, MAML =
Mastermind-like, LRP = Low-Density Lipoprotein Receptor, DVL = Dishevelled, GSK-3b =
Glycogen Synthase Kinase-3b, APC = Adenomatous polyposis coli, CK1α = Casein Kinase 1α,
TCF/LEF = T-cell Factor/Lymphoid Enhancing Factor, CBP = cAMP Binding Protein, PKA =
Protein Kinase A, Hh = Hedgehog, SMO = Smoothened, Gli = glioma associated oncogene, GliR = Restricted Gli, Gli-A = Activated Gli, PHD = Prolyl Hydroxylase Domain, CCNDI = Cyclin
D1, VEGF = Vascular Endothelial Growth Factor, CCNE = Cyclin E, HES1 = Hairy Enhancer
of Split 1. Dashed Arrows = Post-activation.
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to a Wnt ligand promotes the accumulation of β-catenin. The increase in β-catenin promotes its
translocation into the nucleus at which point it functions as a transcriptional activator by binding
with cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) (also
known as CREB binding protein (CBP)) and T-cell factor/lymphoid enhancing factor (TCF/LEF)
transcription factors. The b-catenin-CBP-TCF/LEF complex then increases the transcription of
oncogenes such as v-myc avain myelocytomatosis viral oncogene homolog (c-myc), CCND1,
and Wnt (Howe & Brown, 2004; Macdonald, Semenov, & He, 2007). The Wnt signaling
pathway is constitutively activated in BCSCs by an autocrine mechanism and is associated with
the maintenance of stem cell properties (Giles, van Es, & Clevers, 2003; Jang, et al., 2015). The
importance of Wnt signaling in CSCs was determined in a study where inhibition of Wnt
signaling altered the stem cell phenotype (i.e. CD44+/CD24-/ALDH1-), which resulted in the
reduction of in vitro and in vivo tumor formation and cell migration (Jang, et al., 2015; Zhao, et
al., 2016; Kim do, et al., 2016).
The Hedgehog (Hh) family is comprised of three members: Sonic hedgehog (Shh), Indian
hedgehog (Ihh) and Desert hedgehog (Dhh). The Hedgehog signaling pathway controls
embryonic development by regulating cell proliferation, cell fate determination and cell
patterning (Chen, Wilson, & Chuang, 2007). The Hedgehog signaling pathway has also been
identified to play an important role in maintaining the stem cell population in adult animals
(Justilien & Fields, 2015). There are three Hh zinc finger protein transcription factors that are
sequestered in the inactive state in the cytoplasm with kinesin family member 7 (KIF7) and
suppressor of fused (SUFU): glioma associated oncogene-1 (Gli-1), glioma associated oncogene2 (Gli-2), and glioma associated oncogene-3 (Gli-3). Smoothened (SMO) is located in the
cytosol and is responsible for transduction of Hh signaling inside the cell by regulating the
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activation of the Gli transcription factors (Chen, Wilson, & Chuang, 2007). In the inactive Hh
pathway, patched1 (PTCH1) blocks the activation and migration of SMO. In cancer cells, Hh is
released into the tumor microenvironment and enhances stromal cell activity. Once Hh is
secreted, it binds to PTCH1 on adjacent cells and allows for SMO to activate signal transduction
at the cell membrane (Figure 6). Activated SMO undergoes phosphorylation by casein kinase 1a
(CK1a) and protein kinase A (PKA), then removes the Gli transcription factors away from the
KIF7-SUFU repressor complex (Chen, Wilson, & Chuang, 2007) (Figure 6). The Gli
transcription factors are released and travel to the nucleus to activate transcription of Hh target
genes (Lum & Beachy, 2004). There are several pieces of evidence showing that Hh signaling is
important for breast cancer biology. One example being that overexpression of Hh or PTCH1
mutations results in constitutively active SMO, which causes increased Gli activation (Tao, Mao,
Zhang, & Li, 2011). Furthermore, these alterations have been demonstrated in the more
aggressive breast cancer subtypes, such as TNBC (Tao, Mao, Zhang, & Li, 2011) and is essential
for promoting growth and self-renewal, not just in BCSCs but also in stem cells from other
tumors (Tanaka, et al., 2009; Liu & Micha, 2010; Wicha, Clarke, & Simeone, 2007; Su, et al.,
2012).
The Notch signaling pathway controls self-renewal and asymmetric division of normal
stem cells; however, its reactivation in epithelial cells contributes to tumorigenesis in the early
stages of cancer (D’Angelo, et al., 2015). Notch signaling is predominately activated via cell-tocell interactions through the binding of one of the four Notch receptors (Notch1, Notch2,
Notch3, and Notch4) expressed on the cell surface with one of five Notch ligands (Jagged1
(JAG1), Jagged2 (JAG2), Delta-like ligand 1(DLL1), Delta-like ligand 3 (DLL3), and Delta-like
ligand 4 (DLL4)) that are expressed on the cell surface of the signal receiving cell (Bray, 2006)
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(Figure 7). The Notch ligand and Notch receptor interaction complex promotes the release of the
Notch intracellular domain (NICD) via cleavage by A-disintegrin and metalloproteinase
(ADAM) proteases and by the enzymatic complex g-secretase (Figure 7). Once cleaved, NICD is
released into the cytoplasm and translocates into the nucleus where it binds with co-activators
Mastermind-like (MAML) and p300 to induce transcription of Notch target genes (Bray, 2006;
Ilagan & Kopan, 2007). It was reported that Notch1 expression in breast epithelial cells is
enriched in BCSCs that express the CD44+CD24low/-ALDH1+ phenotype (Clarke, Anderson,
Howell, & Potten, 2003) and was confirmed by D’Angelo et al. The work by D’Angelo et al.
demonstrated that breast cancer cells that exhibit high levels of Notch signaling are capable of
initiating the formation of mammospheres in cell culture, which is a hallmark feature of BCSCs
(Sansone, et al., 2007a; D’Angelo, et al., 2015). Collectively, these results indicate that BCSCs
exhibit high levels of Notch signaling that promote their stem cell like activity.
Hypoxia is a hallmark of solid tumors, where the blood supply is not sufficient to meet
the needs of the growing tumor (Déry, Michaud, & Richard, 2005). It is known that hypoxic
tumors are indictors of poor prognosis and promotes treatment resistance to both radiation and
chemotherapy (Qiang, et al., 2012). Hypoxia Inducible Factor 1a (HIF-1a) is translocated to the
nucleus where it dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT) and
forms an active heterodimeric complex that regulates the expression of several genes responsible
for promoting cell survival in a hostile environment, such as low oxygen levels, high acidity, and
scarce nutrition (Hu, et al., 2014) (Figure 6). Interestingly, hypoxic conditions have been
postulated to drive the formation of BCSCs (Helczynska, et al., 2003). The phenomenon occurs
through a HIF-1a-NICD interaction, which is promoted by NICD stabilizing HIF-1a when in the
absence of ARNT, resulting in the induction of tumor dedifferentiation to breast cancer with
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stem cell characteristics (Cejudo-Martin & Johnson, 2005) (Figure 6). This same interaction
occurs in embryonic stem cells, which is necessary for the stem cell to maintain an
undifferentiated state. Schwab et al. showed that HIF-1a promotes BCSC viability by supporting
the formation of mammospheres and maintaining their CD44+CD24low/-ALDH1+ phenotype in
vivo through the increased expression of cluster of differentiation 133 (CD133), a direct target
gene of the Notch pathway (Schwab, et al., 2012). Moreover, it has been shown in vitro that
there is a high CD44 expression level in TNBC, which has been shown to be mediated by HIF1a (Krishnamachary, et al., 2012). The interaction between HIF-1a and the Notch pathway was
confirmed by Qiang et al. in glioma stem cells (GSCs) by demonstrating that HIF-1a induced
activation of the Notch pathway by binding and stabilizing NICD, driving the maintenance of
GSCs (Qiang, et al., 2012). Collectively, the findings of these papers indicate that crosstalk
between the Notch signaling pathway and HIF-1α is important for promoting stem cell activity in
CSCs under hypoxic conditions.
Inhibitors have been developed that target the embryonic pathways Wnt, Hh, and Notch,
based on the rationale that these pathways are not only important for embryogenesis but also
important for cancer progression (Figure 7). Regarding the Wnt pathway, LGK974 is a
porcupine inhibitor and blocks Wnt palmitoylation and PRI-724 is a CBP/b-catenin antagonist;
both have shown promising results and are currently undergoing phase I trials for breast cancer
(Liu, et al., 2012; Lenz & Kahn, 2014). The inhibition of Hh signaling has also shown promising
results in targeting BCSCs. Salinomycin, a carboxylic polyether ionophore, was shown to be
selectively cytotoxic to BCSCs because it reduced Hh signaling by inhibiting the expression of
the components necessary for the Hh pathway such as PTCH1, SMO, Gli-1, and Gli-2 (Fu, et al.,
2016). This finding has prompted the development of additional Hh inhibitors such as LDE225, a
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Figure 7. Current Therapeutic Strategies for Targeting Wnt, Hedgehog and Notch
Signaling in Breast Cancer Stem Cells
Hedgehog, Notch, and Wnt/β-catenin pathways can be antagonized by molecular targeted agents
including ligand-binding molecules, receptor antagonists, ligand receptor antagonists or agents
inhibiting intracellular effectors. Red font indicates therapy strategies that target the Wnt
signaling pathway, blue font indicates therapy strategies that target the Hedgehog signaling
pathway, while purple font indicates strategies for targeting the Notch signaling pathway. Wnt =
Wingless-type MMTV Integration Site Family, DVL = Dishevelled, LPS = Lipopolysaccharide,
GSK2 = Glycogen Synthase Kinase 2, APC = Adenomatous Polyposis Coli, CK1a = Casein
Kinase 1a, CBP = CREB Binding Protein, TCF/LEF = T-cell Factor/Lymphoid Enhancing
Factor, COX2 = Cyclooxygenase 2, CD44 = Cluster of Differentiation 44, MMP7 = Matrix
Metallopeptidase 7, PPARg = Peroxisome Proliferator-activated Receptor g, Hh = Hedgehog,
COS2 = Kinesin Motor Protein Costal-2, SUFU = Suppressor of Fused, Gli = Glioma Associated
Oncogene, Gli-A = Activated Gli, Gli-R = Restricted Gli, Gli1 = Glioma Associated Oncogene
1, ADAM = A-Disintegrin and Metalloproteinase, NICD = Notch Intracellular Domain, MAML
= Mastermind-like, RBP-Jk = Recombination Signal Binding Protein for Immunoglobulin kJ
Region, CSL = RBP-Jk/Suppressor of Hairless/Lag1, myc = MYC Proto-oncogene, HES1 =
Hairy Enhancer of Split 1, HER2 = Human Epidermal Growth Factor Receptor 2, CDKN1A =
Cyclin-dependent Kinase Inhibitor 1A, CCND1 = Cyclin D1, CCND3 = Cyclin D3, CCNE =
Cyclin E.

23

SMO inhibitor, which is currently undergoing phase II trials for breast cancer (Irvine, et al.,
2016).
More work has focused on the development of Notch inhibitors compared with the
development of Wnt and Hh inhibitors. The g-secretase inhibitors (GSIs) are the most widely
recognized Notch inhibitors that are effective against cancer that is resistant to endocrine therapy
(Olsauskas-Kuprys, Zlobin, & Osipo, 2013). Anti-estrogen therapy with tamoxifen and
fulvestrant increased the activity of BCSCs through activation of the JAG1-Notch4 signaling
axis, but when combined with GSI RO4929097 the activity of BCSCs was suppressed (Simões,
et al., 2015). The major side-effect to GSIs is gastrointestinal (GI) toxicity due to Notch
signaling being vital to maintain the gut epithelium (Wong, et al., 2004). To avoid GI toxicity,
new specific antibodies against the Notch receptors and Notch ligands are being developed for
better selectivity and thus less toxicity. One example of a Notch receptor antibody targeted the
Notch2 and Notch3 receptors (OMP-59R5, tarextumab), which was shown to reduce the breast
cancer stem cell population in vivo. Therefore, targeting the stem cell niche to eradicate BCSCs
represents a new area of therapeutic development to prevent tumor recurrence and metastasis
(Yen, et al., 2015).
1.3. Drug Resistance in Breast Cancer
Despite the complex biological nature of cancer, there have been many recent successes
in the treatment of various cancers due to the increased understanding of the diverse molecular
mechanisms that modulate tumor development. However, the primary limitation of many cancer
drugs is the development of tumors that are drug resistant (Zahreddine & Borden, 2013). Based
on the tumor response to the initial therapy, drug resistance in cancer is categorized as either
primary or acquired (Meads, Gatenby, & Dalton, 2009; Lippert, Ruoff, & Volm, 2011). While
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primary drug resistance exists prior to treatment, acquired resistance occurs after the initial
therapy, and unfortunately many patients will at some point develop resistance to treatment
(Castells, Thibault, Delord, & Couderc, 2012). Therefore, it is vital to understand the various
mechanisms that contribute to drug resistance in breast cancer.
Both primary and acquired resistance can be caused by alterations in drug metabolism,
uptake, efflux, and detoxification (Gottesman, 2002). The method of entry into cells depends on
the chemical nature of the drug. Some drugs that do not enter the cell use receptors to bind to and
activate cell signaling pathways. Other drugs utilize transporters, which allow them to enter the
cell and induce cytotoxicity. From this perspective, resistance can result from mutations that alter
the activity or reduce the expression of cell surface receptors (Atwood, Chang, & Oro, 2012;
Kasper & Toftgård, 2013) or transporters (Galmarini, Mackey, & Dumontet, 2001; Damaraju, et
al., 2003) and has been observed with the Hh signaling component SMO, where mutations
caused a defective uptake in cyclopamine, a common chemotherapy agent (Yauch, et al., 2009).
Increased drug efflux is promoted by the increased expression of adenosine triphosphate
(ATP) binding cassette (ABC) membrane transporters (Gottesman, Fojo, & Bates, 2002). There
are three members of the ABC transporter family that have their expression levels correlated
with cancer chemo-resistance to various drugs: P-glycoprotein (P-gp), multidrug resistanceassociated protein 1 (MRP1), and breast cancer resistance protein (BCRP). P-gp has been
identified to transport a wide variety of hydrophobic anti-cancer agents such as vinblastine,
doxorubicin, vincristine, and taxol (Gottesman, 2002). MRP1 has been shown to transport
natural-products and drugs with a negative charge or that have been modified by glutathione
(GSH), glucuronic acid or sulfate (Hipfner, Deeley, & Cole, 1999; Borst, Evers, Kool, &
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Wijnholds, 2000), while BCRP has been shown to promote resistance to topoisomerase I
inhibitors, anthracyclines, and mitoxantrone (Gottesman, 2002).
To exert cytotoxic effects, many anti-cancer drugs need to undergo metabolic activation
(Sampath, et al., 2006). Therefore, drug inactivation also plays a major role in the development
of drug resistance. One mechanism involves the conjugation of the drug to reduced GSH, a
powerful anti-oxidant that protects the cells against the damaging effects of reactive oxygen
species (ROS) (Wilson, Johnston, & Longley, 2009). GSH has been seen to conjugate with
platinum-based drugs, which makes them susceptible substrates for ABC transporters and
enhances their efflux (Meijer, et al., 1992). Other anti-cancer agents undergo inactivation via
phase I drug metabolism, such as the topoisomerase I inhibitor irinotecan, which becomes
inactivated by CYP450s. Metallothionein (MT) is a cysteine rich protein that acts like a chelator
for various metals and has also been identified to bind platinum-based drugs as another means of
drug inactivation (Kasahara, et al., 1991).
Many cancers develop dependency on a particular oncogene, providing a basis for the
development of targeted therapies. A primary example of this is endocrine therapy, which
utilizes SERMs like tamoxifen, SERDs like fulvestrant, and AIs. Resistance to endocrine
therapies are seen in 50%-60% of early breast cancer cases and eventually develops in almost all
patients with advanced disease (Davies, et al., 2011). There are several mechanisms of resistance
to endocrine therapy including loss or modification of ER expression, epigenetic regulation of
ER expression and crosstalk between ER and different signaling pathways (Ali & Coombes,
2002; Massarweh & Schiff, 2007). Other causes of drug resistance are due to hypoxia, increased
EGFR (Schlessinger, 2004) and HER2 expression (Pietras, et al., 1995), as well as mitogenactivated protein kinase (MAPK) hyperactivation (Ali, Metzger, & Chambon, 1993). However,
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crosstalk between ER and different signaling pathways is the main mechanism of endocrine
resistance, as targeting one protein alone can become ineffective as other parallel pathways can
take over tumor survival. This endocrine crosstalk mechanism was demonstrated in breast cancer
cells by Simões et al. who showed that short-term treatment with tamoxifen or fulvestrant
decreased breast cancer cell proliferation, but increased BCSC activity through activation of
Notch signaling and resulted in tumor recurrence and drug resistance (Simões, et al., 2015). By
targeting the Notch pathway via GSIs, Notch signaling was reversed and suppressed BCSC
activity that was originally induced by tamoxifen alone (Simões, et al., 2015). Current research
shows that inhibiting the Notch signaling pathway via GSIs can decrease drug resistance
(Nefedova, Cheng, Alsina, Dalton, & Gabrilovich, 2004) and promote apoptosis (Séveno, et al.,
2012) by restoring the effects of tamoxifen and other endocrine targeting agents.
Drug resistance could also result by avoiding apoptotic pathways. Apoptotic resistance
can be triggered by inactivating mutations in genes coding for apoptotic proteins (i.e. p53) or by
activating mutations in genes coding for anti-apoptotic proteins, such as B-cell lymphoma-2
(Bcl-2) (Evan & Vousden, 2001). Mutations in p53 have been correlated with resistance to
doxorubicin treatment in patients with advanced breast cancer (Geisler, et al., 2001). In the case
for endocrine therapy, the treatment fails if the balance between proliferation and apoptosis
cannot be maintained because the pro-apoptotic genes are increased, and the anti-apoptotic genes
are decreased (Ali, et al., 2016). Tamoxifen can act as an ER antagonist in breast cancer cells but
in other cell types acts as an ER agonist. As a result, the anti-apoptotic proteins are promoted by
estrogen to protect normal cells from cell death, but in the presence of tamoxifen, the proapoptotic genes are decreased, and anti-apoptotic proteins are increased (Lewis-Wambi &
Jordan, 2009). The tamoxifen resistance is promoted by ER-positive breast cancer via expression
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of Bcl-2 (Kumar, Mandal, Lipton, & Harvey, 1996) and tumor growth factor b (TGFb) (Osborne
& Fuqua, 1994). The HER2-enriched breast cancers already have high levels of Bcl-2 which
leads to reduced tamoxifen-induced apoptosis. Current research shows that inhibiting the Notch
signaling pathway via GSIs can decrease drug resistance and promote apoptosis by restoring the
effects of tamoxifen and other endocrine targeting agents (Wang, et al., 2012). Given the
importance of Notch signaling in cancer progression, the following chapter will cover the Notch
pathway in both cancer and normal physiological functions.
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CHAPTER 2
THE NOTCH SIGNALING PATHWAY
The Notch signaling pathway is a highly conserved evolutionary pathway that plays vital
roles that have been established as fundamental in both multi-cellular and developmental
processes (Borggrefe & Liefke, 2012). The Notch receptor was originally discovered in
Drosophila as a neurogenic gene, and its signaling pathways were revealed to be pleiotropic, as it
affected many other tissues (Artavanis-Tsakonas, Muskavitch, & Yedvobnick, 1983). These
pleiotropic effects and physiological functionalities were identified to hold true in mammalian
species, where the Notch signaling pathway was shown to play a pivotal role in embryonic and
post-natal development (Andersson, Sandberg, & Lendahl, 2011; Ables, Breunig, Eisch, &
Rakic, 2011). More specifically, Notch has been identified to regulate a variety of functional
effects, ranging from cell differentiation, cell proliferation, cell survival and apoptosis. It is
therefore not surprising that the Notch pathway and its functional effects are exploited in cancer
progression (Koch & Radtke, 2010; Ranganathan, Weaver, & Capobianco, 2011).
2.1. Canonical Notch Signaling
When first studied, the Notch signaling pathway appeared to be remarkably simple, as it
was activated through direct interactions between the Notch receptors and its ligands on
neighboring cells (Figure 8). The mammalian Notch receptor family consists of four Notch
receptors (Notch1, Notch2, Notch3, Notch4) and five Notch ligand receptors (JAG1, JAG2,
DLL1, DLL3, and DLL4) (D’Souza, Miyamoto, & Weinmaster, 2008). Notch ligands are DeltaSerrate-Lag1 (DSL)-containing type I transmembrane proteins that bind to the Notch receptor
and induce a conformational change, exposing the cleavage site on the extracellular domain
(ECD) to the ADAM/tumor necrosis factor a (TNFa) converting enzyme (TACE) complex
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Figure 8. Canonical Notch Signaling
Notch signaling is activated by interaction between the ligand-expressing cell and the Notchexpressing cell, followed by proteolytic cleavage that releases the NICD. Before activation of
Notch signaling, CSL is bound to DNA along with CoRs such as SPEN. Upon activation of
Notch, the NICD recruits the co-activator MAML and others, and thus converts the CSLrepressor complex into a transcriptional activator complex and drives the transcription of target
genes. The signal is terminated by phosphorylation of the NICD, followed by ubiquitylation by
FBXW7 and proteasomal degradation. Numb promotes ubiquitylation of the membrane-bound
Notch1 and targets the NICD for proteasomal degradation. Signal transduction from Notch
ligands also occurs. Proteolytic cleavage releases the ICD of the Notch ligands. The PDZ domain
interacts with PDZ-containing proteins, resulting in a signaling cascade. The ICDs of Notch
ligands JAG and DLL can also enter the nucleus and regulate transcription, possibly through
interactions with AP-1 or the Smad proteins. This transcriptional regulation may be antagonized
by the NICD. CoRs = Co-repressors, ICD = Intracellular Domain, PDZ = PSD-95/Dlg/ZO-1,
CDK8 = Cyclin-dependent Kinase 8, ADAM = A-disintegrin and Metalloproteinase, FBXW7 =
F-Box and WD Repeat Domain Containing 7, NICD = Notch Intracellular Domain, CSL = RBPJk/Su(H)/LAG1, SPEN = MINT and SHARP, MAML = Mastermind-like, Ub = Ubiquitin, AP-1
= Activator Protein-1, p = Phosphate Group.

30

(Fleming, 1998). The Notch receptor then undergoes another cleavage in the intercellular domain
by the presenilin-g-secretase complex (Jorissen & De Strooper, 2010). This cleavage cascade
results in the release of the NICD from the plasma membrane and its translocation to the nucleus
(Bray, 2006). Once in the nucleus, the NICD then mediates the conversion of the RBPJk/Suppressor of Hairless (Su(H))/Lag-1 (CSL) repressor complex into a transcriptional
activation complex (Wilson & Kovall, 2006), leading to the recruitment of the co-activator
mastermind-like (MAML) and the induction of gene expression (Nam, Sliz, Song, Aster, &
Blacklow, 2006; Vasquez-Del Carpio, et al., 2011) (Figure 8). Several well-characterized target
genes of the Notch pathway have been identified, such as the transcriptional repressors hairy
enhancer of split (HES) family and the HES related family basic helix-loop-helix (bHLH)
transcription factor with YRPW motif (HEY) family (Borggrefe & Oswald, 2009). Notch
signaling is terminated by phosphorylating the NICD, which is targeted for ubiquinylation by Fbox and WD repeat domain containing 7 (FBXW7) E3 ligase and degraded via the proteasome
(Le Bras, Loyer, & Le Borgne, 2011; Gupta-Rossi, et al., 2001; Le Friec, et al., 2012).
Although the primary role of Notch ligands is to activate Notch signaling, Notch ligands
can also have unique Notch-independent functions (Pintar, De Biasio, Popovic, Vanova, &
Pongor, 2007). Recent evidence has shown that after binding to the Notch receptor, the DSLcontaining ligands also undergo proteolytic cleavage and initiate signaling events that are
independent of the NICD (Ikeuchi & Sisodia, 2003). Signaling induction from DSL-containing
ligands was determined when ectopic expression of JAG1 transformed rat kidney epithelial cells
independently of Notch signaling and required an intact and functional postsynaptic density
protein-95 (PSD-95)/discus large homolog (Dlg)/zona occludens 1 (ZO-1) (PDZ)-ligand motif in
JAG1; this prompted the hypothesis that the Notch-DSL pathway is bidirectional (Ascano,
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Beverly, & Capobianco, 2003). Bidirectional signaling in this case indicates that even though
activation of the Notch pathway is receptor-ligand dependent, the intracellular domains (ICDs)
of each receptor and ligand regulate transcription independently. JAG1 and other Notch ligands
undergo similar processing and proteolytic cleavage to release their respective ICDs. The JAG1
intracellular domain (JICD) has been identified to activate activator protein-1 (AP-1)-mediated
transcription (Duryagina, et al., 2013), and inhibit NICD mediated transcription (Metrich, et al.,
2015). The delta-like ligand (DLL) intracellular domain (DICD) was also able to mediate TGFbActivin signaling through binding to Smads (Hiratochi, et al., 2007), and was also inhibited by
the NICD (Jung, et al., 2011). However, even though Notch-independent DSL signaling has been
reported and established, its physiological relevance in tumorigenesis has yet to be identified.
The Notch pathway does not act independently. Rather, it is part of a complex network of
many signaling pathways that are interconnected (Borggrefe & Liefke, 2012). As an example,
the Notch pathway has been identified to be modulated by Wnt signaling (Jin, et al., 2009) and
HIF-1a (Gustafsson, et al., 2005). Table 2 identifies various Notch-interacting partners that
either inhibit or activate Notch signaling. Within this intricate network are feedback loops, which
are essential for establishing limitations of Notch signaling during development (Kim, et al.,
2011; Fischer & Gessler, 2007). Notch signaling regulates itself by activating the transcription of
regulatory factors that are direct Notch target genes such as hairy enhancer of split 1 (HES1)
(Takebayashi, et al., 1994). These regulatory factors are what establish the positive- and
negative-feedback mechanisms in Notch signaling, which can be classified based on the stages
they act on within the pathway (Figure 9). The first stage that direct feedback regulators act on is
the initiation of the Notch response. The genes that code for the Notch receptors, Notch1 and
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Notch-interacting Partners
Interacting Protein

Partner

β-catenin

NICD

Notch Signaling
Effect
+

NICD

+

NICD

-

NICD/MAML

+

NICD

-

NICD

-

NICD

+

(Jin, et al., 2009)
HIF-1α
(Gustafsson, et al.,
2005)
JICD
(Kim, et al., 2011)
p300
(Oswald, et al., 2001)
RUNX2
(Ann, et al., 2011)
RUNX3
(Gao, et al., 2010)
Smad
(Takizawa, Ochiai,
Nakashima, & Taga,
2003)

Table 2. Notch-interacting Partners
There are many interacting factors that can alter the stability and the composition of the activator
complex, which precisely regulates the Notch signaling output. HIF-1a = Hypoxia Inducible
Factor 1a, JICD = JAG1 Intracellular Domain, RUNX2 = Runt Related Transcription Factor 2,
RUNX3 = Runt Related Transcription Factor 3, NICD = Notch Intracellular Domain, MAML =
Mastermind-like, - = Notch Inactivation, + = Notch Activation.
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Figure 9. Notch Target Genes that Act as Positive- and Negative-feedback Regulators for
the Notch Signaling Pathway
Direct feedback regulators can be classified based on what stages of Notch signaling they can
modulate. (A) The initiation phase of Notch signaling (Pin1 and cis-inhibition). (B) NICD and
corresponding transcription complex levels and stability (Numb and JICD). (C) Co-regulation
gene expression by binding to N-Box (suppressing DNA regions) and E-Box (enhancing DNA
regions) sequences of Notch target genes (HES1 and c-myc). NICD = Notch Intracellular
Domain, JICD = JAG1 Intracellular Domain, Pin1 = Prolyl-cis/trans Isomerase 1, CSL = RBPJk/Su(H)/Lag-1, MAML = Mastermind-like, HES1 = Hairy Enhancer of Split 1, c-myc = V-myc
Avian Myelocytomatosis Viral Oncogene Homolog, PDZ = PSD-95/Dlg/ZO-1, Ub = Ubiquitin.
Green Arrows = Positive-feedback Loops, Red Arrows = Negative-feedback Loops.
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Notch3, and Notch ligand receptors JAG1 and DLL1 were found to be regulated by the Notch
pathway itself (Weng, et al., 2006; Weerkamp, et al., 2006; Chen, et al., 2010; Qian, et al., 2009).
The increased expression of these Notch receptors and ligands acts to promote a positivefeedback loop. However, even though increasing expression of these receptors promotes Notch
signaling on the adjacent cell, the same receptors act as a negative regulator on the originating
cell; a cellular process coined cis-inhibition (del Álamo, Rouault, & Schweisguth, 2011). Nuclear
inhibition has been observed through studying the JICD. After the JICD is released from the
receptor, it translocates to the nucleus and binds the NICD, where it inhibits Notch signaling by
promoting its proteasomal degradation via FBXW7 (Kim, et al., 2011). Therefore, the
intracellular functionality of the JICD serves as an additional negative-feedback loop. A form of
positive-feedback at the initiation step is increased expression of the Notch target gene prolylcis/trans-isomerase 1 (Pin1) (Rustighi, et al., 2009). Once expressed, Pin1 interacts with the
Notch1 receptor at the membrane and helps promote cleavage by g-secretase, which stimulates
the release of the NICD. Therefore, increased Pin1 expression results in elevated Notch1 activity
and transcriptional output.
Direct feedback regulators also play a role in modulating the amount and stability of
NICD. While at the membrane or shortly after release, NICD can interact with Notch target gene
product Numb (Figure 9). Numb acts as a negative-feedback regulator by interacting with the
NICD and induces ubiquitination via the E3 ligase Itch, which stimulates the ubiquitination and
proteasomal degradation of the NICD (Rebeiz, Miller, & Posakony, 2011) (Figure 9). This
negative-feedback regulator results in the reduction of the total amount of NICD present in the
cell and nucleus, hence reducing its transcriptional output. Runt related transcription factor 2
(RUNX2) also acts as negative regulator by inhibiting Notch1 signaling during osteoblast
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differentiation by binding the NICD and inducing its degradation (Ann, et al., 2011). Other
Notch target genes are transcription factors that can transmit the Notch signal to further
downstream target genes. Some well-known examples of Notch target genes that encode
transcription factors include: HES1, hairy enhancer of split 5 (HES5), and HES related family
bHLH transcription factor with YRPW motif 1 (HEY1), which are DNA binding transcription
factors that act through transcriptional elements to induce or suppress the expression of target
genes (Fischer & Gessler, 2007). These enhancer and repressor regions are present in many
Notch target genes and there have been several reports showing that Notch target genes can be
repressed by HES1, including the HES1 gene itself. This feedback loop was identified as an
“incoherent network logic” by Krejcí et al. to signify Notch as a signaling pathway that induces
its target genes along with repressors for those target genes, which could serve a purpose to
create a temporary window of responsiveness after Notch activation (Krejcí, Bernard, Housden,
Collins, & Bray, 2009). Collectively, these positive- and negative-feedback loops play a major
role in modulating the Notch pathway and are essential to convert these modulations into
versatile biological outcomes.
2.2. Physiological Functions of Notch Signaling: Immunity, Inflammation, Hematopoiesis,
and Development
Recent evidence has established that Notch signaling is associated with immunity and
inflammation because of its activity in several inflammatory diseases including rheumatoid
arthritis (RA) (Ando, et al., 2003), atherosclerosis (Fung, et al., 2007), and primary biliary
cirrhosis (Geisler & Strazzabosco, 2015). Expression of Notch receptors and ligands was
detected in RA synovial tissues, and excessive activation of Notch1 was observed in synoviocyte
cultures from RA patients (Nakazawa, et al., 2001). Therefore, it has been predicted that the
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Notch pathway is activated in RA and may modulate the severity of the disease. However,
although the association between Notch signaling and inflammation is supported by a copious
amount of literature, the mechanisms by which Notch regulates inflammation is poorly
understood. Under inflammatory conditions, Notch signaling can be promoted by stimuli from
two different sources, exogenous agents such as pathogens and/or endogenous factors such as
inflammatory cytokines.
Regarding pathogenic infections, macrophages (Palaga, et al., 2008) and dendritic cells
(DCs) (Cheng & Gabrilovich, 2008; Gentle, Rose, Bugeon, & Dallman, 2012; Cheng, Nefedova,
Miele, Osborne, & Gabrilovich, 2003) express toll-like receptors (TLRs) that enable them to
respond rapidly to coordinate innate and adaptive immune responses. TLRs are a single
membrane-spanning, non-catalytic receptor class of proteins that play a key role in the innate
immune system and are usually expressed on sentinel cells that recognize structurally conserved
molecules, such as macrophages and DCs. Concurrently, macrophages and DCs also
constitutively express Notch ligands and receptors on their cellular membrane that respond to
Notch signaling (Cheng, Nefedova, Corzo, & Gabrilovich, 2007; Shang, Smith, & Hu, 2016).
There is plenty of evidence that TLRs can modulate Notch signaling by inducing expression of
Notch receptors as well as Notch ligands JAG1, DLL1, and DLL4 (Fung, et al., 2007; Foldi, et
al., 2010; Monsalve, et al., 2009). By enhancing the expression of Notch receptors and ligands,
TLR signaling indirectly promotes Notch activation in a manner that is predicted to be dependent
on de novo protein synthesis (Palaga, et al., 2008; Hu, et al., 2008). These observations support a
binary model where signal 1 represents tonic signaling and signal 2 represents acute TLR
signaling (Shang, Smith, & Hu, 2016). This binary model allows us to understand that: 1) resting
macrophages show basal levels of the NICD because of constitutive expression of Notch
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receptors and ligands, 2) activation of Notch target gene expression occurs rapidly once triggered
by TLR stimulation, which circumvents the requirement for activation via receptor-ligand
induction, and 3) signal 1 or signal 2 alone is necessary but not sufficient for robust Notch target
gene expression in macrophages. Therefore, the cooperation of both signaling pathways is
required for optimal activation. However, it is important to note that the mechanism that couples
acute TLR signaling to Notch pathway activation is currently unknown.
Inflammatory cytokines such as TNFa and interleukin-1b (IL-1b) are essential for host
defense against a plethora of pathogens and are present during innate and immune responses.
However, these cytokines can become detrimental and pathogenic under conditions with
uncontrolled inflammation and in autoimmune diseases when the expression of these cytokines
becomes dysregulated. In RA, it is well established that TNFa plays a key role in RA
pathogenesis and is currently validated as a drug target in the treatment of RA. Coincidently, in
RA synovial fibroblasts, TNFa induces transcription of Notch1, Notch4, and JAG2 via
activation of the nuclear factor-kB (NF-kB)-inhibitor of NF-kB subunit a (IKKa) signaling
pathway, which in turn promotes NICD nuclear translocation (Ando, et al., 2003). Another
example of TNFa-induced Notch activation is observed in osteoclast precursors, where Notch
signaling is activated by TNFa and as a result inhibits osteoclastogenesis and enhances TNFamediated inflammatory bone resorption in a feedback manner (Zhao, Grimes, Li, Hu, &
Ivashkiv, 2012). Therefore, TNFa appears to function as a promoter of Notch signaling in
various cell types. IL-1b is reported to induce expression of Notch target gene HES1 in
chondrocytes via Notch1 activation (Ottaviani, et al., 2010). In addition, TGFb has also been
identified to directly induce HES1 expression in several cell types (Ostroukhova, et al., 2006).
While there are multiple cytokines that positively regulate Notch signaling, interferon-g (IFNg)
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functions as a negative regulator of Notch signaling (Hu, et al., 2008) and was observed in
human macrophages, where IFNg suppressed transcription of Notch target genes by TLR and
Notch ligands. However, the precise mechanism of how this occurs has not been identified.
Hematopoiesis is the developmental process where pluripotent hematopoietic stem cells
(HSCs) produce progeny that undergo proliferation and differentiation as a response to both cellbound factors and cytokines in a positive and negative manner, which results in the production of
mature blood cells of various lineages. The Notch signaling pathway modulates the interactions
between HSCs (which express all four Notch receptors) and bone marrow stromal cells (which
express various Notch ligands) in the developing immune system (Bigas, Martin, & Milner,
1998). It is important to understand the role of Notch signaling in myeloid cell development and
differentiation, even though there are some discrepancies regarding the mechanism(s) involved.
One collection of evidence was able to demonstrate that Notch signaling is vital in the
maintenance of progenitor cells and blocking terminal differentiation of myeloid cells (Shang,
Smith, & Hu, 2016) and was supported when retroviral transduction of activated Notch1
intracellular domain (NICD1) in 32D myeloid progenitor cells inhibited the differentiation of
mature granulocytes in response to granulocyte colony-stimulating factor (G-CSF) but not
granulocyte macrophage colony-stimulating factor (GM-CSF), without affecting the proliferation
of undifferentiated cells. Interestingly, the Notch2 intracellular domain (NICD2) inhibited
differentiation of 32D cells in response to GM-CSF but not G-CSF (Milner, et al., 1996; Bigas,
Martin, & Milner, 1998), which suggests that even though both Notch1 and Notch2 inhibited
myeloid differentiation, there may be independent functions taking place in HSCs depending on
the specific differentiation signal involved. Over-expression of HES1 resulted in a similar
phenotype and, in addition, also blocked erythroid differentiation (Lam, Ronchini, Norton,
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Capobianco, & Bresnick, 2000; Kumano, et al., 2001). On the other hand, Notch has been shown
to be required for differentiation of mature myeloid cells. Schroeder & Just were able to
demonstrate that conditional expression of the NICD in 32D cells decreased self-renewal and
enhanced granulocyte differentiation through JAG1 activity in a transcriptionally active form of
RBP-Jk (Schroeder & Just, 2000).
It was more recently demonstrated by Klinakis et al. that Notch modulated early HSC
differentiation in vivo. In a mouse model, Notch signaling was inhibited by targeting g-secretase
complex member nicastrin, and resulted in excessive accumulation of granulocyte and or
monocyte progenitors in the blood, spleen, and liver; which is diagnostic of the induction of
chronic myelomonocytic leukemia (CMML)-like disease (Klinakis, et al., 2011). Gene
expression analysis was able to reveal that the Notch pathway regulates a myelomonocyticspecific gene signature by suppressing gene expression via HES1. Furthermore, in samples from
CMML patients, somatic mutations were identified in multiple components of the Notch
pathway such as nicastrin, MAML and Notch2, suggesting a potentially tumor-suppressive role
for Notch signaling in addition to its involvement in early HSC differentiation (Shang, Smith, &
Hu, 2016).
Notch signaling is remarkably pleiotropic. There is not a cell or tissue that is not affected
by cell fate choices regulated by Notch signaling (Hori, Sen, & Artavanis-Tsakonas, 2013). With
regard to developmental signaling, the consequences of either activating or inhibiting Notch is
strictly context-specific. For example, the same Notch signal in one circumstance can promote
proliferation while another can result in apoptosis (Hori, Sen, & Artavanis-Tsakonas, 2013).
Therefore, how Notch signaling is incorporated with other signaling pathways in the context of a
particular cellular physiology will ultimately dictate how Notch activity affects cell fate. Even
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though there are a lot of spatial and temporal complexities intertwined within the dynamics of
this pathway, cis-inhibition is the hallmark of Notch-regulated cell fate and lateral specification
(Greenwald, 1998). Cis-inhibition describes the mechanism by which cells that are in the process
of adopting one particular cell fate influence the fate of the neighboring cell. Due to this pathway
being so evolutionarily conserved, most eukaryotic lineages rely on cis-inhibition. One classic
example of the developmental action of Notch is the case of neuroblast differentiation in
Drosophila embryo. In neuroblast differentiation, a cell that is about to become a neuroblast
prevents its adjacent neighbors from adopting the same fate and has two important implications
to consider when regarding morphogenesis: 1) Notch signaling helps in the separation of specific
lineages from a field of developmentally equivalent cells and 2) is a crucial mechanism that
specifies borders between cellular fields (Bray, 2006).
Stem cells exist in most embryonic and adult organisms and are defined as cells having
the ability for self-renewal. Stem cells also have the ability to generate all cell types of a given
organ. During the developmental process, stem cells give rise to all lineages of tissues, but in
adults they are responsible for maintaining tissue homeostasis in damaged tissue (Liu, Sato,
Cerletti, & Wagers, 2010). Therefore, the balance between self-renewal and differentiation is
under tight regulation to allow for proper development to occur and avoid excessive growth,
which could potentially lead to cancer. Conditional gain- and loss-of-function studies
demonstrated that Notch regulates quiescence and cell cycle exit in neuronal stem cells.
Chapouton et al. showed that high Notch activity maintained neuronal stem cells in a quiescent
state but inhibiting Notch signaling resulted in increased neuronal stem cell division followed by
differentiation, which in turn depletes the neuronal stem cell population (Chapouton, et al.,
2010). Once again, this study suggests that cis-inhibition may act as the mechanism that
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generated the results. Similar results were obtained in mice with conditional ablation of RBP-Jk
in the adult brain, where all neuronal stem cells differentiated into transit-amplifying cells and
neurons. As a result, transient neurogenesis was increased but later depleted the neuronal stem
cell population and neurogenesis was completely lost (Ehm, et al., 2010). These results indicate
that the Notch pathway is an absolute necessity for the maintenance of neuronal stem cells and
for the proper control of neurogenesis in both embryonic and adult brains.
2.3. JAG1-dependent Notch Signaling in Cancer
The Notch pathway is increasingly attracting attention as a new target for cancer
treatments considering that ligand-induced Notch signaling has been shown to promote cancer
progression (Li, Masiero, Banham, & Harris, 2014). Even though Notch inhibitors such as GSIs
are currently undergoing clinical trials and have been extensively researched, targeting Notch
ligands provides a more attractive option due to 1) their more restricted expression, 2) betterdefined functions and 3) lower mutation rates in cancer. JAG1 is the most extensively researched
Notch ligand, is over expressed in various cancer types, has been linked with poor prognosis, and
plays a vital role in several functions of tumor biology.
JAG1 is a member of the DSL family that encodes a Type I transmembrane receptor
protein. The extracellular portion of this receptor contains a calcium-binding (C2) domain at the
N-terminus that binds to the phospholipid bilayer once undergoing glycosylation to modulate
JAG1-dependent Notch activation (Cordle, et al., 2008; Whiteman, et al., 2013) (Figure 10). The
DSL binding domain is located below the C2 domain which is responsible for binding Notch
receptors; this domain was also recently discovered to bind cluster of differentiation 46 (CD46)
receptor to regulate T-cell functionality (Le Friec, et al., 2012) (Figure 10). Following the DSL
binding domain are multiple highly conserved EGF repeats (human JAG1 consists of 16 EGF
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Figure 10. The JAG1 Ligand Receptor and its Roles in Cancer Biology
JAG1 is a type I transmembrane receptor protein. The extracellular portion of the receptor
consists of a C2 phospholipid recognition domain, DSL-binding domain, 16 EGF repeats and a
CRD. JAG1 can be cleaved by ADAM upon binding to the NOTCH receptor and then undergoes
a second cleavage by 𝛾-secretase to release the JICD. The JICD contains a PDZ-ligand binding
motif that is responsible for the intrinsic bidirectional signaling induced by JAG1. In cancer and/
or in stromal cells, JAG1 induces tumor cell growth and inhibits apoptosis. JAG1 also plays a
key role in cancer stem cell maintenance and promotes metastasis. In the tumor
microenvironment, JAG1 was also linked to promoting tumor angiogenesis and increasing the
Treg cell population to inhibit tumor-specific immunity. The genes that are listed along the arrow
leading to their corresponding role in cancer biology are regulated in a JAG1-dependent manner
either in a direct or indirect manner. Genes represented in green are increased by JAG1 while the
genes decreased by JAG1 are represented in red. DSL = Delta/Serrate/Lag-1, EGF = Epidermal
Growth Factor, C2 = Calcium-binding, CRD = Cysteine-rich Domain, JICD = JAG1 Intracellular
Domain, PDZ = PSD95/Dlg/ZO-1, ADAM = A-Disintegrin and Metalloproteinase, avb3integrin = Integrin av and Integrin b3, IL-2 = Interleukin-2, IL-6 = Interleukin-6, IL-10 =
Interleukin-10, IL-17 = Interleukin-17, CD44 = Cluster of Differentiation 44, CD34 = Cluster of
Differentiation 34, µPA = Urokinase-type Plasminogen Activator, MMP2 = Matrix
Metallopeptidase 2, MMP9 = Matrix Metallopeptidase 9, DLL4 = Delta-like Ligand 4, Bcl-2 =
B-cell Lymphoma-2, c-myc = V-myc Avian Myelocytomatosis Viral Oncogene Homolog,
Foxp3 = Forkhead Box P3, PDGFR-β = Platelet-derived Growth Factor Receptor–β, RUNX3 =
Runt Related Transcription Factor 3, SOX2 = Sex Determining Region Y (SRY) Box 2, ZEB1 =
Zinc-finger E-box Binding Homeobox 1, OX40L = Tumor Necrosis Factor Receptor,
Superfamily Member 4.
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repeats) (Figure 10). The DSL family is classified in the JAG- or DLL-subgroups, but the
defining motif that determines the JAG1-subgroup is the presence of a cysteine-rich domain
(CRD) between the EGF-repeats and transmembrane domain (Luca, et al., 2017; Chillakuri, et
al., 2013). The intracellular domains of DSL proteins vary in length and are not conserved in the
primary amino acid sequence. Additionally, the JICD contains a PDZ-ligand binding domain
located at the C-terminal end of the JAG1 receptor (Ascano, Beverly, & Capobianco, 2003;
LaVoie & Selkoe, 2003) (Figure 10). The JICD is released after undergoing cleavage by ADAM
and g-secretase upon binding to the Notch receptor. Upon this release, the JICD induces intrinsic
bidirectional signaling in the JAG1 expressing cell (Lu, et al., 2013) (Figure 8). Furthermore,
JAG1-dependent Notch signaling is directly implicated in tumor growth by maintaining CSC
populations (Simões, et al., 2015), promoting cell survival (Purow, et al., 2005), inhibiting
apoptosis (Wang, et al., 2010a), and influencing cell proliferation (Cohen, et al., 2010) as well as
metastasis (Leong, et al., 2007). Additionally, JAG1 can also affect cancer tumors indirectly by
interacting with components of the tumor microenvironment to promote angiogenesis (Chen, et
al., 2016) and T-cell regulation (Kumar, et al., 2017). Considering that the focus of this
dissertation is based on the regulation of the Notch ligand receptor JAG1, this section will
primarily focus on JAG1-dependent Notch signaling and its roles in cancer biology as well as its
potential as a therapeutic target in breast cancer. Figure 10 depicts a synopsis of this section and
contains an overview of the structure of JAG1 along with a summary of its roles in both direct
and indirect regulation of gene expression for various functions in cancer biology.
2.3.1. Angiogenesis
Angiogenesis is the growth of new blood vessels from existing ones and is a
physiological process that normally takes place during embryonic development and wound
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healing (Carmeliet & Jain, 2011). Angiogenesis is also a hallmark function of cancer
progression, as this process allows the tumor to receive nutrients (Hanahan & Weinberg, 2000).
Notch ligands expressed on endothelial cells can interact with their respective receptors on
endothelial and perivascular cells, smooth muscle cells, and pericytes, which are involved in
multiple stages of blood vessel formation from initial sprouting until maturation of the blood
vessel (Sainson & Harris, 2008). JAG1 has been proven to promote endothelial cell proliferation
and sprouting and inhibit DLL4-dependent Notch signaling in endothelial cells (Kofler, et al.,
2011). Therefore, inhibition of JAG1 reduces sprouting angiogenesis, while increased expression
suppresses DLL4-dependent signaling to promote sprouting angiogenesis.
When it comes to vascular smooth muscle cell coverage of blood vessels and maintaining
the interaction between endothelial cells and perivascular cells, JAG1 is indispensable. High et
al. showed that the expression of JAG1 in endothelial cells is required for vascular smooth
muscle development because its knockout from the endothelium induced defects in vascular
smooth muscle turned out to be fatal (High, et al., 2008) due to JAG1-mediated increases in
integrin av and integrin b3 (avb3-integrin), which confers activity to von Willebrand Factor
(VWF). The activation of VWF is important for maintaining smooth muscle adhesion and vessel
maturation (Scheppke, et al., 2012). It was shown by Liu et al. that Notch3-expressing
perivascular cells can also be induced by JAG1-expressing endothelial cells (Liu, Kennard, &
Lilly, 2009). As a result, the upregulation of JAG1 expression on perivascular cells induces an
auto-regulatory loop that promotes pericyte maturation and angiogenesis. This auto-regulatory
loop is important, considering that inhibition of Notch signaling by Notch3 or JAG1 knockdown
abrogates angiogenesis. The platelet-derived growth factor (PDGF) signaling pathway functions
to promote angiogenesis when endothelial cells secrete the ligand platelet-derived growth factor-
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b (PDGF-b) (Kofler, et al., 2011). Interestingly, the platelet-derived growth factor receptor-b
(PDGFR-b) has been shown to be a direct target gene of JAG1-induced Notch activation (Liu,
Kennard, & Lilly, 2009).
In the case of tumor associated blood vessels, JAG1 has been reported to be highly
expressed in blood vessels that are in contact with brain and ovarian tumors (Lu, et al., 2007). In
head and neck squamous cell carcinoma (HNSCC) tumors, growth factors such as human growth
factor (HGF) and TGFa are secreted from the tumor and, in an autocrine and or juxtacrine
fashion, upregulate the expression of JAG1 via the MAPK pathway. As a result, JAG1 then
stimulates endothelial sprouting, promoting angiogenesis and tumor growth in the mouse model
(Zeng, et al., 2005). Moreover, JAG1 expression has a positive correlation with micro-vessel
formation in HNSCC. The pro-angiogenic role of JAG1 has also been reported in ovarian cancer
models because silencing JAG1 expression in stromal cells significantly reduced tumor
microvascular density and neoplastic growth (Steg, et al., 2011). Overall, this data suggests that
inhibiting the JAG1 pathway could be beneficial to cancer patients, even in the absence of
tumoral JAG1 expression due to its role in the promotion of angiogenesis.
2.3.2. Cancer Stem Cells
Even though CSCs were discussed extensively in the previous chapter, this section will
cover the functionality of JAG1-dependent Notch signaling in the CSC population. Due to the
significance of the Notch pathway in normal stem cell biology, treatment using GSIs in cancer
patients to inhibit all Notch signaling factors (pan-Notch ablation) resulted in intolerable levels
of GI toxicity (Imbimbo, 2008). Unlike the DLL1 and DLL4 Notch ligands, JAG1 was found to
be dispensable for the homeostatic maintenance of normal intestinal stem cells (Pellegrinet, et
al., 2011) suggesting that targeting JAG1 specifically is likely to have less GI side-effects.
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Considering we know that Notch signaling is important for both CSC maintenance and selfrenewal (Wang, Li, Banerjee, & Sarkar, 2009; Espinoza, Pochampally, Xing, Watabe, & Miele,
2013), several studies indicated that JAG1 is functionally linked to “stemness” in cancer and
appears to be the primary ligand that drives Notch signaling in the CSC population (Patrawala, et
al., 2005; Harrison, et al., 2010).
In breast cancer, it was shown that high levels of JAG1 promote mammosphere formation
in vitro by mediating the pro-cancer effects of Notch3 (Sansone, et al., 2007a), interleukin-6 (IL6) (Sansone, et al., 2007b), carbonic anhydrase IX (CAIX) (Lock, et al., 2013) and NF-kB
(Yamamoto, et al., 2013). In a mouse model, deletion of lunatic fringe (Lfng), an Nacetylglucosamine transferase that prevents JAG1-dependent Notch activation, induced basallike breast cancer with higher JAG1 activity and enhanced the CSC proliferation (Xu, et al.,
2012). JAG1 is also involved in CSC biology in other tumor types such as glioblastoma (Zhu, et
al., 2011), lymphoma (Cao, et al., 2014), and colorectal cancer (Lu, et al., 2013). Overall, these
observations indicate that JAG1 is a vital inducer of the CSC phenotype in different types of
cancer, which suggests its targeting could suppress CSCs.
2.3.3. Epithelial-Mesenchymal Transition (EMT), Invasion, and Metastasis
Metastasis is a complex process with multiple steps that gives tumor cells the ability to
invade the surrounding tissue and to colonize distant organs; both are key features of cancer
aggressiveness. To escape their local environment, epithelial cells can exploit a reversible
developmental process called the epithelial-mesenchymal transition (EMT) (Hanahan &
Weinberg, 2011). EMT is a phenotypic switch that converts epithelial cells into motile
mesenchymal-like cells, which requires epithelial cells to undergo a spectrum of changes that
reduce their adhesion to other cells and increase their migratory process. EMT is essential during
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embryonic development and in tissue repair (Kong, Li, Wang, & Sarkar, 2011), but a large body
of evidence indicates that it contributes to the early stages of tumor metastasis. Notch signaling
has been extensively studied in this context and several reports describe JAG1 involvement in
EMT, invasion, and metastasis in breast cancer and other cancer types (Espinoza, Pochampally,
Xing, Watabe, & Miele, 2013). Leong et al. demonstrated that JAG1-induced Notch signaling in
breast cancer could inhibit the epithelial phenotype by increasing expression of EMT masterregulator SLUG, which in turn promoted tumor growth and metastasis (Leong, et al., 2007).
JAG1 was also shown to be integrated with TGFb-induced EMT in mammary gland cells
(Zavadil, Cermak, Soto-Nieves, & Böttinger, 2004). Moreover, JAG1 increases the migratory
and invasive behavior of TNBC cells through the induction of urokinase-type plasminogen
activator (µPA), a well-established marker of recurrence and metastasis (Shimizu, et al., 2011).
Lastly, JAG1 has been identified to be involved in the tissue specificity of breast cancer
dissemination, as was described to play a vital role in metastasis to the bone and brain (Sethi,
Dai, Winter, & Kang, 2011; Xing, et al., 2013).
JAG1 was also described to promote EMT in other cancer types such as 1) cervical
cancer, where JAG1 expression positively correlated with induction of PI3K-mediated EMT
(Veeraraghavalu, et al., 2005), in 2) hepatocellular carcinoma, where JAG1 was reported to
suppress the expression of tumor suppressor runt related transcription factor 3 (RUNX3)
(Tanaka, et al., 2012), and in 3) drug resistant pancreatic cancer, where JAG1-Notch2 signaling
promoted several EMT transcription factors such as Snail, Slug, and zinc-finger E-box binding
homeobox 1 (ZEB1) (Wang, et al., 2009). In prostate cancer, JAG1 was able to promote invasive
and migratory functions through the NF-kB signaling pathway (Wang, et al., 2010a). Lastly, in
colon cancer, JAG1 mediated apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) pro-
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tumorigenic functions and induced expression of metastatic markers matrix metallopeptidase 2
(MMP2) and matrix metallopeptidase 9 (MMP9) (Kim, et al., 2013; Dai, et al., 2014). As a
whole, JAG1-dependent Notch signaling appears to be implicated in various steps of EMT,
invasion, and metastasis, which was demonstrated in several tumor types and further promotes
the interest of JAG1 as a therapeutic target to inhibit tumor cell invasiveness and metastasis.
2.3.4. Proliferation, Cell Cycle Regulation, Drug Resistance, and Survival
JAG1 regulates basic cellular functions such as cell cycle progression, proliferation,
apoptosis, and cell survival. In several types of cancer, JAG1 was shown to induce tumor cell
growth and to promote cell cycle progression. For example, Cohen et al. showed that JAG1 can
directly regulate the cell cycle by identifying CCND1 as a direct target of JAG1-dependent
Notch activation in breast cancer cells (Cohen, et al., 2010). The same observation was also
demonstrated in colon cancer where JAG1-dependent Notch signaling induced the expression of
CCND1, cyclin E (CCNE), and c-myc (Dai, et al., 2014). In prostate cancer, JAG1 promoted
cyclin-dependent kinase 2 (CDK2) activity while repressing p27, a cell cycle suppressor (Zhang,
et al., 2006). Similar proliferative promoting functionality has also been reported in glioma
(Purow, et al., 2005), myeloma (Jundt, et al., 2004), and ovarian cancer (Choi, et al., 2008; Steg,
et al., 2011). Knowing the role of JAG1 in cell proliferation, it is not surprising that JAG1 is
indicated as the Notch ligand that exerts anti-apoptotic functions. Evidence for the anti-apoptotic
functions of JAG1 was produced by Wang et al. who demonstrated that JAG1 suppressed
apoptosis by activating serine-threonine protein kinase (Akt), mechanistic target of rapamycin
(mTOR), and NF-kB signaling pathways in glioma cells and by upregulating Bcl-2 (Wang, et al.,
2010a). In regard to drug resistance, JAG1 prevented chemotherapy-induced apoptosis in
lymphoma with respect to doxorubicin (Cao, et al., 2014), taxanes with ovarian cancer (Steg, et
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al., 2011), breast cancer with tamoxifen (Simões, et al., 2015), and pancreatic cancer with
gemcitabine (Wang, et al., 2009). The chemo-protective effects of JAG1 represent a key finding
as it highlights the opportunity to treat drug resistant cancers via combination therapy that
includes inhibition of JAG1-dependent Notch signaling through the potential use of monoclonal
antibodies or small molecules.
2.3.5. T-cell Regulation
The tumor microenvironment is a vital component for cancer growth and survival. There
is a plethora of immune cells that are found within close proximity of tumors that include Tcells, DCs, macrophages and neutrophils. However, there are very few natural killer cells
present, which are extremely effective in killing tumor cells (Whiteside, 2008). It is important to
note that in many cancer types, there is an increased concentration of T-regulatory (Treg) cells
that can suppress immune responses that are tumor-specific, which in turn allows tumor cells to
evade tumor surveillance (Strauss, et al., 2007). Treg cells in combination with myeloid-derived
suppressor cells and cytokines help foster and maintain a favorable immunosuppressive tumor
microenvironment that supports tumor growth (Whiteside, 2008).
JAG1-induced Notch activation plays an important role in the induction and expansion of
Treg cells in the tumor microenvironment, which involves cross-talk between tumor cells and
DCs. JAG1-Notch3 signaling has been identified to stimulate tumor necrosis factor superfamily
receptor 4 (OX40L) in order to initiate Treg cell induction and expansion (Gopisetty, et al.,
2013), while JAG1 expression in antigen presenting cells induces antigen-specific Treg cells.
Furthermore, the maturation of DCs via JAG1 is what promotes the survival and proliferation of
Treg cells (Bugeon, Gardner, Rose, Gentle, & Dallman, 2008). JAG1-induced Notch activation
may also have an impact on CD46 T-cell activation, which was demonstrated by Le Friec et al.
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by identifying a new interaction between JAG1 and CD46 (Le Friec, et al., 2012). CD46 is a
ubiquitously expressed human type I transmembrane glycoprotein that is currently identified as a
complement regulatory protein and cell-entry receptor (Le Friec, et al., 2012). The activation of
CD46 on CD4+ T-cells was shown to regulate the expression of Notch as well as its ligands.
Furthermore, JAG1 was identified as an additional physiological ligand for CD46, as the JAG1
binding site of CD46 overlaps with that of Notch receptors. Therefore, targeting JAG1dependent Notch signaling may promote the eradication of tumor cells by augmenting the effects
of cancer chemotherapeutics and by bolstering the capability of the immune system to destroy
cancer cells.
2.3.6. A Synopsis of JAG1-Notch Signaling in Breast Cancer
To date, there are multiple lines of evidence that establish Notch signaling in the
involvement of breast cancer development, maintenance and metastasis (Takebe, Nguyen, &
Yang, 2014). Over expression of Notch1, Notch3, and Notch4-activated ICDs caused aggressive
and metastatic mammary tumors in mice (Kofler, et al., 2011; Simões, et al., 2015), while active
forms of Notch1 and Notch4 receptors induce transformation of both normal human and murine
mammary epithelial cells (Leong, et al., 2007). Additionally, loss of Numb, a negative regulator
of Notch signaling, is found to be associated with higher grade and poorer prognosis in breast
cancer (Chen, et al., 2016), while suppression of Notch activity via Notch3 and CSL knockdown
promotes cancer cell apoptosis and inhibits tumor cell growth (Liu, Kennard, & Lilly, 2009).
It is important to note that unlike in T-cell acute lymphoblastic leukemia (T-ALL), which
normally stems from Notch1 gene mutations (Vlierberghe & Ferrando, 2012), the induction of
Notch signaling in breast cancer, as well as others, is mainly associated with ligand-dependent
methods of activation. Studies currently indicate that JAG1 is the most prominent ligand

51

involved in excessive activation of Notch signaling in breast cancer as both messenger RNA
(mRNA) and protein are over expressed in breast cancer and these higher expressions are
established indicators of poor prognosis (Dickson, et al., 2007; Reedijk, et al., 2005; Buckley, et
al., 2013). Therefore, it is critical to identify methods and or natural cellular mechanisms that
inhibit or reduce JAG1 expression as a means for the treatment and prevention of various
cancers.

52

CHAPTER 3
THE ARYL HYDROCARBON RECEPTOR (AHR): A MULTI-FACETED
TRANSCRIPTION FACTOR
3.1. A Brief History and Introduction to AHR Biology
During the Vietnam War, US and allied military sprayed approximately 77 million liters
of tactical herbicide (Yi & Ohrr, 2014). Agent Orange was the most commonly used agent and
was contaminated with 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). In animals, TCDD is a
lipophilic environmental toxicant that acts as a potent multisite carcinogen and has been shown
to disrupt multiple endocrine pathways (Vanden Heuvel & Lucier, 1993; Sycheva, et al., 2016;
Rappe, 1990). Later, it was discovered that TCDD binds its cognate cytoplasmic ligand-activated
transcription factor, the aryl hydrocarbon receptor (AHR). TCDD is very stable and highly
selective for the AHR, making it the ideal ligand for discovering AHR-regulated genes and
pathways. To date, most TCDD effects have been reported to be mediated via the AHR and
changes in gene expression. Although TCDD is best known for inducing developmental and
immune toxicity, there are many reports showing that it also modulates several cancer processes
(Warner, et al., 2011) including cell invasion (Hall, et al., 2010), movement (Zhang, et al., 2012),
and proliferation (Zhang, et al., 2009).
Since the Vietnam War and over the past 50 years, there have been advances in
understanding the role of the AHR in both cancerous and normal tissue. The industrial revolution
during the twentieth century promoted extremely rapid growth in the mass production of various
plastic and metal materials. As a result, increased chemical waste production led to increased risk
of exposure to potentially hazardous environmental pollutants/toxicants. Chemical spills and
accidental exposure to polycyclic halogenated aromatic hydrocarbons (PHAHs) or polycyclic
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aromatic hydrocarbons (PAHs) have unveiled a wide array of detrimental health effects, which
has been and is continuing to be extensively studied by researchers (Zack & Suskind, 1980;
Collins, Bodner, Aylward, Wilken, & Bodnar, 2009). In 1949, one of the earliest PAH/PHAH
chemical spills occurred in Nitro WV, about 40 miles from Marshall University, and industrial
workers that manufactured Agent Orange were exposed to the AHR agonist TCDD. Aside from
being a carcinogen, exposure to TCDD resulted in chloracne, liver disease, ischemic heart
disease, and even death in some workers (Collins, Bodner, Aylward, Wilken, & Bodnar, 2009).
However, the exact mechanism by which TCDD causes toxicity in humans is still unclear.
The discovery of benzpyrene hydroxylase was a result of some of the earliest research
with PAHs (Conney, Miller, & Miller, 1957). Benzpyrene hydroxylase was an enzyme named
due to its ability to form hydroxylated products of 3,4-benzpyrene, but it was quickly renamed
aryl hydrocarbon hydroxylase (AHH) because several PAHs induced its activity (Nebert &
Bausserman, 1971; Gielen & Nebert, 1971). During the 1970s, there were numerous studies
showing that there was a direct correlation between activated AHH and increased cytochrome
P450, family 1 subfamily A member 1 (CYP1A1) activity; and that this response varied between
different mouse strains, specifically C57BL/6 and DBA/2 mice (Nebert & Bausserman, 1970). 3Methylcholanthrene (3-MC) was able to stimulate increases in AHH activity in C57BL/6 mice
more effectively than DBA/2 mice. Researchers wondered whether diminished AHH activity in
DBA/2 mice in response to 3-MC was due to these mice having a genetic defect, or whether they
express a PAH/PHAH receptor with reduced binding affinity (Poland, Glover, Robinson, &
Nebert, 1974). Researchers used radioactive TCDD to discover that it accumulated highly in the
liver of C57BL/6 mice, where it bound a receptor leading to induction of AHH activity (Poland,
Glover, & Kende, 1976). In DBA/2 mice, the levels of radio-labeled TCDD in liver extracts were
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much lower, supporting the previous theory that they express a receptor with reduced binding
affinity. These radioactive TCDD experiments allowed the Nebert lab to dub this newly
identified receptor, the AHR (Okey, et al., 1979). During this time, it was also determined that
the AHH and CYP1A1 were one and the same; CYP1A1 will be used henceforth to refer to this
important enzyme (Okey, 2007).
The Bradfield group validated the hypothesis that DBA/2 mice expressed an altered AHR
that was proposed in the 1970s when they cloned the AHR in 1992. These studies revealed that
reduced AHR ligand affinity was due to an altered AHR ligand binding domain in DBA/2 mice
(Burbach, Poland, & Bradfield, 1992). When the AHR coding sequences from the DBA/2 and
C57BL/6 were compared, two critical alterations were noted: 1) the AHR had undergone a
substitution (valine instead of alanine) at position 375 and 2) a T to C mutation in the stop codon
was observed in the DBA/2 mouse strain (Ema, et al., 1994). The mutated stop codon causes a
lengthening of the carboxy-terminus in the mature AHR protein in DBA/2 mice resulting in a
ligand-binding domain with lowered ligand binding affinity (Ema, et al., 1994). The major
advances in AHR biology, after these initial findings were discovered, was made possible by
uncovering the canonical AHR signaling pathway and will be discussed in the next section.
3.2. The Canonical AHR Signaling Pathway
When the AHR is activated by a ligand such as TCDD, it becomes a transcription factor
by moving into the nucleus to regulate the expression of various genes (Figure 11). In the
cytoplasm, the inactive AHR is bound with two HSP90 proteins (Chen, Singh, & Perdew, 1997)
(Figure 11). These HSP90 proteins function as chaperones to prevent degradation of the AHR as
well as for steroid hormone receptors (Pratt & Toft, 1997) (Figure 11). The inactivated AHR
complex also contains a third protein, which was identified as hepatitis B Virus X-associated
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Figure 11. The Canonical AHR Signaling Pathway
Ligands diffuse through the cellular membrane and bind to the cytosolic AHR complex, which in
turn exposes the NLS. The activated AHR complex is then translocated into the nucleus where
the ARNT displaces chaperone proteins and binds the AHR, resulting in AHR-ARNT dimers
that bind to and activate transcription from gene promoters that contain DREs such as various
CYP450s. Activation of CYP450s can result in metabolism of exogenous and endogenous AHR
ligands. The AHRR lacks a transactivation domain and exerts negative-feedback regulation on
the AHR pathway through its competition for ARNT proteins and formation of inactive AHRRARNT transcriptional complexes on DREs. Following transcription, AHR is exported and
degraded by the proteasome in the cytoplasm. NLS = Nuclear Localization Sequence, AHRR =
Aryl Hydrocarbon Receptor Repressor, AHR = Aryl Hydrocarbon Receptor, XAP2 = Hepatitis B
Virus X-associated Protein 2, HSP90 = Heat-shock Protein 90, ARNT = Aryl Hydrocarbon
Receptor Nuclear Translocator, DRE = Dioxin Response Element, OH = hydroxyl group,
CYP450s = Cytochrome P450s. Red Arrows = Post-activation.
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protein 2 (XAP2) (Carver & Bradfield, 1997; Meyer, Pray-Grant, Vanden Heuvel, & Perdew,
1998). However, the function of XAP2 has not been determined. Later research showed that p23
was also part of the inactive AHR complex in the cytoplasm, and it was identified to help
maintain AHR stability (Figure 11). This inactive AHR complex serves to keep the AHR from
entering the nucleus by concealing the AHR nuclear localization sequence (NLS) in the absence
of ligand (Petrulis, Hord, & Perdew, 2000; Kazlauskas, Poellinger, & Pongratz, 1999; Petrulis,
Kusnadi, Ramadoss, Hollingshead, & Perdew, 2003). Once TCDD binds to the AHR, a
conformational change occurs in the complex that exposes the NLS of the AHR and translocates
the activated complex into the nucleus (Jain, Dolwick, Schmidt, & Bradfield, 1994) (Figure 11).
Once the complex enters the nucleus, XAP2 and p23 are released and the AHR binds to the
ARNT with its bHLH motif (Rowlands, McEwan, & Gustafsson, 1996) (Figure 11). As a result,
the ARNT keeps the AHR in the nucleus and induces the release of the HSP90 chaperones,
leading to the activation of gene expression via the TCDD-AHR-ARNT complex (Figure 11).
Canonical AHR signaling stimulates the expression of genes involved in phase I and
phase II drug metabolism, such as CYP1A1 and cytochrome P450, family 1 subfamily B
member 1 (CYP1B1) (Korashy, Abuohashish, & Maayah, 2013). In the liver, these
monooxygenase enzymes are important for “first pass” metabolism where a large portion of
drugs and xenobiotics are bio-transformed via hydroxylation in order to aid in the excretion and
elimination of various compounds by increasing their solubility in water (Meyer, 1996).
Cytochrome P450s 1A1 and 1B1 have been highly associated with cancer. CYP1A1 has been
shown to regulate breast cancer proliferation and survival as well as initiate cancer growth by
converting toxicants such as benzo[a]pyrene (B[α]P) into genotoxic agents (Rodriguez & Potter,
2013; Schwarz, Kisselev, Cascorbi, Schunck, & Roots, 2001). Silencing of CYP1A1 resulted in
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decreased colony formation, proliferation, and CCND1 levels as well as inducing cell cycle
arrest and apoptosis in human breast cancer cells (Rodriguez & Potter, 2013). CYP1B1 has been
coined as a “universal tumor marker” due to its over-expression in many tumor types, including
lung, breast, and colorectal tumors (Murray, et al., 1997). CYP1B1 has been shown to convert
estrogen into genotoxic metabolites like 4-hydroxyestradiol to initiate tumor formation.
Glutathione-S-transferases (GSTs) are phase II enzymes whose expression is also induced by
TCDD via AHR activation (Li, Seidel, Pritchard, Wolf, & Friedberg, 2000; Schrenk, Stüven,
Gohl, Viebahn, & Bock, 1995). GSTs aid in the detoxification of xenobiotics by catalyzing the
conjugation with GSH (Ketterer, Coles, & Meyer, 1983). Specific polymorphisms in the genes
that encode the GST enzyme superfamily have been reported to be linked with resistance to
chemotherapy in tumors (McIlwain, Townsend, & Tew, 2006).
The AHR and ARNT target genes possess a unique sequence in a specific region of DNA
called dioxin response elements (DREs). The specific consensus DNA sequence for the TCDDAHR binding complex (5’-TGCGTGA-3’) was first identified in the CYP1A1 gene promoter,
which lies upstream and proximal to the transcription start site (TSS). The function of the DREs
is to confer transcriptional activation to TCDD-AHR target genes upon binding TCDDstimulated AHR-ARNT complexes (Denison, Fisher, & Whitlock, 1988). In addition to AHRARNT, TCDD also stimulates the recruitment of transcriptional cofactors to DREs in TCDDAHR target genes including acetyltransferase p300 (Beischlag, Luis Morales, Hollingshead, &
Perdew, 2008; Beischlag, et al., 2002), CBP (Bedford & Brindle, 2012), nuclear receptor coactivator 1 (NCOA-1) (Spencer, et al., 1997) and brahma-related gene 1 (BRG1) (Trotter &
Archer, 2008). These transcriptional cofactors stimulate gene expression by promoting histone
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acetylation and inducing chromatin to assume a confirmation that is more conducive to active
transcription (Spencer, et al., 1997).
The discovery of DREs was a landmark moment in AHR biology and gave way for the
identification of other genes regulated by TCDD, such as ATP binding cassette sub-family G
member 2 (ABCG2) (Tan, et al., 2010) and aldehyde dehydrogenase 1, family member A3
(ALDH1A3) (Marcato, et al., 2011; Contador-Troca, et al., 2015). The transporter ABCG2
promotes the efflux of drugs from tumor cells while ALDH1A3 is overexpressed in BCSCs and
has been identified as a prognostic marker (Marcato, et al., 2011). The transcriptional regulation
of CYP1A1 (Rodriguez & Potter, 2013), CYP1B1 (Murray, et al., 1997), ABCG2 (Tan, et al.,
2010), ALDH1A3 (Marcato, et al., 2011) has been shown to play roles in several different types
of cancer, indicating that a better understanding of AHR signaling could provide new insights
into the modulation of several cancers including breast cancer. One of the objectives in this
dissertation was to use genome-wide RNA-sequencing (RNA-seq) analysis to identify novel
TCDD-AHR regulated genes that could play important roles in the regulation of breast cancer
progression. My findings revealed that stimulating human MCF7 breast cancer cells with TCDD
for 6 hours induced changes in the expression of 660 genes including: CYP1A1, CYP1B1,
ABCG2 and ALDH1A3. This novel result indicates that TCDD-AHR signaling may modulate
breast cancer initiation and progression by inducing changes in the expression of a large set of
genes that regulate various cancer processes. Indeed, my RNA-seq results provided the impetus
to investigate a novel hypothesis in this dissertation by which TCDD-AHR signaling modulates
breast cancer progression by regulating the JAG1-Notch1 pathway. As detailed in chapters 1 and
2, the JAG1-Notch signaling pathway is an embryonic pathway that also promotes breast cancer
progression.

59

3.3. Non-canonical AHR Signaling
Although the canonical AHR signaling pathway is important, AHR activation can also
alter gene expression by cross-talking with other important transcription factors. The AHR has
also been shown to cross-talk with the ER (Matthews & Gustafsson, 2006), NF-kB (Denison,
Soshilov, He, DeGroot, & Zhao, 2011; Vogel, et al., 2014), and HIF-1a (Vorrink & Domann,
2014) to modulate estrogen, inflammatory and hypoxia signaling, respectively.
There are various ways that the AHR can cross-talk with transcription factors, but the
interaction between the AHR and ER has been the most extensively studied (Figure 12).
Experiments studying long-term TCDD exposure in female Sprague Dawley rats were the first to
suggest that the AHR and ER signaling pathways cross-talk, because it was identified that TCDD
inhibited the growth of estrogen responsive mammary and uterine tumors (Kociba, et al., 1978).
Other reports have shown that TCDD inhibited estrogen-stimulated increases in the expression of
ER target genes (Safe & Wormke, 2003). There are several mechanisms by which TCDD-AHR
signaling influences estrogen signaling (Figure 12). The first mechanism is mediated by
CYP1A1-induced metabolism of estrogen upon exposure to TCDD. As noted earlier, CYP1A1
reduces estrogen by promoting its metabolism (Spink, et al., 1992) (Figure 12). Other recent
findings have identified that TCDD-activated AHR signaling stimulates increases in ER
ubiquitination and degradation (Wormke, et al., 2003) as well as inhibits estrogen-stimulated
gene expression by binding to inhibitory DREs (iDREs) in the promoter regions of ER target
genes (Krishnan, Porter, Santostefano, Wang, & Safe, 1995) (Figure 12). Because the AHR and
ER share common transcriptional co-activators, they have been reported to compete for a limited
pool of transcriptional co-activators, which can lead to reductions in ER transcriptional activity
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Figure 12. Mechanisms of AHR-ER Crosstalk
(A) AHR activation upregulates CYP450 expression and promotes estrogen metabolism. (B)
Activation of AHR squelches co-activator proteins preventing them from binding with ER
transcriptional complexes. (C) Activated AHR-ARNT complexes can bind to iDREs in ER target
genes to silence expression. (D) The AHR targets ER for proteasomal degradation. ER =
Estrogen Receptor, AHR = Aryl Hydrocarbon Receptor, ARNT = Aryl Hydrocarbon Receptor
Nuclear Translocator, DRE = Dioxin Response Element, ERE = Estrogen Response Element,
iDRE = Inhibitory Dioxin Response Element, HSP90 = Heat Shock Protein 90, XAP2 =
Hepatitis B Virus X-associated Protein 2.
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(Brunnberg, et al., 2003) (Figure 12). TCDD has also been reported to mimic estrogen signaling
by promoting the recruitment of unliganded ER to the estrogen response element (ERE) in ER
target genes (Brunnberg, et al., 2003).
TCDD has also been reported to crosstalk with the NF-kB pathway (Tian, 2009;
Beischlag, Luis Morales, Hollingshead, & Perdew, 2008; Kim, et al., 2000; Salisbury & Sulentic,
2015). The NF-kB canonical pathway is induced by pro-inflammatory cytokines, IL-6 and TNFa
(Yamamoto, et al., 2013; Hayden & Ghosh, 2008; Kolasa, Houlbert, Balaguer, & Fardel, 2013)
(Figure 13). IL-6, by activating its cognate receptor, induces the phosphorylation of inhibitor of
NF-kB (IκB) by the inhibitor of NF-kB kinase (IκBK) complex, leading to its ubiquitination and
subsequent degradation by the 26S proteasome (Hayden & Ghosh, 2008) (Figure 13). The V-Rel
avian reticuloendotheliosis viral oncogene homolog A (RelA)-p50 complex is then free to
translocate to the nucleus to activate the transcription of target genes (Hayden & Ghosh, 2008;
Bash, et al., 1999) (Figure 13). TNFa induces a non-conical NF-kB pathway, which results in
the activation of IkB by NF-kB Inducing Kinase (NIK) (Yamamoto, et al., 2013) (Figure 13).
The formation of the NIK-IkB-p100 complex leads to the phosphorylation of the p100 subunit
(Hayden & Ghosh, 2008) (Figure 13) and results in 26S proteasome-dependent processing of
p100 to p52. The production of p52 leads to the activation of the V-Rel avian
reticuloendotheliosis viral oncogene homolog B (RelB)-p52 heterodimer that targets a distinct
NF-κB element and induces the transcription of target genes (Vogel & Matsumura, 2009) (Figure
13). The AHR crosstalks with the NF-kB pathway by binding to RelA and forms an inactivated
AHR-RelA dimer that perturbs RelA-stimulated transcription (Salisbury & Sulentic, 2015; Tian,
2009) (Figure 13). The AHR has also been reported to bind to RelB, forming an active AHRRelB heterodimer that increases the transcriptional activity of AHR-RelB response
62

Ligand

A. Canonical Signaling
IL-6

TNFα
Ub
Ub

P

P

P
IκB

Ub

Proteasomal
Degradation

Ub
Ub

HSP90

P

HSP90

AHR

S
LP

IκBK

B. Non-canonical Signaling

ic
plasm
Cyto rane
b
m
Me

XAP2
p23

P

Proteasomal
Degradation

LP
S

Ub

NIK
IκB

p100
RelB

IκB

NIK
RelA p50

AHR

p100

IκB

IκB
RelA p50

RelA p50

RelB

C. AHR-Dependent Modulation
of NFκB Signaling
p50
RelA

RelA

RelB

AHR

RelB
p50

p52

RelB

p52
AHR

p52
AHR

RelB-DRE

RelA
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A) The canonical pathway is induced by cytokines such as IL-6. The activation results in the
phosphorylation of IκB by the IκBK complex, leading to its ubiquitylation and subsequent
degradation by the 26S proteasome. The RelA-p50 complex is free to translocate to the nucleus
to activate the transcription of target genes. B) The non-canonical pathway results in the
activation of IκBK by the NIK after stimulation by cytokines. The formation of the NIK-IκBp100 complex leads to the phosphorylation of the p100 subunit and results in 26S proteasome
dependent processing of p100 to p52 and leads to the activation of the RelB-p52 complex that
target distinct NF-κB elements and induce the transcription of target genes. C) Direct protein
binding between the AHR and RelA was proposed to induce repressive effects that are mediated
by formation of transcriptionally inactive AHR-RelA heterodimers that also reduced the
concentration of available nuclear AHR and RelA necessary for normal AHR- and NF-κBmediated gene expression. In contrast to RelA, direct interactions between the TCDD-activated
AHR and RelB also occur and were reported to produce an active AhR-RelB heterodimer
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Interleukin-6, LPS = Lipopolysaccharide, p = phosphate group.
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elements in specific pro-inflammatory genes such as interleukin 8 (IL-8) (Vogel & Matsumura,
2009; Vogel, et al., 2014; Vogel, et al., 2007) (Figure 13).
The AHR has also been seen to cross-talk with HIF-1a (Vorrink & Domann, 2014)
(Figure 14). Oxygen is essential for aerobic organisms and is an important component of many
cellular processes such as aerobic metabolism and energy homeostasis (Majmundar, Wong, &
Simon, 2010). The amount of available oxygen in tissues can become reduced under certain
physiological conditions or disease states. The key players that regulate the adaptive responses to
hypoxia are the hypoxia-inducible factors. HIF-1a, one of the main regulators of the hypoxic
response, is a transcription factor that also requires the ARNT protein as a dimerization partner
(Kewley, Whitelaw, & Chapman-Smith, 2004). Under normal oxygen (normoxic) conditions,
HIF-1a undergoes hydroxylation via prolyl hydroxylase domain (PHD) proteins and then
subsequently ubiquinated by the von Hippel-Lindau tumor suppressor gene product (pVHL)
before undergoing proteasomal degradation (Déry, Michaud, & Richard, 2005; Ohh, et al., 2000)
(Figure 14). However, hypoxic conditions stabilize HIF-1a, and this transcription factor induces
gene expression by forming a heterodimer with the ARNT (Kewley, Whitelaw, & ChapmanSmith, 2004) (Figure 14). In cancer, the activation of HIF-1a-ARNT signaling can maintain and
promote the self-renewal capacity of GSCs by promoting the Notch signaling pathway (Qiang, et
al., 2012). The high binding-affinity of the ligand-activated AHR to ARNT proteins compete
against HIF-1α for a limited pool of ARNT proteins and other co-activators, which in turn can
negatively impact the activity of HIF-1a (Vorrink & Domann, 2014) (Figure 14).
3.4. TCDD-induced Negative-feedback Loops that Limit AHR Signaling
There are two TCDD-induced negative-feedback loops that limit AHR signaling (Figure
15). Soon after its induction by TCDD, the AHR is ubiquitinated and then degraded by the
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Normoxic conditions lead to HIF-1α hydroxylation and degradation. HIF-1α proteins are
hydroxylated by PHD proteins, ubiquinated by pVHL and ultimately degraded via the
proteasome. In contrast, hypoxic environments cause HIF-1α stabilization and translocation to
the nucleus. In the nucleus, HIF-1α binds to the ARNT to induce transcription of HREcontaining genes. The AHR is quiescent in the cytoplasm until ligand binding occurs, which
initiates translocation to the nucleus. In the nucleus, the AHR binds to the ARNT to induce
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proteasome (Ma & Baldwin, 2000) (Figure 15). The proteins that mediate the ubiquitination of
TCDD-induced AHR include: cullin 4B (CUL4B), ring box 1 (RBX1) and damaged DNA
binding protein 1 (DDB1), which are recruited by AHR in response to TCDD (Morales &
Perdew, 2007) (Figure 15). Interestingly, TCDD-induced AHR also promotes the ubiquitination
of the ER and the AR, which in part explains how TCDD inhibits estrogen and androgen
signaling (Ohtake, Fujii-Kuriyama, & Kato, 2009) (Figure 15). The second TCDD-induced
negative-feedback loop that limits AHR signaling involves the AHR repressor (AHRR) (Figure
15).
The AHRR and AHR contain a bHLH motif and, therefore, AHRR proteins can bind to
ARNT proteins (Evans, et al., 2008) (Figure 15). TCDD induces the transcription and expression
of the AHRR, which in turn removes ARNT proteins from the AHR and suppresses AHR
activity (Mimura, Ema, Sogawa, & Fujii-Kuriyama, 1999) (Figure 15). However, other reports
suggest that AHRR binds directly to DREs in AHR target genes, which also inhibits AHR
activity (Hahn, Allan, & Sherr, 2009) (Figure 15). Thus, the primary mechanism by which
TCDD-induced AHRR exerts its negative feedback inhibition on AHR signaling is still not clear;
however, it is clear that AHRR suppresses TCDD-induced AHR signaling.
3.5. Physiological Roles of AHR: Immunity, Development, and Reproduction
For reasons detailed in the previous paragraphs, the historical role of AHR has been
linked with TCDD and TCDD-induced toxicity. However, the development of AHR-null mice
during the 1990s showed that the AHR has significant activity in mice not treated with TCDD.
Indeed, AHR-null mice exhibited defects in immunity, proper organ development, and
reproduction. For instance, AHR-null mice showed decreased lymphocyte accumulation in the
spleen and lymph nodes compared to wild-type mice, but not the thymus (Fernandez-Salguero,
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Hilbert, Rudikoff, Ward, & Gonzalez, 1996; Schmidt, Su, Reddy, Simon, & Bradfield, 1996;
Andreola, et al., 1997). This suggested that AHR signaling has a role in innate immunity. Further
investigation into the role of the AHR in immunity has identified that different AHR ligands
have different effects on T-cells. For instance, TCDD and the endogenous AHR ligand
kynurenine promote the activity and differentiation of T-cells into Treg cells, which in turn
suppresses immune responses and favors the growth of tumors (Mezrich, et al., 2010; Quintana,
et al., 2008). However, the endogenous AHR ligand 6-formylindolo [3,2-b] carbazole (FICZ)
stimulates the differentiation of naïve T-cells into pro-inflammatory T-helper 17 (Th17) cells and
this exacerbates immune responses (Veldhoen, et al., 2008). Some dietary AHR ligands such as
indolo [3,2-b] carbazole (ICZ) and 3,3-diindolylmethane (DIM) have also been shown to play a
role in the immune response (Veldhoen & Brucklacher-Waldert, 2012). Indole-3-carbinol (I3C)
is a dietary AHR ligand that comes from cruciferous vegetables and is converted by stomach
acid to the products ICZ and DIM, which then act as high affinity AHR ligands in the gut. As a
result, ICZ- and DIM-activated AHR helps maintain gut microflora, intraepithelial lymphocytes,
interleukin-22 (IL-22) expression and Th17 cell activity (Veldhoen & Brucklacher-Waldert,
2012). These studies and observations allowed researchers to establish that there are AHRdependent roles in developmental and functional immunity.
The liver expresses the highest levels of the AHR compared with all other tissues
(Dolwick, Schmidt, Carver, Swanson, & Bradfield, 1993). The liver of AHR-null mice is smaller
and exhibits thickening, and fibrosis of the portal vein compared with wild-type mice, suggesting
that proper liver development is AHR-dependent (Schmidt, Su, Reddy, Simon, & Bradfield,
1996). Further work has fostered a hypothesis by which the observed diminished liver growth in
AHR-null mice is attributed to significant inflammatory changes in the bile ducts (cholangitis)
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compared to wild-type mice (Fernandez-Salguero, et al., 1995). Although the activation of the
AHR by endogenous ligands is important for proper development of the liver, its activation by
TCDD causes developmental and endocrine toxicity. For instance, TCDD dramatically reduced
ovarian follicle number and size in female Holtzman rats, which provided a mechanism that
explains why TCDD reduces fecundity in female rats (Heimler, Trewin, Chaffin, Rawlins, &
Hutz, 1998). In a rodent model, other teratogenic effects include blocked ovulation (Li, Johnson,
& Rozman, 1995), atypical release of FSH and LH (Li, Johnson, & Rozman, 1997) as well as
development of cleft palate and kidney deficiencies in offspring (Mimura, et al., 1997). Work
comparing wild-type mice with AHR-null mice has confirmed that TCDD-induced toxicity is
mediated through AHR signaling. Mouse studies have revealed that AHR has a role in mammary
development and function, including pregnancy-associated changes in the mouse mammary
gland and in utero mammary gland development. More specifically, AHR-null mice exhibit
improper mammary development compared to wild-type mice, including reductions in mammary
gland size and less mammary gland terminal end buds, which are the proliferative structures
found at the tips of ducts (Mimura, et al., 1997). This result suggests that normal development
and proliferation in the mammary gland could be dependent on endogenous AHR ligands.
3.6. AHR Signaling and Cancer
There have been numerous reports linking AHR signaling to cancer biology and a high
degree of complexity has emerged with pro-tumorigenic and anti-tumorigenic activities of the
AHR in studies using cell culture and in vivo models of malignancy (Murray, Patterson, &
Perdew, 2014). Whether the AHR promotes or inhibits the initiation or progression of cancer is
dependent on the ligand it binds. Consequently, there are tumor promoting AHR ligands as well
as tumor suppressive AHR ligands. The activity of these ligands are also cancer specific. The
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AHR modulates these tumor-promoting and -suppressing pathways in different cancer types and
this seemingly indecisive role of AHR in cancer has been attributed to 1) differences in cancer
models, 2) species differences, 3) different AHR ligands having different (and opposite) effects
in cancer and 4) that AHR exhibits promiscuous binding with multiple ligands that have different
chemical structures (Denison, Soshilov, He, DeGroot, & Zhao, 2011). The importance of
defining whether the AHR is tumor promoting or tumor suppressing in each cancer type has
important implications for drug development, because AHR antagonism may work well for some
cancers, and AHR agonism may work better for other cancers. The following section will
provide a balanced discussion of the tumor-promoting and -suppressing roles for the AHR in
cancer. Although the AHR has been proposed to bind hundreds of ligands, I will focus my
discussion on the best characterized AHR ligands in cancer, which are shown in Table 3 and 4.
There are multiple cases and studies identifying AHR signaling promotes tumorigenic
activity. Overexpression of the AHR and constitutively active AHR signaling is common in
breast and prostate cancer, as well as other cancers (Shin, Sánchez-Velar, Sherr, & Sonenshein,
2006; Kolluri, Jin, & Safe, 2017; Schlezinger, et al., 2006). Moreover, the AHRR has also been
identified as a tumor suppressor (Zudaire, et al., 2008). Overexpression of the AHR in normal
human mammary cells induces malignant traits such as increased EMT (Barretina, et al., 2012;
Brooks & Eltom, 2011), a cellular process where cells lose adhesion to each other in preparation
to invade and or migrate. Endogenous AHR ligands that are products of tryptophan metabolism
such as kynurenine and kynurenic acid have also been identified to promote tumor survival by
suppressing the immune response through autocrine and paracrine mechanisms (Opitz, et al.,
2011; DiNatale, et al., 2010; D’Amato, et al., 2015). CYP1B1, a known AHR gene target, has
also been identified to be highly expressed in metastatic tumors compared to healthy tissue and
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AHR Agonists that Possess Anti-cancer Effects
Source

AHR Agonists

Cell Lines that Exhibited
Anti-Cancer Effects
•
•
•

LNCaP
MCF7
SKBR3

•

•
•
•

Panc-1
MiaPaCa2
MCF7

• MDA-MB-231

•
•
•

Panc-1
MiaPaCa2
MCF7

•

MDA-MB231

Flavonoids:
•
Quercetin

•
•

MCF7
HL60

•

CCRF-CEM

•
Kaempferol
Indoles:

•
•

MCF7
PaCa-2

•

Panc-1

•

Indole-3-carbinol (I3C)

•
•

MCF7
MDA-MB-231

• MDA-MB-468

3,3’-Diindoylmethane (DIM)

•
•

MCF7
MDA-MB-231

•
•

•
•
•

HCCLM3
OVVAR-3
SKOV-3

• HepG2
• LNCaP
• U87

Polycyclic Halogenated Aromatic Hydrocarbons
(PHAHs):
•
Xenobiotic

Pharmaceuticals:
•

•

Dietary

•
Endogenous

TCDD

Tranilast

Omeprazole

Tryptophan Metabolites:
•
2-(1’H-indole-3’-carbonyl)-thiazole-4carboxylic acid methylester (ITE)

Table 3. AHR Agonists that Possess Anti-cancer Effects
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•
•

MDA-MB231
BT474
T47D

SKBR3
T47D

Molecular Structures of AHR agonists that Promote Anti-cancer Effects
AHR Agonist

Molecular Structure

TCDD

Tranilast

Omeprazole

Quercetin

Kaempferol

Indole-3-carbinol

3,3’-Diindolylmethane

2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid
methylester (ITE)

Table 4. The Molecular Structures of AHR Agonists that Promote Anti-cancer Effects
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has been identified as a metastatic marker in lung, colon, prostate, and breast cancer (Murray, et
al., 1997; Murray, Melvin, Greenlee, & Burke, 2001). Elevated CYP1B1 levels promote the
synthesis of the genotoxic metabolite 4-hydroxyestradiol and increases chemo-resistance by
metabolizing certain chemotherapy agents into inactive metabolites (Li, Seidel, Pritchard, Wolf,
& Friedberg, 2000).
TCDD is considered as both a complete epigenetic carcinogen and a potent tumor
promoter through sustained AHR activation (Safe, 1990; Poland & Knutson, 1982). However,
whether TCDD is a tumor promoter or a tumor suppressor is dependent on the cancer. For
instance, TCDD inhibits the proliferation of ER-positive breast cancer cells, because it inhibits
estrogen signaling (Hanieh, 2015; Wang, Wyrick, Meadows, Wills, & Vorderstrasse, 2011).
TCDD has also been reported to inhibit the proliferative, migratory and invasive activity of
breast cancer cells that are of the TNBC subtype (Zhang, et al., 2009; Hall, et al., 2010). The
application of TCDD to TNBC cells induced decreases in the expression of sex-determining
region Y (SRY)-box 4 (SOX4), which is a transcription factor that promotes metastatic behavior
of breast cancer cells (Hanieh, 2015). TCDD suppressed the expression of SOX4 by inducing the
expression of the microRNA-212/132 cluster, which directly targets SOX4 (Hanieh, 2015).
Although TCDD is too toxic to be used for cancer treatments, finding that TCDD inhibits the
aggressiveness of TNBC cells suggests that increasing the activity of AHR with a non-toxic
AHR ligand could be a new way to treat this disease.
With regard to non-toxic AHR ligands (Tables 3 and 4), dosing rodents with the dietary
AHR ligand I3C inhibited the growth of mammary (Wu, et al., 2010; Tin, Park, Sundar, &
Firestone, 2014) and cervical (Qi, Anderson, Chen, Sun, & Auborn, 2005) tumor xenografts
without causing toxicity. In addition to mammary and cervical cancer, I3C has also been reported
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to suppress prostate cancer progression in vivo (rodent models) by promoting cell cycle arrest
and increasing apoptosis (Chinni & Sarkar, 2002). The search for endogenous AHR ligands led
to the purification and characterization of an endogenous ligand with high affinity and
selectively for AHR, known as 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid
methylester (ITE) (Song, et al., 2002; Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). ITE
was purified from porcine lung. Recent reports indicate that ITE has anticancer activity that is
attributed to its function as an AHR ligand (Wang, et al., 2013). The application of ITE to glioma
cancer cells inhibited the expression of octamer-binding protein 4 (OCT4), which encodes a
transcription factor that plays a key role in embryonic development and stem cell pluripotency
(Cheng, et al., 2015). Upregulation of OCT4 in adult tissues promotes tumorigenesis. Therefore,
finding that ITE inhibited OCT4 provided a new insight into how this endogenous AHR ligand
inhibited the stem cell-like cancer cells in glioblastoma. Importantly, in contrast to TCDD, ITE is
not toxic when tested in rodent models (Nugent, et al., 2013). The dosing of mice with ITE,
however, suppressed the growth of glioblastoma tumor grafts in nude mice, indicating that this
endogenous AHR ligand has anti-cancer activity in vivo (Cheng, et al., 2015).
The anti-inflammatory drug tranilast functions as an AHR ligand and it has been reported
to inhibit mammary cancer in mice (Rogosnitzky, Danks, & Kardash, 2012). Interestingly,
tranilast inhibits the BCSC population in vivo and in vitro models at pharmacologically relevant
concentrations (200 micromolar (µM)) (Prud’homme, et al., 2010). Further work showed that
knockdown of AHR prevented the effects of tranilast, indicating that this anti-inflammatory drug
inhibits breast cancer by activating AHR (Prud’homme, et al., 2010). The translation of AHR
ligands for breast cancer therapy into the clinic mandates the identification of non-toxic AHR
ligands that have anti-cancer activity in vivo and a complete understanding of the pathways that
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are regulated by AHR ligands. In this regard, my work in this dissertation has identified for the
first time that the non-toxic AHR ligand ITE inhibits TNBC cell aggressiveness by reducing the
levels of JAG1 and NICD, which are known to promote breast cancer progression.
3.7. Current Problematic Observation and Overall Hypothesis
Although there are various AHR ligands that have been shown to promote various anticancer effects, the mechanism(s) by which they occur have yet to be determined or fully
characterized. As a result, the controversy of utilizing non-toxic AHR ligands as a potential
therapy along with current chemotherapy regimens is still prominent, unless a more concrete
mechanism behind the anti-cancer effects is proposed. Characterizing the mechanism that
promotes these anti-cancer effects via non-toxic AHR ligands may also shed light on specific
proteins or signaling pathways that may also be considered to be novel therapy targets for the
treatment of cancer. It is also important to note that investigating the changes in JAG1 levels in
the presence of known anti-cancer AHR ligands can provide important insight on how the
expression of JAG1 in cancer cells as well as changes in cell migration and invasion are altered
in a ligand-dependent manner in cancer cells (Hall, et al., 2010). Therefore, I hypothesize that
non-toxic AHR ligands can induce anti-cancer effects through regulating the expression of JAG1
and the Notch signaling pathway.

75

CHAPTER 4
METHODS FOR STUDYING AHR SIGNALING
4.1. Materials
The purpose of this introductory methods section is to provide a brief overview of the
methods that were used in this dissertation. MCF7 (ER-positive), T47D (ER-positive) MDAMB-231 (ER-negative) breast cancer cells were purchased from ATCC (Manassas, VA). MDAMB-157 (ER-negative) cells were generously provided by Dr. Ruth Keri (Case Western
Reserve). TCDD in dimethyl sulfoxide (DMSO) (155µM) was purchased from Cambridge
Isotopes Laboratory (Andover, MA). ER status of these cell lines were determined via western
blot. The AHR agonist ITE was purchased from Tocris Bioscience (San Diego, CA). The TCDD
antagonist CH-223191 was purchased from Sigma-Aldrich (St. Louis, MO). Non-targeting
siRNA (cat # D-001810-01-20), ON-TARGET plus human siRNA against AHR (cat # J-00499008-0010) and JAG1 (cat # J-011060-11-0005) were purchased from GE Dharmacon (Lafayette,
CO). Dulbecco’s Modified Eagle Medium (DMEM)/High glucose with L-glutamine and sodium
pyruvate, fetal bovine serum (FBS), phosphate buffer saline (PBS), penicillin/streptomycin, and
DMSO were purchased from Thermo Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate
(SDS), 30% acrylamide/bis solution, ammonium persulfate, Tween-20, b-mercaptoethanol
(BME) and polyvinylidene difluoride (PVDF) membranes were obtained from BIO-RAD
(Hercules, CA).
4.2. RNA-sequencing
RNA-sequencing (RNA-seq) analysis was based on four biological replicates in each
experimental group. For TCDD stimulation, MCF7 (ER-positive) cells were plated at 250,000
cells/milliliter (mL) on 35 millimeter (mm) cell culture plates in DMEM containing 10% FBS
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(DMEM/FBS (10%)) and were grown for 24 hours before being serum starved in phenol red-free
DMEM for 16 hours prior to treatment. Cells were then treated with TCDD (100 nanomolar
(nM)) for 6 hours. Total RNA purification kits (Qiagen, Valencia, CA) were used to extract total
RNA. RNA sample quality was assessed using Bioanalyzer RNA Nano chips (Agilent); all RNA
samples had an RNA Integrity Number (RIN) greater than or equal to 8. The RIN is an algorithm
for assigning integrity values to RNA measurements and assigns an electropherogram a value of
1 to 10, with 10 being the least degraded. RNA-seq libraries were prepared from 1 microgram
(µg) of total RNA using a TruSeq RNA Prep Kit (Illumina Inc., San Diego, CA). RNA-seq was
performed using an Illumina HiSeq1000 in a 2 x 100 base paired end design yielding a minimum
of 50 million reads per sample. Differentially expressed genes were identified at a False
Discovery Rate (FDR) of 5%. For pathway analysis, TCDD-regulated genes (TRGs) expressed
as a ratio of TCDD/DMSO were loaded into Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Redwood City, CA). The IPA Core Analysis tool was used to identify
significant associations between TRGs and pathways. We configured the core analysis to report
Benjamini-Hochberg corrected p-values.
4.3. Cell Culture and Treatments
Cell lines were maintained at 37°C with 5% carbon dioxide (CO2). Cells were grown in
DMEM/FBS (10%) and 1% pencillin/streptomyocin. Cells were plated onto 35mm tissue culture
plates in DMEM/FBS (10%) at a cell density of 250,000 cells per plate 24 hours prior to
treatment. The medium containing ITE (10µM) was reapplied to cells every 12 hours, based on
the findings of a prior report showing that ITE induces its maximal effect at 10µM, and it has to
be applied to cells every 12 hours based on its stability in cell culture (Cheng, et al., 2015;
Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). The medium containing TCDD (10nM or
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100nM) was applied once to cells, because TCDD is stable in cell culture. The AHR antagonist
CH-223191 (10µM) was applied 1 hour prior to treatment with ITE or TCDD.
4.4. Short-interfering RNA (siRNA): Gene Knockdown Experiments
Gene specific siRNA were used to knockdown the expression of specific genes to
evaluate their function. A concentration of 200,000 cells/mL in DMEM/FBS (10%) were mixed
directly with 100nM of siRNA that was either non-targeting (control), JAG1-targeting or AHRtargeting. Transfection reagent (3 microliters (µL)) (Lipofectamine RNAi Max, Life
Technologies) was then added and plated onto 35mm tissue culture plates. After 36 hours, cells
were treated with vehicle, TCDD (10nM, 24 hours), or ITE (10uM, 72 hours). Treatments were
removed, and total cellular RNA or protein was extracted with RNA-purification kits (Qiagen
RNeasy) or 2× Laemmli sample lysis buffer, respectively. In some experiments, total RNA was
isolated using TRI-reagent in accordance with protocols provided by the manufacturer (Sigma
Aldrich).
4.5. mRNA Analysis: Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted using RNA purification columns (Qiagen). Reverse
transcription was performed on 300 nanograms (ng) of RNA using cDNA synthesis kits (Applied
Biosystems (Foster City, CA)) in accordance with the suppliers’ instructions. StepOnePlus
(Applied Biosystems) was used to take quantitative polymerase chain reaction (qPCR)
measurements. Amplifications were carried out using SYBR green master mixes (Applied
Biosystems) according to the manufacturer’s protocols. Samples were run in triplicate, and the
average normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was quantitated
using the 2−ΔΔCT formula. CYP1A1 and GAPDH primers have been published (Tomblin &
Salisbury, 2014). JAG1 primers used were: forward 5′-GAGCCCGGCCTCCTTTTATT, reverse
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5′-GCGTCATTGTGTTACCTGCG.
4.6. Protein: Western Blotting
Cells were scraped in 300uL of 2x SDS sample buffer to isolate total cellular
extract. Proteins were heat denatured and then separated by SDS/polyacrylamide gel
electrophoresis (PAGE) followed by transfer to a PVDF membrane. Equal protein loading
(~15µg/sample) was confirmed by western blotting. Blots were incubated overnight at 4°C in
primary antibody followed by a 1 hour incubation in secondary antibody at room temperature.
Antibodies from Cell Signaling Technology were: JAG1 (IC4) (1:1000), AHR (D5S6H)
(1:1000), Cleaved-NICD (D3B8) (1:1000), HES1 (D6P2U) (1:1000), Snail (C15D3) (1:1000),
rabbit-HRP (1:10,000) and mouse-HRP (1:10,000). GAPDH antibody was purchased from
Millipore (Cat #MAB374). Densitometry was calculated with ImageLab PC-based software
(Biorad).
4.7. Functional Assay: Scratch Analysis
Scratch assays were conducted with MDA-MB-231 cells. Cells were first seeded into 12well plates at a concentration of 50,000 cells per well and were grown for 24 hours in
DMEM/FBS (10%) and 1% pencillin/streptomyocin. Cells were then rinsed with PBS solution
and treated with vehicle or 10µM ITE every 12 hours for 5 days in DMEM containing 1% FBS
(DMEM/FBS (1%)). After 5 days, a scratch was made in each well with a pipette tip. The media
was then aspirated to remove floating cells, then vehicle or 10µM ITE treated complete media
was reapplied. The scratches were photographed at 0 hour and at 24 hours using the Lycia
Microscope. The exposed surface area of the plates was measured using ImageJ analysis
software. Regarding ITE (10µM) treatments, cells were grown and treated in the same manner as
detailed in section 4.3, except ITE treatments, which continued for five days before the scratch
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was made; ITE treatments were reapplied every 12 hours for five days. As for JAG1 siRNA
transfections, JAG1 knockdown cells were scratched and incubated for 12 hours; cells were
photographed at 0 hours and 24 hours.
4.8. Functional Assay: Boyden Chamber
Cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) and 1%
penicillin/streptomycin for 24 hours prior to treatment. After cells were treated with vehicle or
10µM ITE in DMEM/FBS (10%) and 1% penicillin/streptomycin every 12 hours for the
indicated number of days, they were detached from tissue culture plates (using trypsin) and
counted. Cells were immediately transferred to cell invasion chambers in DMEM at a
concentration of 50,000 cells/well. Chambers filled with cells were then incubated in 24-well
tissue culture plates containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each
experiment included a negative control in which chambers filled with cells were incubated with
DMEM lacking FBS. Following the 36h incubation in the presence of DMSO vehicle or 10µM
ITE, a cotton swab removed non-adherent cells that were not invasive. Invasive cells were
stained with crystal violet for 10 minutes at room temperature and then rinsed gently with tap
water. Stained cells were then incubated in DMSO for 10 minutes with orbital shaking to extract
crystal violet. Cell lysates were measured at 560 nanometers (nm) for invasive activity. For the
indicated siRNA experiments, the cell invasion was assayed 48 hours after transfection. Boyden
cell invasion chambers were purchased from ThermoFisher Scientific.
4.9. Statistical Analysis
The Tukey’s post-hoc test was used to determine statistically significant differences
among groups following one-way analysis of variance (ANOVA). One-tailed, unpaired t-tests
with confidence intervals of 95% were used to determine statistically significant differences
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between two groups. All studies were conducted in triplicate.
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5.1. Abstract
The AHR is a ligand-activated transcription factor that binds pollutants, therapeutic
drugs, and endogenous ligands. The AHR is expressed in all breast cancer subtypes and it can
switch the aggressiveness of breast cancer cells from low to high depending on the ligand that it
binds. JAG1 is a Notch receptor ligand that is overexpressed in TNBC and promotes breast
cancer progression in part by increasing the migratory and invasive activity of TNBC cells. The
regulation of JAG1 by the AHR in ER-positive and ER-negative breast cancer cells by two AHR
ligands (TCDD and ITE) was investigated in this report in order to determine the anti-metastatic
roles of AHR activation. TCDD is the prototype AHR ligand, and ITE is a non-toxic endogenous
AHR ligand with anti-cancer activity. IPA revealed a significant association between TRGs and
cell movement. Experiments involving siRNA-directed knockdown of AHR confirmed TCDDstimulated decreases in JAG1 required AHR expression. TCDD-induced reductions in JAG1
were also inhibited by the AHR antagonist CH-223191. The non-toxic AHR ligand ITE also
reduced JAG1 by activating the AHR in breast cancer cells, as confirmed by AHR knockdown
experiments. RNA-seq findings coupled with published TCDD-stimulated AHR-chromatin
immunoprecipitation (ChIP)-sequencing (ChIP-seq) results suggest that ligand-activated AHR
reduces the expression of JAG1 by increasing the expression of HES1. HES1 is a direct AHR
target gene and is also known as a JAG1 suppressor. MDA-MB-231 cells are TNBC cells that
are highly migratory and invasive, and these cancer cell attributes were significantly inhibited by
ITE. We reduced JAG1 with targeting siRNA, and the outcome mirrored ITE by suppressing
TNBC cell migration and invasive activity. Collectively, these findings are the first showing that
ITE is a tumor-suppressing AHR ligand in TNBC cells in part because it reduces JAG1
expression.
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5.2. Introduction
The AHR mediates tumor-promoting and -suppressing pathways in different cancer types
(Safe, Lee, & Jin, 2013; Murray, Patterson, & Perdew, 2014). The seemingly indecisive role of
the AHR in cancer, sometimes tumor-promoting, other times tumor-suppressing, has been
attributed to differences in cancer models, species differences and the receptor’s promiscuous
binding with multiple ligands that have different chemical structures including: halogenated
polycyclic hydrocarbons (i.e. TCDD), polycyclic aromatic hydrocarbons (i.e. benzo[a]pyrene),
tryptophan-derived ligands (i.e. kynurenine) and indole glucosinolates (i.e. indole-3-carbinol)
(Denison, Soshilov, He, DeGroot, & Zhao, 2011; Murray, Patterson, & Perdew, 2014). The
industrial byproduct TCDD is the prototype AHR ligand, whose combined stability and
selectivity for the AHR exceeds all other AHR ligands (Denison, Soshilov, He, DeGroot, &
Zhao, 2011). Gene expression changes induced by TCDD, therefore, reflect the purest AHR
response that can be obtained by RNA-seq. The AHR is a cytoplasmic protein that binds HSP90
(Perdew, 1988; Kazlauskas, Sundstrom, Poellinger, & Pongratz, 2001), XAP2 (Carver &
Bradfield, 1997; Meyer, Pray-Grant, Vanden Heuvel, & Perdew, 1998) and the co-chaperone
protein p23 (Kazlauskas, Poellinger, & Pongratz, 1999). The binding of TCDD to the AHR
induces AHR translocation from the cytoplasm to the nucleus where it forms a heterodimer with
the ARNT (Denison, Soshilov, He, DeGroot, & Zhao, 2011; Beischlag, Luis Morales,
Hollingshead, & Perdew, 2008). Primary TCDD-stimulated AHR target genes harbor inducible
DREs that confer transcriptional activity to TCDD target genes upon their binding to AHR
activated complexes (Beischlag, Luis Morales, Hollingshead, & Perdew, 2008).
TNBC cells fail to express ER, PR and HER2 (Foulkes, Smith, & Reis-Filho, 2010).
Absence of these three receptors make TNBC more difficult to treat, because there are no
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targeting therapies for this breast cancer subtype (Foulkes, Smith, & Reis-Filho, 2010). The
AHR, however, is expressed in all TNBC cells studied to date (Zhang, Liu, Wang, & Zhang,
2016; Tomblin, et al., 2016; Hall, et al., 2010). Further, TCDD signaling reduces the
aggressiveness of TNBC cells by suppressing their proliferation (Zhang, Liu, Wang, & Zhang,
2016), promoting their differentiation (Hall, et al., 2010) and suppressing their invasive activity
(Zhang, et al., 2012). This is contrary to the AHR ligand kynurenine where it is known to
promote the survival of TNBC cells by suppressing anoikis pathways (D’Amato, et al., 2015).
Thus, AHR may increase or decrease the aggressiveness of TNBC cells depending on which
ligand it binds. The effects of ITE, a nontoxic endogenous AHR ligand, (Henry, Bemis, Henry,
Kende, & Gasiewicz, 2006; Song, et al., 2002) has not been investigated in breast cancer cells.
However, the known anti-cancer activity of ITE in other types of cancer (Cheng, et al., 2015;
Wang, et al., 2013) motivated us to test its effects on breast cancer cells.
The Notch signaling pathway has also been implicated in breast cancer progression.
There are five Notch receptor ligands (JAG1, JAG2 and DLL1, DLL3, and DLL4); however,
JAG1 is the predominant tumor-promoting Notch receptor ligand in breast cancer (Li, Masiero,
Banham, & Harris, 2014; Previs, Coleman, Harris, & Sood, 2015). Upon binding JAG1, the
Notch receptor undergoes two proteolytic cleavage events (Borggrefe & Liefke, 2012) that
release the NICD (Bray, 2006). Following its release, the NICD translocates to the nucleus and
binds to the transcription factor RBP-Jk (Borggrefe & Oswald, 2009), which induces the
exchange of corepressors for coactivators at RBP-Jk and this in turn stimulates increases in the
transcription of NICD gene targets (Bray, 2006).
In this report, we performed an RNA-seq analysis to identify TRGs in MCF-7 breast
cancer cells and identified 660 TRGs. HES1 was identified as a direct AHR target gene that
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functions as a transcriptional repressor and a regulator of neurogenesis. HES1 is also a
downstream target gene of the Notch signaling pathway and has been identified to suppress the
expression of Notch receptor ligands, JAG1 and DLL1, as a negative-feedback regulatory
mechanism. Interestingly, JAG1 which is associated with breast cancer recurrence and poor
breast cancer outcome (Reedijk, et al., 2005; Dickson, et al., 2007; Buckley, et al., 2013), was
one of the 660 TRGs. Because JAG1 is associated with poor breast cancer outcomes (Buckley, et
al., 2013; Li, Masiero, Banham, & Harris, 2014), we investigated its regulation by two AHR
ligands, TCDD and ITE, in order to determine if the anti-cancer effects of AHR activation was
due to regulating JAG1 expression. Our results are the first to show that TCDD and ITE reduce
JAG1 expression in breast cancer cells and confirm that JAG1 is critical for TNBC cell
migratory and invasive activity.
5.3. Materials and Methods
5.3.1 Materials
MCF7 (ER-positive), T47D (ER-positive) MDA-MB-231 (ER-negative) breast cancer
cells were purchased from ATCC (Manassas, VA). MDA-MB-157 (ER-negative) were
generously donated by Ruth Keri (Case Western University). TCDD in DMSO was purchased
from Cambridge Isotopes Laboratory (Andover, MA). The AHR antagonist CH-223191 was
purchased from Sigma-Aldrich (St. Louis, MO). The AHR ligand ITE was purchased from
Tocris Bioscience (Bristol, United Kingdom). Non-targeting siRNA (D-001810-01-20), ONTARGET plus siRNA against AHR (J-004990-08-0010) and JAG1 (J-011060-11-0005) were
purchased from GE Dharmacon (Lafayette, CO). DMEM/High glucose with L-glutamine and
sodium pyruvate, FBS, PBS, penicillin/streptomycin, DMSO, and Lipofectamine RNAiMAX
were purchased from Fisher Scientific (Pittsburgh, PA). SDS, 30% acrylamide/bis solution,
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ammonium persulfate, Tween-20, BME and PVDF membranes were obtained from BIO-RAD
(Hercules, CA).
5.3.2 Cell Culture, siRNA-mediated Gene Knockdown and CH-223191
Cells were cultured in DMEM/FBS (10%) and 1% penicillin/streptomycin at 37°C with
5% CO2. For TCDD (10nM, 24 hours) and ITE (10µM, 72 hours) stimulation, 250,000 MCF7
(ER-positive), T47D (ER-positive), MDA-MB-231 (ER-negative), and MDA-MB-157 (ERnegative) cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) and grown to
~90% confluency. Cells treated with ITE had the media and treatments replenished every 12
hours over the course of three days to compensate for the metabolism of ITE (Cheng, et al.,
2015; Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). Transient transfection with siRNA was
performed as described in our previous publications (Tomblin & Salisbury, 2014; Tomblin, et
al., 2016). In brief, cell suspensions (200,000 cells/mL) were mixed with 100nM of the indicated
siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes. Cells
were then immediately plated on 35mm tissue culture plates in DMEM/FBS (10%) and cultured
for 48 hours before the indicated treatments. Previous reports have shown that CH-223191 is an
AHR antagonist that selectively antagonizes AHR ligands with structures similar to TCDD
(Kim, et al., 2006; Zhao, Degroot, Hayashi, He, & Denison, 2010). Cells were treated with the
indicated concentrations of TCDD or ITE in the absence of presence of 10µM CH-223191 for
the indicated periods of time followed by western blot analysis of GAPDH (loading control),
JAG1, AHR, Cleaved-NICD, and HES1.
5.3.3 TCDD RNA-sequencing
RNA-seq was conducted as described in our previous report (Salisbury, et al., 2014).
Briefly, RNA-seq analysis was based on four biological replicates in each experimental group.
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Total RNA purification kits (Qiagen, Valencia, CA) were used to extract total RNA. RNA
sample quality was assessed using Bioanalyzer RNA Nano chips (Agilent); all RNA samples had
an RIN greater than or equal to 8. RNA-seq libraries were prepared from 1µg of total RNA using
a TruSeq RNA Prep Kit (Illumina Inc., San Diego, CA). RNA-seq was performed using an
Illumina HiSeq1500 in a 2 x 100 base paired end design yielding a minimum of 50 million reads
per sample. Differentially expressed genes were identified at a FDR of 5% as detailed in our
prior report (Salisbury, et al., 2014). Raw reads and processed data (un-normalized and
normalized read counts by gene) were deposited in the Gene Expression Omnibus (GEO) at the
National Center for Biotechnology Information and are accessible via accession number
GSE98515. For pathway analysis, TRGs are expressed as a ratio of TCDD/DMSO were loaded
into IPA software (Ingenuity Systems, Redwood City, CA). Of the 660 TRGs identified by
RNA-seq, 536 were mapped to known functions and pathways by Ingenuity Pathway Analysis
(IPA, Qiagen Bioinformatics). The IPA Core Analysis tool was used to identify significant
associations between TRGs and curated pathways. To account for testing the TRGs against
multiple pathways, we configured IPA Core Analysis to report Benjamini-Hochberg corrected pvalues.
5.3.4. RT-qPCR
Total RNA was extracted using RNA purification columns (Qiagen). Reverse
transcription was performed on 300ng of RNA using cDNA synthesis kits (Applied Biosystems
(Foster City, CA)) in accordance with the suppliers’ instructions. Quantitative PCR (qPCR) was
conducted with the StepOnePlus (Applied Biosystems) using SYBR green master mix (Applied
Biosystems) in accordance with the suppliers’ protocols. Samples were run in triplicate and the
average was normalized to GAPDH loading control. Relative changes in gene expression was
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quantitated using the 2−ΔΔCT formula. We have published the GAPDH primer sequences
(Salisbury, et al., 2014). JAG1 primers used were: forward 5′-GAGCCCGGCCTCCTTTTATT,
reverse 5′-GCGTCATTGTGTTACCTGCG.
5.3.5. Western Blotting
Cells were rinsed with PBS and total cellular extract was isolated in SDS sample buffer
(40% glycerol, 8% SDS, 5% BME, 0.04% bromophenol blue in tris-hydrochloride (Tris-HCl),
pH 6.8). Proteins were heat denatured and then separated by SDS/PAGE followed by transfer to
a PVDF membrane, then blocked with milk (5%) in PBS with 0.05% Tween-20 (PBST). Blots
were incubated overnight at 4°C while rocking in primary antibody followed by an incubation
period of 90 minutes in secondary antibody at room temperature. Blots were then rinsed five
times (5 minutes per rinse) with PBST. Protein targets were detected via chemiluminescence
(Millipore, Billerica, MA). JAG1 (1C4), AHR (D5S6H), Cleaved-NICD (D3B8), and HES1
(D6P2U) antibodies were purchased from Cell Signaling Technology (Danvers, MA). GAPDH
antibody was purchased from Millipore (Cat #MAB374). Primary antibodies were diluted 1:1000
in PBST. Secondary antibodies were diluted 1:10000 in PBST. ChemiDoc MP Imaging System
was used to quantify band density and acquire western blot images.
5.3.6. Scratch Migration Assay
Cells were plated on 12-well tissue culture plates at a concentration of 50,000 cells per
well and grown to ~90% confluency prior to treatment. After cells were treated with vehicle or
10µM ITE in DMEM/FBS (1%) every 12 hours for five days, a scratch was made in each well
with a pipette tip. Media was then aspirated to removed floating cells, then vehicle or 10µM ITE
was reapplied in DMEM/FBS (1%). The scratches were photographed at 0 hours and at 24 hours
post scratch using the Lycia Microscope. The exposed surface area of the plates was measured
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using ImageJ analysis software. For the indicated siRNA experiments, cell migration was
assayed ~48 hours after transfection.
5.3.7. Boyden Chamber Invasion Assay
Cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior
to treatment. After cells were treated with vehicle or 10µM ITE in DMEM/FBS (10%) every 12
hours for the indicated number of days, they were detached from tissue culture plates (using
trypsin) and counted. Cells were immediately transferred to cell invasion chambers in DMEM at
a density of 100,000 cells per 500µL. Chambers filled with cells were then incubated in 24-well
tissue culture plates containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each
experiment included a negative control in which chambers filled with cells were incubated with
DMEM lacking FBS. Following the incubation period in the presence of vehicle (DMSO) or
10µM ITE, a cotton swab was used to remove non-adherent cells that were not invasive. Invasive
cells were stained with crystal violet for 10 minutes at room temperature and then rinsed gently
with deionized water. Stained cells were then incubated in DMSO for 10 minutes with orbital
shaking to extract crystal violet. Cell lysates were measured at 560nm for invasive activity. For
the indicated siRNA experiments, the cell invasion was assayed 48 hours after transfection.
Boyden cell invasion chambers were purchased from ThermoFisher Scientific.
5.3.8. Statistics
The Tukey’s Post-Hoc test was used to determine statistically significant differences
among groups following an ANOVA. One-tailed, unpaired t tests with confidence intervals of
95% were used to determine statistically significant differences between two groups.
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5.4. Results
5.4.1. TCDD RNA-seq
We have recently shown that treating MCF7 cells with 10nM TCDD for 6 hours changed
the expression of 137 genes (Tomblin, et al., 2016). Here, we have analyzed gene expression
changes in MCF7 cells treated with 100nM TCDD for 6 hours compared with vehicle controls.
Even though the 100nM TCDD concentration may not be consistent with human exposure, the
purpose behind the analysis of 100nM TCDD concentrations was to identify robust AHRregulated target genes in order to elucidate novel AHR-dependent transcriptional mechanisms.
This new differential expression-sequencing analysis identified 660 genes that were regulated by
100nM TCDD, including a high representation of genes regulated by 10nM TCDD (123) and
genes uniquely regulated by 100nM TCDD (537) (Figure 16). We performed gene expression
analyses in IPA to identify biological functions that were most significant to the published TRG
and new TRG gene sets. Pathway analysis of the published TRGs (123 genes) revealed
enrichment in functions regulated by TCDD, such as cell cycle (Puga, et al., 2000), cell death
and survival (Bekki, et al., 2015), lipid metabolism (Bui, Solaimani, Wu, & Hankinson, 2012;
Yang, Solaimani, Dong, Hammock, & Hankinson, 2013) and drug metabolism (Nebert &
Dalton, 2006) (Table 5), while the new TRGs (537 genes) were enriched in pathways associated
with other aspects of breast cancer (Table 6). These included cell morphology (Diry, et al.,
2006), cell assembly and organization, cell-to-cell signaling, cell development and cellular
movement (Hall, et al., 2010; Zhang, et al., 2012), signifying a potential broader role for TCDD
in breast cancer.
TRGs can be roughly divided into two groups. One group is directly regulated by TCDD
via the AHR binding to DREs, and the other group is indirectly regulated by TCDD because the
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Tomblin, JK 2016
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RNA-seq
RNA-seq
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14

Figure 16. Comparison of Published 10nM TRGs with the More Extensive List of 100nM
TRGs
Analysis of the 100nM TRGs showed enrichment for published TRGs (123) (Tomblin, et al.,
2016) and new TRGs (537). Genes from the 10nM TCDD-treated MCF7 cells are highly
represented in the 100nM TCDD-treated MCF7 cells gene set.
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IPA Biofunctions Associated with 123 Published TRGs from
10nM and 100nM TCDD-treated MCF7 Cells
Category

*B-H p-value

# TRGs

Cell Cycle

1.34E-03-2.79E-02

18

Cell Death and Survival

3.03E-03-2.79E-02

32

Lipid Metabolism

5.18E-03-2.79E-02

13

Small Molecule Biochemistry

5.18E-03-2.79E-02

26

Cell Morphology

5.31E-03-2.79E-02

30

Cell Function and Maintenance

5.31E-03-2.79E-02

23

Gene Expression

6.8E-03-2.79E-02

12

Carbohydrate Metabolism

7.54E-03-2.79E-02

12

Drug Metabolism

7.54E-03-2.79E-02

9

Energy Production

7.54E-03-2E-02

7

*p-values are calculated by Fishers exact test and corrected for multiple testing by the
Benjamini-Hochberger p-values (B-H) method (B-H p-value). Column 2 shows the range of
B-H corrected p-values for the biofunction in a given category.
Table 5. IPA Biofunctions Associated with 123 TRGs from 10nM and 100nM TCDDtreated MCF7 Cells
Biofunctional analysis was conducted on the 123 overlapped genes to identify if there are any
associated biofunctions related to cancer biology. Column 1 identifies the biofunctional category
that IPA linked to the 123 TRGs. Column 2 shows the range of B-H corrected p-values for the
biofunction in a given category and the strength of biofunctional association is ordered from top
to bottom. Cancer-related biofunctions found in this table include cell morphology, cell death
and survival, cell-to-cell signaling, cell movement, cell cycle, cell development, cell growth and
proliferation, and cell assembly and organization. Column 3 identifies the number of genes
within the dataset to be associated within the given biofunctional category.
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IPA Biofunctions Associated with 537 Uniquely Regulated Genes from
100nM TCDD-treated MCF7 Cells
Category

*B-H p-value

# TRGs

Cell Morphology

1.14E-06-1.31E-02

111

Cell Assembly and Organization

1.14E-06-9.46E-03

81

Cell Function and Maintenance

1.14E-06-9.46E-03

114

Cell-To-Cell Signaling

4.87E-06-1.31E-02

66

Cell Development

1.1E-05-1.44E-02

128

Cell Growth and Proliferation

1.1E-05-1.31E-02

120

Amino Acid Metabolism

1.45E-05-3E-03

18

Post-Translational Modification

1.45E-05-1.28E-03

41

Small Molecule Biochemistry

1.45E-05-1.44E-02

46

Cellular Movement

2.63E-04-1.38E-02

83

*p-values are calculated by Fishers exact test and corrected for multiple testing by the
Benjamini-Hochberger p-values (B-H) method (B-H p-value). Column 2 shows the range of
B-H corrected p-values for the biofunction in a given category.
Table 6. IPA Biofunctions Associated with 537 Uniquely Regulated Genes from 100nM
TCDD-treated MCF7 Cells
Biofunctional analysis was conducted on the 537 regulated genes from the 100nM TCDD-treated
MCF7 cells in order to identify if there are any associated biofunctions related to cancer biology.
Column 1 identifies the biofunctional category that IPA linked to the 123 TRGs. Column 2
shows the range of B-H corrected p-values for the biofunction in a given category and the
strength of biofunctional association is ordered from top to bottom. Column 3 identifies the
number of genes within the dataset to be associated within the given biofunctional category.
Cancer-related biofunctions found in this table include cell morphology, cell assembly and
organization, cell-to-cell signaling, cell development, cell growth and proliferation, and cellular
movement. Because this biofunctional analysis contained categories that were more relevant to
cancer biology compared to the 123 overlapped gene set (Table 5), bioinformatic and genomic
analysis was conducted with the 100nM TCDD gene set.
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gene does not possess DREs; however, they are part of the TCDD pathway. Previously, 2,594
TCDD-stimulated AHR binding sites were identified in MCF7 cells by ChIP-seq (Lo &
Matthews, 2012). We overlapped these published 2,594 TCDD-AHR binding sites (Lo &
Matthews, 2012) with our complete TRGs set and identified that 189 genes were common
between the two groups (Figure 17). The 189 shared genes represent probable direct TCDDstimulated AHR gene targets (Table 7), while the remaining 471 TRGs are regulated indirectly
by TCDD-stimulated AHR activation. IPA biological function analysis of the primary 189 TRGs
showed enrichment in functions downstream of TCDD including gene expression, cell cycle
(Barhoover, Hall, Greenlee, & Thomas, 2010; Puga, et al., 2000; Marlowe, Knudsen,
Schwemberger, & Puga, 2004), cell death and survival (Bekki, et al., 2015), cell morphology
(Diry, et al., 2006), cell-to-cell signaling, cellular movement (Hall, et al., 2010; Zhang, et al.,
2012), cellular development and cell assembly and organization, all of which provide insight into
how TCDD may act in breast cancer (Table 8).
We filtered this list to binding sites that appeared less than 5000 bases upstream of an
annotated TSS in order to identify direct AHR target genes. This analysis identified 224 genes
that had TCDD-stimulated AHR binding sites identified by ChIP-Seq (Lo & Matthews, 2012)
less than 5 kilobases (Kb) upstream of their TSS. We compared this list of 224 genes with our
complete list of TRGs (660) and identified that 41 were common (Figure 18). The 41 shared
genes represent gene targets where the TCDD-AHR binding site is within 5Kb of the TSS (Table
9), while the remaining 619 TRGs are regulated either indirectly by TCDD-AHR or the TCDDAHR binding site is greater than 5Kb of the TSS.
Next, an IPA upstream regulator analysis was used to determine if genes within the
100nM TRG set (660 genes) were regulated through a common upstream regulator (Table 10).
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Figure 17. Comparison of Published 100nM TRGs with TCDD-stimulated AHR Binding
Sites Identified by ChIP-seq in MCF7 Cells
To better understand AHR-ARNT signaling in breast cancer cells, Lo et al. used chromatin
immunoprecipitation linked to high-throughput sequencing to identify AHR and ARNT binding
sites across the genome in TCDD-treated MCF-7 cells (Lo & Matthews, 2012). They identified
2594 AHR-bound regions, which were overlapped with the 100nM TRGs analysis to determine
any potential direct AHR target genes. This overlap identified 189 genes that are directly bound
by AHR when stimulated by TCDD which are displayed in Table 7.
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Gene
Name
CYP1A1
CYP1B1
DRD1
PITPNM2
STRA6
TRPM6
LMCD1
SLC7A5
ALDH1A3
ABCG2
HAR1A
NCCRP1
RUNX2
HAR1B
BMF
HAR1A
ST3GAL1
GLDN
RND1
LEF1
FAM105A
TIPARP
C9orf169
MAPRE2
SYT12
TTC39B
PLEKHF1
MCOLN2
HECW2
EDC3
HEY1
TMEM45B

The 189 TRGs that Overlap with Reported TCDD-stimulated AHR-ChIP-seq from Lo & Matthews (2012)
*Fold
*Fold
*Fold
Gene
*Fold
*Fold
*Fold
Change Gene Name Change Gene Name Change
Name
Change Gene Name Change Gene Name Change
713.9
TMTC2
2.5
ELF4
2.0
TUFT1
1.6
CCDC88C
1.4
CD47
1.3
12.5
TNFRSF11B
2.4
FAM198B
1.9
RRS1
1.6
LPP
1.4
FREM2
1.3
8.0
NEDD9
2.4
FAM110B
1.9
PKP1
1.6
SIPA1L2
1.4
NPEPPS
1.3
6.7
C1orf116
2.4
PRDM16
1.8
LRIG3
1.6
ABCC5
1.4
GMNN
1.3
6.0
ITPR1
2.3
PHEX
1.8
INPP4B
1.6
SIPA1L3
1.4
C4orf32
1.3
5.8
TSKU
2.3
ATP1B1
1.8
NEK6
1.5
FARP1
1.4
SSBP2
1.3
5.5
ZIC2
2.3
SLC16A14
1.8
FRMD4A
1.5
TRAFD1
1.4
RCC2
1.3
5.0
DNMBP
2.2
DLL1
1.8
DDIT4
1.5
PDZRN3
1.4
TRIO
1.3
4.2
STC2
2.2
FOSL2
1.8
PSPC1
1.5
RAP1GAP
1.4
PARP4
1.3
4.2
AGPAT9
2.2
GAD1
1.8
GLI3
1.5
MSX2
1.4
SPTBN1
1.3
3.8
PYGL
2.2
HES1
1.8
IL1RAPL2
1.5
NR3C1
1.4
MED13L
1.3
3.8
ATP9A
2.2
NRP1
1.8
ADAP1
1.5
USP3
1.4
SLC4A7
1.3
3.8
FAM84A
2.2
SAMD12
1.8
NADK
1.5
CDC25B
1.4
MYO6
1.3
3.7
CABLES1
2.2
C9orf3
1.8
DSP
1.5
MEIS1
1.4
TRPS1
1.2
3.6
SALL4
2.2
AHRR
1.7
SOS1
1.5
MTMR2
1.4
HBP1
0.8
3.6
LEKR1
2.2
SLC2A11
1.7
REL
1.5
IER5
1.4
HDAC5
0.8
3.4
NFE2L2
2.2
SLC27A2
1.7
GDF15
1.5
SPAG17
1.4
MYB
0.8
3.3
HS6ST3
2.1
RUNX1
1.7
EGFR
1.5
RIOK1
1.4
GPRC5A
0.8
3.2
GPR115
2.1
KLF7
1.7
IGF1R
1.5
PIK3C2B
1.4
KITLG
0.8
3.1
VIPR1
2.1
ZFHX3
1.7
NHS
1.5
ROCK2
1.3
TESK2
0.8
3.0
LRP5
2.1
SCARA5
1.7
C15orf39
1.5
TSHZ2
1.3
KIAA1467
0.7
3.0
ADAM12
2.1
VDR
1.7
SPRED2
1.5
LPHN2
1.3
FAM5B
0.7
3.0
CLSTN2
2.1
SHISA2
1.7
GPR157
1.5
CPEB4
1.3
AGR3
0.7
2.9
NBPF1
2.0
TMEM120B
1.6
HOXC11
1.5
GNL3
1.3
CSRNP1
0.7
2.8
KIAA1549
2.0
ACOXL
1.6
PTPRJ
1.5
QSOX1
1.3
LYN
0.7
2.8
PPARG
2.0
TNS3
1.6
DOCK5
1.5
PSD3
1.3
NPY1R
0.7
2.7
WNK2
2.0
PRPS1
1.6
CARD10
1.5
ARHGEF10L
1.3
SLC30A1
0.7
2.6
WSCD1
2.0
ZBTB7C
1.6
SPIRE2
1.5
PAK2
1.3
RBM24
0.7
2.6
RARRES1
2.0
TDH
1.6
BMPR1B
1.4
SYDE2
1.3
GSC
0.6
2.6
DUSP10
2.0
TIMP3
1.6
JARID2
1.4
EHD4
1.3
MAF
0.6
2.5
SLC16A7
2.0
SNX25
1.6
CUX1
1.4
BOD1
1.3
TP73
0.5
2.5
TPCN1
1.6
DPP9
1.3

*RNA-fold change expression values from 100 nM TCDD-treated MCF7 cells compared with vehicle expressed as a ratio/vehicle

Table 7. The 189 TRGs that Overlap with Reported TCDD-stimulated AHR-ChIP-seq
from Lo & Matthews (2012)
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IPA Biofunctions Associated with 189 Primary TRGs from the 100nM TCDD-treated
MCF7 Cells Overlapped with ChIP-seq Analysis from Lo & Matthews (2012)
Category

*B-H p-value

# TRGs

Cell Morphology

3.83E-06-1.37E-02

60

Cell Death and Survival

2.58E-05-8.62E-03

63

Cell-To-Cell Signaling

2.66E-05-1.14E-02

33

Cell Movement

3.15E-05-1.36E-02

53

Cell Cycle

3.33E-05-1.41E-02

46

Cell Development

3.84E-05-1.29E-02

69

Gene Expression

8.38E-05-7.81E-03

50

Cell Function and Maintenance

1.2E-04-1.37E-02

63

Cell Growth and Proliferation

3.41E-04-1.17E-02

70

Cell Assembly and Organization

1.48E-03-1.37E-02

39

*p-values are calculated by Fishers exact test and correct for multiple testing by the
Benjamini-Hochberger p-values (B-H) method (B-H p-value).
Table 8. IPA Biofunctions Associated with 189 Primary TRGs from the 100nM TCDDtreated MCF7 Cells Overlapped with ChIP-seq Analysis from Lo & Matthews (2012)
Biofunctional analysis was conducted on the 189 primary TRGs in order to identify if there are
any associated biofunctions related to cancer biology. Column 1 identifies the biofunctional
category that IPA linked to the 189 TRGs. Column 2 shows the range of B-H corrected p-values
for the biofunction in a given category and the strength of biofunctional association is ordered
from top to bottom. Cancer-related biofunctions found in this table include cell morphology, cell
death and survival, cell-to-cell signaling, cell movement, cell cycle, cell development, cell
growth and proliferation, and cell assembly and organization. Column 3 identifies the number of
genes within the dataset to be associated within the given biofunctional category.
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Figure 18. Comparison of Published 100nM TRGs with TCDD-stimulated AHR Binding
Sites Identified by ChIP-seq Less than 5Kb Upstream of their TSS
The identified 2594 AHR-bound regions via ChIP-seq analysis (Lo & Matthews, 2012) were
filtered down to genes that contained AHR-binding sites within 5Kb of the TSS, in order to
determine bonafide direct AHR target genes. This analysis identified 224 genes that met the
criteria and were then overlapped with the 100nM TCDD RNA-seq to determine what genes may
be directly targeted by AHR within our gene set. This overlap identified 41 genes that are
directly bound by AHR and are within 5Kb of the transcription start site which are displayed in
Table 9.
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The 41 Genes Within the 100nM TCDD RNA-seq Data Set with an
AHR Binding Site Within 5Kb of the TSS in MCF7 Cells
Gene Name
*Fold Change Gene Name
*Fold Change
CYP1A1
713.9
RUNX1
1.7
CYP1B1
12.5
VDR
1.7
LMCD1
5.5
PRPS1
1.6
ABCG2
4.2
LSMEM1
1.6
NCCRP1
3.8
TUFT1
1.6
C9orf169
3.0
DDIT4
1.5
SYT12
2.8
ADAP1
1.5
RNF224
2.8
NADK
1.5
PLEKHF1
2.7
SOS1
1.5
TMTC2
2.5
REL
1.5
AC018816.3
2.4
IGF1R
1.5
ITPR1
2.3
CARD10
1.5
ZIC2
2.3
USP3
1.4
SALL4
2.2
CPEB4
1.3
PPARG
2.0
DPP9
1.3
FAM198B
1.9
FREM2
1.3
SLC34A3
1.8
SSBP2
1.3
GAD1
1.8
SYBU
0.7
HES1
1.8
RBM24
0.7
NRP1
1.8
TP73
0.5
SLC2A11
1.7
*RNA-fold change expression values from TCDD-treated MCF7 cells
compared with vehicle expressed and a ratio/vehicle
Table 9. The 41 Genes Within the 100nM TCDD RNA-seq Data Set with an AHR Binding
Site Within 5Kb of the TSS in MCF7 Cells
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IPA Upstream Regulators Associated with 100nM TRGs (660)
Predicted
Activation *p-value of Target Genes Number of Genes
Upstream
Regulator
Overlap
in Dataset
in the Network
State
Beta-estradiol
1.8E-12
87
203
PGR
5.4E-10
26
199
SOX2
2E-09
27
131
Progesterone
Activated
1.6E-08
37
184
TP63
3.2E-08
28
182
TNF
7.4E-08
73
219
Valproic Acid
3.5E-07
29
170
Estrogen Receptor
3.7E-07
20
179
Fulvestrant
4.4E-07
21
185
NOTCH1
Activated
5.1E-07
20
163
AHR
Activated
6.1E-06
22
162
TCDD
Activated
8.3E-05
21
155
*p-value of overlap are calculated by Fisher exact test
Table 10. IPA Upstream Regulators Associated with 100nM TRGs (660)
An IPA upstream regulator analysis was conducted to identify transcription factors and other
upstream molecules that may be responsible for gene expression changes observed. Column 1
indicates the transcription factors and or small molecules that IPA predicted to be associated with
the 100nM TCDD TRGs. Column 2 uses the activation z-score algorithm to predict IPA
upstream regulator activity, which is determined by comparing reported gene responses to a
given upstream regulator to the observed expression changes in 100nM TRGs. Column 3 shows
the strength of overlap and is ordered from top to bottom, based on the calculated p-value by the
Fisher exact test. Column 4 shows the number of TRGs in the RNA-seq 100nM TCDD dataset
that are within the gene network under a specific IPA-upstream regulator. Column 5 indicates the
total number of genes in the network under a specific IPA upstream regulator pathway.
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This analysis revealed that TRGs were significantly enriched under the following upstream
regulators: beta-estradiol (endogenous hormone), PR (ligand-activated transcription factor), SRY
box 2 (SOX2) (transcription factor), progesterone (endogenous hormone), tumor protein 63
(TP63) (transcription factor), tumor necrosis factor (TNF) (cytokine), valproic acid (chemical
drug), ER (ligand-activated transcription factor), fulvestrant (chemical drug), Notch1
(transcription factor), AHR (ligand-activated transcription factor) and TCDD (chemical toxicant)
(Table 10). Of the 37 TRGs in the progesterone pathway, 21 exhibited patterns of expression
consistent with activation of progesterone signaling activity (Table 10). For Notch1, the pattern
of expression of 13 of the 20 TRGs was consistent with activation of the Notch1 pathway (Table
11).
In ER-expressing breast cancer cells (e.g. MCF7 and T47D), TCDD increases: 1)
posttranscriptional downregulation of the ER (Wormke, et al., 2003), 2) the binding of the AHR
to inhibitory dioxin response elements (iDREs) that perturb the binding of ER and associated
transcriptional activators to ER target genes (Krishnan, Porter, Santostefano, Wang, & Safe,
1995), 3) the co-recruitment of AHR and ER complexes to the promoters of AHR and ER target
genes (Beischlag & Perdew, 2005; Matthews, Wihlen, Thomsen, & Gustafsson, 2005) and 4) the
recruitment of receptor interacting protein 140 (RIP140) (negative transcriptional regulator) to
certain ER target genes that are suppressed by TCDD-stimulated AHR signaling (MadakErdogan & Katzenellenbogen, 2012). Based on the findings of these prior reports, identifying
that 87 of 203 beta-estradiol target genes are TRGs is not surprising. Finally, TRGs were
significantly enriched within the AHR (20 of 162 AHR network genes) and TCDD pathways (21
of 155 TCDD network genes), which is consistent with cells being treated with TCDD. The IPApredicted AHR activation and TCDD activity was based in part on the induction of canonical
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TCDD-stimulated AHR target genes CYP1A1 (~ 714-fold) (Spink, et al., 1998), CYP1B1
(~12.5-fold) (Spink, et al., 1998) and ALDH3A1 (~ 4.2-fold) (Vasiliou, Reuter, Williams, Puga,
& Nebert, 1999) in TCDD-treated cells compared with controls (Table 7).
The 20 TRGs that are grouped under the IPA-defined Notch1 network are shown in Table
11. Overlap analysis with predicted direct TCDD-AHR regulated genes (Table 7) shows that half
of the genes within the Notch1 network were predicted direct TCDD-AHR gene targets and the
other half were indirect TCDD-AHR gene targets that did not bind the AHR (Table 11). The
predicted direct TCDD-AHR gene targets that are also Notch1 network genes include RUNX2
(Hilton, et al., 2008), v-rel avian reticuloendotheliosis viral oncogene homolog (c-Rel) (Cheng,
et al., 2001), PPARg (Sciaudone, Gazzerro, Priest, Delany, & Canalis, 2003), MYC protooncogene (myc) (Weng, et al., 2006), lymphoid enhancing factor 1 (LEF1) (Spaulding, et al.,
2007), IGF-1R (Eliasz, et al., 2010), HEY1 (Borggrefe & Liefke, 2012), HES1 (Borggrefe &
Liefke, 2012), EGFR (Baumgart, et al., 2010), and DLL1 (Jaleco, et al., 2001). Overlap analysis
with TCDD-stimulated AHR regulated genes that have TCDD-AHR binding sites within 5Kb of
the TSS (Table 9) shows that four TRGs that meet these criteria are within the Notch1 network.
Those genes include c-Rel (Cheng, et al., 2001), PPARg (Sciaudone, Gazzerro, Priest, Delany, &
Canalis, 2003), IGF-1R (Eliasz, et al., 2010), and HES1 (Borggrefe & Liefke, 2012) (Table 9).
The group of 10 Notch1 network genes that are regulated by TCDD-AHR through an indirect
mechanism included JAG1 (Table 9). JAG1 is the predominant Notch receptor ligand in TNBC
that is also implicated in breast cancer progression (Reedijk, et al., 2005; Dickson, et al., 2007;
Cohen, et al., 2010). Because JAG1 is clinically linked to breast cancer progression (Dickson, et
al., 2007; Reedijk, et al., 2005) (Figure 10), we investigated the mechanism by which TCDD
reduces the expression of JAG1.
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TRGs (100 nM) that are IPA-determined Notch1 Regulated Genes
Genes in Dataset

Predicted State of
Activation

Expression Log
Ratio of TRGs

Predicted TRG

TRG Within 5Kb
of TSS

RUNX2

Activated

1.914

Yes

No

REL

Activated

0.567

Yes

Yes

PPARG

Activated

1.021

Yes

Yes

NCF1

Activated

-0.518

No

No

MYC

Activated

0.881

Yes

No

LEF1

Activated

1.645

Yes

No

IGFBP3

Activated

-0.628

No

No

IGF1R

Activated

0.56

Yes

Yes

HEY1

Activated

1.336

Yes

No

HES1

Activated

0.852

Yes

Yes

EGFR

Activated

0.561

Yes

No

DKK1

Activated

-0.729

No

No

CHST1

Activated

-1.005

No

No

MYCL

Inhibited

-0.568

No

No

CAD

Affected

0.586

No

No

DLL1

Affected

0.872

Yes

No

ITGA6

Affected

-0.399

No

No

JAG1

Affected

-0.336

No

No

LFNG

Affected

-0.678

No

No

WNT5A

Affected

1.998

No

No

Table 11. TRGs (100nM) that are IPA-determined Notch1 Regulated Genes
According to the IPA upstream regulator analysis, Notch1 was predicted to be activated based on
the gene expression changes present within the 100nM TRGs (660) and shows 20 genes that are
downstream of the Notch signaling pathway to be affected in the presence of TCDD. Column 1
shows the name of the 100nM TRG. Column 2 is the predicted activation state of Notch
signaling based on the direction of gene expression change. Column 3 shows the fold change of
TRGs. Column 4 shows if the gene is a direct AHR target gene based from overlapping 100nM
TCDD RNA-seq with TCDD-AHR ChIP-seq (Table 5). Column 5 identifies primary TRGs that
bind to TCDD-AHR binding sites within 5Kb of transcription start site (Table 7).
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5.4.2. TCDD Reduces JAG1 mRNA in MCF7 Cells
In an effort to confirm the RNA-seq analysis, we treated MCF7 cells with DMSO or the
indicated concentrations of TCDD for 6 hours. The relative mRNA levels of JAG1 normalized to
GAPDH loading control were determined by RT-qPCR. We verified that JAG1 expression was
reduced by TCDD and found that 10nM and 100nM TCDD treatment significantly reduced
JAG1 mRNA (by ~40%) in MCF7 cells after 6 hours of treatment (Figure 19).
5.4.3. TCDD Reduces JAG1 Protein but Activates Notch Signaling in MCF7 Cells
After establishing that TCDD significantly reduced JAG1 mRNA levels after 6 hours in
MCF7 cells, we sought to determine if TCDD also reduced the levels of JAG1 protein and
whether changes in the levels of JAG1 were correlated with changes in the activity of the Notch
signaling pathway. We, therefore, treated MCF7 cells with 10nM TCDD for 24 hours and
extracted total cellular protein to analyze by western blot (Figure 20). We probed blots with
JAG1, AHR, and HES1 antibodies. The activation of Notch signaling induces the proteolysis of
the Notch receptor, and this releases the NICD, which functions as a transcription factor that
activates Notch target genes like HES1 (Borggrefe & Liefke, 2012). We, therefore, also probed
blots with an antibody that specifically recognizes activated cleaved-NICD as the readout for
changes in Notch signaling. The western blot signals for JAG1, AHR, HES1, and cleaved-NICD
were normalized to GAPDH. We have shown in prior reports that GAPDH is a suitable loading
control for western blots analysis because its levels are not changed in response to AHR ligands
(Salisbury, et al., 2014).
The western blot findings showed that after 24 hours TCDD significantly reduced the
levels of AHR protein compared with vehicle (Figure 20). The observed reduction in AHR in
response to TCDD is consistent with prior reports that have shown that TCDD-activated AHR is
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Figure 19. TCDD Decreases JAG1 mRNA Levels in MCF7 Cells
MCF7 cells were treated with vehicle or the indicated concentrations of TCDD for 6 hours. The
relative mRNA levels of JAG1 normalized to GAPDH loading control were determined by RTqPCR (as detailed in the Material and Methods). Results shown are the means ± standard error
margin (SEM) of three independent experiments. Significant reductions by TCDD are indicated
by *P < 0.05.
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Figure 20. TCDD Decreases JAG1 Protein Levels but Activates the Notch Signaling
Pathway in MCF7 Cells
MCF7 cells were treated with vehicle or 10nM TCDD for 24 hours. Total cellular protein was
isolated and subjected to western blot analysis. Blots were probed with the indicated antibodies.
Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH. Results shown
are the means ± SEM of three independent experiments. Significant changes in expression by
TCDD are indicated by *P < 0.05 or **P<0.01.
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ubiquitinated and then degraded by the proteasome and that this regulation is a negativefeedback loop in the TCDD signaling pathway (Ma & Baldwin, 2000). We also observed TCDDstimulated reductions in the levels of JAG1 protein (Figure 20), which is consistent with our
RNA-seq and RT-qPCR results showing that TCDD reduced the expression of JAG1 mRNA.
We hypothesized that TCDD-induced reductions in JAG1 would lead to the attenuation of Notch
signaling, because JAG1 is a Notch receptor ligand. The findings, however, revealed that TCDDstimulated a robust increase in the levels of NICD (Figure 20). This result indicates that in ERexpressing MCF7 cells, TCDD is sufficient to activate the Notch pathway, even when the levels
of JAG1 protein are reduced in response to TCDD (Figure 20). To further investigate whether
TCDD-stimulated increases in the NICD have a functional impact in MCF7 cells, we evaluated
the expression of HES1, which is a direct Notch target gene (Borggrefe & Liefke, 2012). In
accordance with the observed increases of cleaved-NICD levels in response to TCDD, we
identified that TCDD stimulated HES1 expression in MCF7 cells (Figure 20). Collectively, these
results indicate that TCDD is sufficient to increase Notch signaling, because it induced cleavedNICD levels and promoted the expression of the Notch target gene, HES1. TCDD, however,
reduced the expression of the Notch receptor ligand JAG1 at the level of mRNA and protein.
5.4.4. TCDD Reduces JAG1 mRNA in MDA-MB-231 Cells
We sought to further investigate the regulation of JAG1 and Notch signaling by TCDD in
MDA-MB-231 TNBC cells. The impetus for including MDA-MB-231 cells in our TCDD
analysis stems from prior reports showing that the JAG1-Notch pathway is more active in TNBC
compared with ER-positive breast cancer. We first evaluated the levels of JAG1 mRNA, and the
findings showed that treating MDA-MB-231 cells with 10nM TCDD for 24 hours significantly
reduced the levels of JAG1 mRNA compared with cells treated with vehicle (Figure 21).
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Figure 21. TCDD Decreases JAG1 mRNA Levels in MDA-MB-231 Cells
MDA-MB-231 cells were treated with vehicle or 10nM TCDD for 6 hours. The relative mRNA
levels of JAG1 normalized to GAPDH loading control was determined by RT-qPCR (as detailed
in the Material and Methods). Results shown are the means ± SEM of three independent
experiments. Significant reductions by TCDD are indicated by *P < 0.05.
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5.4.5. TCDD Reduces JAG1 Protein and Inhibits Notch Signaling in MDA-MB-231
Cells
Having established that TCDD significantly reduces the expression of JAG1 mRNA, we
sought to investigate whether this prototype AHR ligand also reduces the levels of JAG1 protein
in MDA-MB-231 cells. The western blot findings showed that 10nM TCDD (24 hours)
significantly reduced the levels of JAG1 protein in MDA-MB-231 cells, which is similar to what
we had observed in MCF7 cells (Figure 22). Next, we investigated Notch signaling activity by
measuring the cleaved-NICD levels by western blot in MDA-MB-231 cells treated with vehicle
or 10nM TCDD (24 hours). In accordance with prior reports, the levels of cleaved-NICD were
high in control MDA-MB-231 cells (Figure 22). This result indicates that MDA-MB-231 cells
exhibit constitutive Notch signaling under basal conditions, which is different than what we
observed in MCF7 cells. As shown in Figure 20, control MCF7 cells do not express cleavedNICD under basal conditions. The western blot findings also revealed that TCDD-stimulated
reductions in levels of cleaved-NICD in MDA-MB-231 cells (Figure 22). Collectively, these
results indicate that TCDD-activated AHR signaling reduces JAG1 and cleaved-NICD levels in
the TNBC MDA-MB-231 cell line.
5.4.6. AHR Mediates TCDD-stimulated Reductions in JAG1 and Cleaved-NICD in
MDA-MB-231 Cells
We performed AHR knockdown experiments in MDA-MB-231 cells to determine
whether this receptor mediates TCDD-induced downregulation of JAG1. Control cells were
transfected with control siRNA that was non-targeting. As anticipated, TCDD significantly
reduced JAG1 protein (by ~ 44%) in control cells (Figure 23A). Western blot analysis of cells
transfected with AHR-targeting siRNA revealed that AHR was significantly reduced (by ~ 95%)
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Figure 22. TCDD Decreases JAG1 Protein Levels and Inhibits the Notch Signaling
Pathway in MDA-MB-231 Cells
MDA-MB-231 cells were treated with vehicle or 10nM TCDD for 24 hours. Total cellular
protein was isolated and subjected to western blot analysis. Blots were probed with the indicated
antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH.
Results shown are the means ± SEM of three independent experiments. Significant changes in
expression by TCDD are indicated by *P < 0.05 or ***P<0.001.
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Figure 23. AHR Mediates TCDD-stimulated Reductions of JAG1 in MDA-MB-231 Cells
A) Control cells were transfected with non-targeting short interfering RNA and AHR knockdown
cells were transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells
were treated with vehicle or 10nM TCDD for 24 hours. B) Control cells were treated with
vehicle or 10nM TCDD. CH-223191 groups were treated with 10µM CH-223191 in the absence
or presence of 10nM TCDD for 24 hours. Total cellular protein was isolated and subjected to
western blot analysis. Blots were probed with the indicated antibodies. Levels of AHR and JAG1
were normalized to GAPDH. Data shown are the means ± SEM of three independent
experiments. Significant reductions by TCDD or AHR-targeting siRNA are indicated by * P <
0.05.
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compared to control cells, indicating that our approach to knocking down AHR was highly
effective (Figure 23A). We observed that cells with AHR knockdown were unresponsive to
TCDD-stimulated reductions in JAG1, indicating that the suppressive effect of TCDD on JAG1
expression is dependent on AHR activation (Figure 23A). The observed reduction in AHR
protein in response to TCDD in control cells (Figure 23A) is mediated by a posttranscriptional
mechanism that increases the ubiquitination of AHR, which in turn causes AHR to be degraded
by the proteasome (Wormke, et al., 2003; Pollenz, 2002). The AHR antagonist CH-223191 is
reported to selectively antagonize the binding of halogenated polycyclic aromatic hydrocarbons
(e.g. TCDD) to AHR (Zhao, Degroot, Hayashi, He, & Denison, 2010) and allows us to test if
TCDD binding to AHR reduces the expression of JAG1. The findings showed that CH-223191
prevented TCDD-stimulated reductions in JAG1 protein (Figure 23B) and supports our
hypothesis that TCDD reduces JAG1 by binding to and activating the AHR.
5.4.7. ITE Reduces JAG1 in MCF7 and T47D Cells
TCDD inhibits the growth and proliferation of ER-positive breast cancer cells by
antagonizing estrogen signaling (Ohtake, Fujii-Kuriyama, & Kato, 2009). However, there are no
reports indicating that TCDD or other AHR ligands modulate the JAG1-Notch pathway in ERpositive breast cancer cells. Considering that a recent report has shown that increases in JAG1
plays a role in tamoxifen resistance in ER-positive breast cancer (Simões, et al., 2015), we
further investigated the regulation of JAG1-Notch signaling by AHR in MCF7 and T47D breast
cancer cells. To this end, we stimulated MCF7 and T47D cells with the non-toxic endogenous
AHR ligand ITE then assayed JAG1 and cleaved-NICD levels by western blot. Cells were
treated with vehicle or 10µM ITE every 12 hours for three days. Our rationale for treating cells
every 12 hours with 10µM ITE was based on a prior report showing that ITE exerts its maximal
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effect at this concentration and that cells must be replenished with ITE every 12 hours due to its
rapid metabolism by cells (Cheng, et al., 2015; Henry, Bemis, Henry, Kende, & Gasiewicz,
2006). The western blot results showed that ITE induced downregulation of AHR protein levels,
which is consistent with our expectation that ITE is functioning as an AHR ligand in ER-positive
breast cancer cells (Ohtake, Fujii-Kuriyama, & Kato, 2009) (Figure 24). As noted earlier,
downregulation of AHR protein in response to an AHR ligand is mediated by the ubiquitination
of AHR, followed by degradation of AHR by the proteasome (Ma & Baldwin, 2000). The levels
of JAG1 protein in MCF7 and T47D cells treated with ITE were significantly lower compared
with cells treated with vehicle (Figure 24). Thus, our findings show that TCDD and ITE decrease
JAG1 in ER-expressing MCF7 and T47D cells. Next, we analyzed the amount of cleaved-NICD,
and the results showed that ITE stimulated increases of cleaved-NICD levels in MCF7 cells
compared with the control group (Figure 24). Considering that HES1 is a direct Notch target
gene, we questioned whether ITE, by inducing NICD, also promoted the expression of HES1.
The findings showed that ITE did indeed increase the levels of HES1 compared with cells treated
with vehicle (Figure 24). Collectively, these results suggest that TCDD and ITE decrease JAG1,
but are sufficient to activate Notch signaling in ER-positive breast cancer cells. These results are
the first to show that the AHR signaling pathway cross-talks with the JAG1-Notch signaling
pathway in ER-positive breast cancer cells.
5.4.8. ITE Reduces JAG1 in MDA-MB-231 and MDA-MB-157 Cells
Considering that the JAG1-Notch pathway has been shown to promote the progression of
TNBC, we questioned whether the non-toxic AHR ligand ITE reduces JAG1 expression and
suppresses Notch signaling in TNBC cells. To this end, we applied vehicle (DMSO) or ITE
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Figure 24. ITE Decreases JAG1 Protein Levels but Activates the Notch Signaling Pathway
in ER-positive Breast Cancer Cells
MCF7 and T47D cells were treated with vehicle or 10µM ITE every 12 hours for 3 days. Total
cellular protein was isolated and subjected to western blot analysis. Blots were probed with the
indicated antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to
GAPDH. Results shown are the means ± SEM of three independent experiments. Significant
changes in expression by ITE are indicated by * P < 0.05 or ** P<0.01.
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(10µM) to MDA-MB-231 cells every 12 hours for 1, 3 and 5 days to investigate whether it
reduces JAG1 expression in TNBC cells. We found that the levels of JAG1 protein were 2-fold
higher in vehicle-treated cells on day 5 compared with day 1 (Figure 25). Conversely, ITE
reduced JAG1 protein on day 1 (by~40%), day 3 (by ~ 50%) and day 5 (by ~ 63%) compared
with vehicle-treated controls (Figure 25). Based on these results, we also tested whether ITE
treatment would reduce JAG1 mRNA. The mRNA results mirrored the protein findings, showing
that JAG1 mRNA levels increased by day 5 compared with day 1 in control cells, and that JAG1
mRNA levels were significantly reduced by ITE on day 3 and day 5 compared with vehicletreated controls (Figure 25). Collectively, these data indicate that ITE reduces JAG1 mRNA,
which may in turn lead to reductions in JAG1 protein. To determine if ITE reduces JAG1 in
another TNBC cell line, we applied ITE (10µM) to MDA-MB-157 cells every 12 hours for 3
days and measured the levels of JAG1 protein. We also treated MDA-MB-231 cells as a positive
control based on our prior data showing that ITE reduced JAG1 in this TNBC cell line (Figure
25).
Similar to MDA-MB-231 cells, we found that JAG1 expression was also reduced in
MDA-MB-157 cells in the ITE-treated group compared to the control group (Figure 26). We also
tested whether ITE inhibited Notch signaling by measuring the levels of cleaved-NICD by
western blot analysis. The results showed that ITE decreased the amount of cleaved-NICD
present in both MDA-MB-231 and MDA-MB-157 cells (Figure 26). To investigate whether the
observed reductions in cleaved-NICD levels correlated with a decrease in the levels of a Notch
target gene, we probed blots with HES1 antibody. The findings showed that the levels of HES1
were reduced in MDA-MB-231 and MDA-MB-157 breast cancer cells in response to ITE
(Figure 26). Based on these findings, we postulate that ITE-stimulated AHR signaling reduces
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Figure 25. ITE Reduces JAG1 mRNA and Protein in MDA-MB-231 Cells
MDA-MB-231 cells were treated with vehicle or ITE every 12 hours for 1, 3 and 5 days. Total
cellular protein was isolated and western blot analysis was performed. Blots were probed with
JAG1 and GAPDH. Levels of JAG1 were normalized to GAPDH. Relative mRNA levels of
JAG1 normalized to GAPDH loading control was determined by RT-qPCR (as detailed in the
Material and Methods). Data shown are the means ± SEM of three independent
experiments. Significant increases on Day 5 compared with Day 1 are indicated by # P <
0.05. Significant decreases by ITE are indicated by * P < 0.05 or ** P<0.01.
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Figure 26. ITE Decreases JAG1 Protein Levels and Inhibits the Notch Signaling Pathway
in MDA-MB-231 and MDA-MB-157 Cells
MDA-MB-231 and MDA-MB-157 cells were treated with vehicle or 10µM ITE every 12 hours
for 3 days. Total cellular protein was isolated and subjected to western blot analysis. Blots were
probed with the indicated antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were
normalized to GAPDH. Results shown are the means ± SEM of three independent experiments.
Significant reductions by ITE are indicated by *P < 0.05, **P<0.01, or ***P<0.001.
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JAG1, which leads to reductions in cleaved-NICD levels and the expression of the Notch target
gene HES1 in TNBC cells.
5.4.9. AHR Mediates ITE-stimulated Reductions in JAG1, Cleaved-NICD, and HES1
Because ITE is an AHR ligand, we postulated that AHR knockdown cells would not
respond to ITE. To investigate this postulate, we transfected MDA-MB-231 cells with nontargeting siRNA or AHR-targeting siRNA. Cells were then treated with vehicle or 10µM ITE
every 12 hours for 3 days. We found a significant reduction in the levels of JAG1 and AHR
protein in the control cells transfected with non-targeting siRNA in response to ITE compared
with vehicle (Figure 27). We observed that cells transfected with AHR-targeting siRNA were not
responsive to ITE-stimulated reductions in JAG1, indicating that the suppressive effect of ITE on
JAG1 expression is transmitted through the AHR (Figure 27). Moreover, the findings showed
that siRNA-mediated knockdown of the AHR restored the levels of cleaved-NICD in ITE-treated
cells to that observed in control cells treated with vehicle (Figure 27).
Collectively, these results suggest that ITE-activated AHR signaling reduces the
expression of JAG1 and inhibits Notch signaling. We reasoned that reductions in JAG1 and
cleaved-NICD levels in response to ITE in control cells (transfected with non-targeting siRNA)
would lead to reductions in the levels of HES1. We, therefore, probed blots with HES1 antibody,
and the findings showed that ITE reduced the levels of HES1 in control cells, but not in the AHR
knockdown cells (Figure 27). Collectively, these data suggest that ITE-activated AHR signaling
suppresses JAG1-Notch-HES1 signaling in TNBC MDA-MB-231 cells.
As discussed in section 5.3.6., the AHR antagonist CH-223191 preferentially inhibits the
binding of TCDD to AHR; however, it does not inhibit the binding of non-halogenated AHR
ligands to the AHR (Zhao, Degroot, Hayashi, He, & Denison, 2010). Because ITE is a non-
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Figure 27. AHR Knockdown Indicates ITE-stimulated Suppression of JAG1 Expression in
MDA-MB-231 Cells is AHR-dependent
Control cells were transfected with non-targeting siRNA and AHR knockdown cells were
transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells were treated
with vehicle or 10µM ITE every 12 hours for 3 days. Total cellular protein was isolated and
subjected to western blot analysis. Blots were probed with the indicated antibodies. Levels of
JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH. Data shown are the means
± SEM of three independent experiments. Significant reductions by TCDD or AHR-targeting
siRNA are indicated by *P < 0.05, **P<0.01, or ***P<0.001.
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halogenated AHR ligand, we expected that it would not be antagonized by CH-223191. We
assessed the levels of JAG1 protein in MDA-MB-231 cells treated with ITE in the absence or
presence of CH-223191 and the results showed that this particular AHR antagonist does not
block ITE-mediated downregulation of the AHR or JAG1 (Figure 28). This selective-antagonism
is consistent with a prior report showing that CH-223191 selectively antagonizes TCDD, but not
other types of AHR ligands including ITE (Zhao, Degroot, Hayashi, He, & Denison, 2010). This
observed selectivity of CH-223191 for TCDD also suggests that ITE and TCDD reduce JAG1 by
activating the AHR through different binding sites on the AHR.
5.4.10. Tranilast Reduces JAG1 in MDA-MB-231 Cells
In addition to investigating the mechanism of how TCDD induces decreases in JAG1
expression, I have addressed how the non-toxic AHR agonist ITE also regulated JAG1
expression in breast cancer cells (Figure 24-28). Therefore, we performed AHR knockdown
experiments in MDA-MB-231 cells to determine whether this receptor mediates both TCDDand ITE-induced downregulation of JAG1 (Figures 23, 27-28). We observed that AHR
knockdown cells were unresponsive to both TCDD- and ITE-stimulated reductions in JAG1,
indicating that the suppressive effects of TCDD and ITE on JAG1 expression is dependent on
AHR activation. We questioned whether there are any other AHR ligands that have been known
to promote anti-cancer effects in breast cancer cells that can also reduce expression of JAG1 and
have clinical relevance. To answer this question, we treated MDA-MB-231 cells with tranilast to
see if it reduces JAG1 expression. Tranilast is a non-toxic AHR ligand that possesses clinical
relevance because it is a daily medication that targets inflammatory signaling to treat various
allergy symptoms and was shown to inhibit MDA-MB-231 cell growth and metastasis in vivo
(Prud’homme, et al., 2010). However, the mechanism behind the anti-cancer effects of tranilast
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Figure 28. AHR Antagonism via CH-229131 does not Inhibit ITE-stimulated Suppression
of JAG1 in MDA-MB-231 Cells
Control cells were treated with vehicle or 10µM ITE every 12 hours for 3 days. CH-223191
groups were treated with 10µM CH-223191 in the absence or presence of 10µM ITE every 12
hours for 3 days. Total cellular protein was isolated and subjected to western blot analysis. Blots
were probed with the indicated antibodies. Levels of AHR and JAG1 were normalized to
GAPDH. Data shown are the means ± SEM of three independent experiments. Significant
reductions by ITE or CH-229131 are indicated by *P < 0.05.
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has yet to be determined. We applied tranilast (200µM) to MDA-MB-231 cells every 24 hours
for 1, 3 and 5 days to investigate whether it reduces JAG1 expression in TNBC cells. We found
that the levels of JAG1 protein were significantly higher in vehicle-treated cells on day 5
compared with day 1 (Figure 29). Conversely, tranilast significantly reduced JAG1 on day 3 (by
~ 65%) and day 5 (by ~ 75%) compared with vehicle-treated controls (Figure 29). This data
reveals tranilast as another AHR ligand that promotes anti-cancer effects due to decreasing JAG1
expression and is critically important because it adds clinical relevance to this newly discovered
mechanism.
5.4.11. Invasive and Migratory Studies with ITE and JAG1 Knockdown in MDAMB-231 Cells
Because JAG1 has been reported to be important for the invasive and migratory activity
of MDA-MB-231 cells (Shimizu, et al., 2011), we sought to determine whether these MDA-MB231 processes are inhibited by ITE. To determine the effect of ITE on cell migration, we treated
cells with vehicle or ITE every 12 hours for 5 days and then used a pipette tip to make an
artificial gap in the confluent cell mass and monitored their capacity to migrate over the gap. We
found a significant decrease in the migration of cells treated with ITE compared with those
treated with vehicle (40% versus 85% of cells treated with ITE and vehicle, respectively, filled
the gap) (Figures 30A and 30B). We also predicted that ITE would suppress the ability of MDAMB-231 cells to invade through a matrigel-based basement membrane towards a chemoattractant
gradient provided by 10% FBS. We first determined whether MDA-MB-231 cells could invade
through the matrigel-based basement membrane towards medium supplemented with 10% FBS
as the chemoattractant. We observed significant increases (by ~ 155%) in the migration of
control cells towards 10% FBS compared with cell culture medium lacking FBS (Figure 30C).
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Figure 29. Tranilast Inhibits the Expression of JAG1 in MDA-MB-213 Cells at 1, 3, and 5
Days
MDA-MB-231 cells were treated with vehicle or tranilast every 24 hours for 1, 3 and 5 days.
Total cellular protein was isolated and western blot analysis was performed. Blots were probed
with JAG1 and GAPDH. Levels of JAG1 were normalized to GAPDH. Data shown are the
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Figure 30. ITE by inhibiting JAG1 Reduces the Migratory and Invasive Activity of MDAMB-231 Cells
A) Image of the scratch at 0 hours and 24 hours. B-C) Cells were treated with vehicle (DMSO)
or 10 µM ITE every 12 h for 5 days prior to the indicated assay. D-F) Control cells were
transfected with non-targeting siRNA. JAG1 knockdown cells were transfected with JAG1targeting siRNA. The indicated assays were performed 48 hours after transfection. D) Total
protein was subjected to western blot analysis and blots were probed with indicated antibodies.
JAG1 was normalized to GAPDH. B-F) Data shown are means ± SEM of at least 3 independent
experiments. Significant increase by 10% FBS is indicated by #P < 0.05. Significant reductions
by ITE or JAG1-targeting siRNA are indicated by * and $P < 0.05, respectively
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Introduction of ITE resulted in a significant decrease (by ~ 40%) in the invasive activity of cells
compared with control cells (Figure 30C).
We hypothesized that if ITE inhibits MDA-MB-231 migration by reducing JAG1, then
reducing JAG1 with JAG1-targeting siRNA should be sufficient to suppress the invasive and
migratory activity of MDA-MB-231 cells. Measuring the levels of JAG1 in MDA-MB-231 cells
transfected with JAG1-targeting siRNA showed that JAG1 protein was significantly reduced (by
~ 95%) compared with control cells transfected with non-targeting siRNA, indicating that our
JAG1 knockdown approach was valid (Figure 30D). We observed that the cells with JAG1
knockdown had defects that mirrored cells treated with ITE, namely reductions in migratory and
invasive activity compared with control cells transfected with non-targeting siRNA (Figures 30E
and 30F). Our finding that ITE treatment mimics the loss of migratory and invasive activity of a
JAG1 knockdown suggests that ITE affects the behavior of these TNBC cells by reducing JAG1.
5.5. Discussion
The findings of this study have provided the first evidence for crosstalk between ligandactivated AHR signaling and JAG1-Notch signaling pathways in ER-positive and ER-negative
breast cancer cells. Considering that the JAG1-Notch pathway has been shown to promote the
aggressiveness of breast cancer, our findings suggest that modulating the activity of AHR with
AHR ligands could be a novel way to suppress breast cancer progression. This discovery is
therefore novel and provides a new perspective into the mechanism(s) by which ligand-activated
AHR signaling inhibits breast cancer hallmarks including cell proliferation, invasion and
migration (Zhang, et al., 2009; Hall, et al., 2010; Zhang, et al., 2012). We have expanded our
previous list of TRGs (137) in MCF7 cells and found that this more extensive list of TRGs (660)
is significantly enriched in pathways, which represent new TCDD effects on breast cancer
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development (i.e. cell-to-cell communication) (Table 5 and 6). Interestingly, the new TRGs (660)
were significantly enriched in cell movement pathways (Table 6 and 8), which supports and
extends prior reports showing that TCDD regulates the migratory and invasive activity of breast
cancer cells (Zhang, et al., 2012; Hsu, et al., 2007).
It is important to also point out that the ability of ITE to reduce JAG1 expression in
breast cancer cells indicates that ITE could be an effective AHR ligand for the treatment of this
disease (Figures 24-28). Because the survival of the CSC population is dependent on JAG1Notch4 signaling (Harrison, et al., 2010; Simões, et al., 2015), it suggests that ITE could target
this population of highly tumorigenic cells by targeting JAG1. JAG1 expressed in breast cancer
activates Notch signaling in bone, which induces pathways that make bone more amenable to
breast cancer cell invasion and therefore metastasis (Sethi, Dai, Winter, & Kang, 2011). Future
studies of the role of ITE in these areas of breast cancer research (CSC and metastasis) may lead
to new possibilities in the treatment of both ER-positive and ER-negative breast cancer.
This research also acknowledges that AHR activation has a different outcome in ERpositive breast cancer cells, as the Notch pathway was shown to be activated in the presence of
TCDD and ITE (Figures 20 and 24). However, the Notch pathway that is activated in ERpositive breast cancer cells may result in a different physiological outcome (i.e. cell morphology)
compared to JAG1-dependent Notch activation due to JAG1 having the ability to regulate gene
expression independent of the NICD via its intracellular domain (JICD) (Ascano, Beverly, &
Capobianco, 2003). Therefore, further research is required to identify unique direct JICD-gene
targets that may play a role in the promotion of metastatic behavior and CSC maintenance in
breast cancer.
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5.5.1. Potential Mechanisms by which TCDD and ITE Differentially Regulate Notch
Signaling in ER-negative and ER-positive Breast Cancer Cells
Our results showing that TCDD and ITE increase the levels of cleaved-NICD and HES1
in MCF7 cells suggest that these two AHR ligands activate Notch signaling in ER-expressing
breast cancer cells (Figures 20 and 24). In the canonical Notch pathway, the binding of a Notch
ligand induces the proteolytic cleavage of the NICD from the Notch receptor and this is mediated
by γ-secretase and ADAM (Borggrefe & Liefke, 2012). In mammals, there are five Notch
ligands (JAG1, JAG2, DLL1, DLL3 and DLL4) (Chillakuri, et al., 2013). Our finding that ITE
and TCDD increase the levels of cleaved-NICD suggests that these two AHR ligands may have
increased the expression of a Notch receptor ligand in MCF7 cells. We can rule out JAG1 as a
potential Notch ligand that is induced by TCDD and ITE, because our data shows that these two
AHR ligands reduce JAG1 expression (Figures 19-29). When considering the remaining four
Notch ligands, our RNA-seq analysis identified almost a two-fold increase in the expression of
DLL1 in response to the 6 hour 100nM TCDD treatment in MCF7 cells (Table 7 and 11). This
suggests that TCDD and ITE may potentially increase the levels of cleaved-NICD by inducing
the expression of DLL1, which in turn binds to and activates the Notch1 receptor in MCF7 and
T47D cells (Figure 31). However, this observation is speculative. Proving that TCDD and ITE
induce Notch signaling in MCF7 and T47D cells by promoting the binding of DLL1 to the Notch
receptor will require future experiments. Our findings indicate that ITE and TCDD increase the
levels of cleaved-NICD in MCF7 and T47D cells, yet these two ligands decrease the levels of
cleaved-NICD in MDA-MB-231 cells (Figures 22-23, 25-28), and ITE decreases levels of
cleaved-NICD in MDA-MB-157 cells (Figure 26). Our discovery that TCDD and ITE selectively
increased the levels of cleaved-NICD in ER-positive breast cancer cells yet decreased its levels
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Figure 31. Potential Mechanism(s) that Inhibit JAG1 Expression via AHR Activation in
ER-positive Breast Cancer Cells
TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin, ITE = 2-(1’H-indole-3’-carbonyl)-thiazole-4carboxylic acid methylester, AHR = Aryl Hydrocarbon Receptor, DLL1 = Delta-like Ligand 1,
ER = Estrogen Receptor, NICD = Notch Intracellular Domain, HES1 = Hairy Enhancer of Split
1, JAG1 = Jagged1, miRNA-21 = microRNA-21. Green Arrows = Increased Expression, Red
Arrows = Decreased Expression.
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in TNBC cells, suggests that the ER may contribute to the observed increases in cleaved-NICD
in response to ligand-activated AHR. The findings of prior reports showing that the AHR and ER
crosstalk supports our postulate that the ER may play a role in mediating ITE- and TCDDstimulated increases in cleaved-NICD levels in ER-positive breast cancer cells.
With regard to TNBC cells, we postulate that the observed decrease in cleaved-NICD
levels in response to ITE and TCDD is secondary to the reductions in JAG1 protein. Prior reports
have identified that JAG1 is the primary Notch ligand that triggers activation of the Notch1
receptor (leading to increases in cleaved-NICD levels) in TNBC cell lines (Cohen, et al., 2010;
Yamamoto, et al., 2013; Dickson, et al., 2007; Reedijk, et al., 2005). We, therefore, hypothesize
that TCDD and ITE first downregulate JAG1, which in turn leads to decreases in the activity of
Notch signaling and reduces the levels of cleaved-NICD in TNBC cells (MDA-MB-231 and
MDA-MB-157). Based on the findings in these prior reports, we propose that the downregulation
of cleaved-NICD levels in response to TCDD and ITE in TNBC cells (MDA-MB-231 and
MDA-MB-157) is caused by the observed reductions in JAG1 protein levels.
5.5.2. Potential Mechanisms by which TCDD and ITE Reduce JAG1 Expression in
ER-negative and ER-positive Breast Cancer Cells
We propose that there are several mechanisms by which TCDD and ITE could reduce the
expression of JAG1 in ER-positive and ER-negative breast cancer cells. Regarding ERexpressing breast cancer cells (MCF7 and T47D), the levels of HES1 protein were induced by
TCDD and ITE (Figures 20 and 24). Given that HES1 is a transcriptional repressor that has been
shown to directly suppress the transcription of JAG1 in other cellular systems (So, et al., 2015;
Kobayashi & Kageyama, 2010), it is possible that TCDD and ITE inhibit the expression of JAG1
by increasing the levels of HES1 (Figure 31). However, TCDD and ITE do not increase HES1 in
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MDA-MB-231 and MDA-MB-157 cells, indicating that these two AHR ligands do not suppress
the expression of JAG1 by increasing the HES1 in these two TNBC cell lines (Figure 26). In
addition to HES1, prior reports have shown that miRNA-21 (microRNA-21) inhibits the
translation of JAG1 mRNA in MCF7 cells (Selcuklu, Donoghue, Kerin, & Spillane, 2012).
Considering that the non-toxic AHR ligand DIM has been reported to increase the expression of
miRNA-21 in MCF7 cells (Jin, 2011), it is possible that TCDD and ITE reduces the expression
of JAG1 in ER-positive breast cancer cells by increasing the levels of miRNA-21 (Figure 31).
The potential for a miRNA-21-based mechanism for suppressing the expression of JAG1 in
response to ligand-activated AHR is more likely to occur in ER-positive breast cancer cells and
not TNBC cells, given that prior reports have shown that this particular microRNA is not
inducible in TNBC cells (i.e., MDA-MD-231 and MDA-MB-468) (Selcuklu, Donoghue, Kerin,
& Spillane, 2012; Jin, 2011).
For reasons detailed in the previous paragraph, we postulate that increases in HES1 or
miRNA-21 in response to TCDD or ITE could induce the observed downregulation of JAG1 in
ER-positive, but not TNBC cells. We hypothesize that AHR-mediated suppression of NF-kB is
the primary mechanism by which ITE and TCDD suppress the transcription of JAG1 in TNBC
cells (MDA-MB-231 and MDA-MB-157) (Figure 32). NF-kB is a transcription factor that is
more highly expressed and active in TNBC compared with ER-positive breast cancer
(Yamamoto, et al., 2013; Yamaguchi, et al., 2009). The higher activity and expression of NF-kB
in TNBC cells is attributed to constitutive expression of pro-inflammatory cytokines (i.e., IL-6
and TNFα), which act through their cell surface receptors to induce signaling that increases the
levels and activity of NF-kB (Figure 13). The NF-kB family is composed of five members p50,
p52, RelA, RelB, and c-Rel, which promote JAG1 expression (Yamamoto, et al., 2013).
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p50-RelA
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Figure 32. Potential Mechanism that Inhibits JAG1 Expression via AHR Activation in ERnegative Breast Cancer Cells
TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin, ITE = 2-(1’H-indole-3’-carbonyl)-thiazole-4carboxylic acid methylester, AHR = Aryl Hydrocarbon Receptor, IL-6 = Interleukin-6, RelA =
V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A. Green Arrows = Increased
Expression, Red Arrows = Decreased Expression.
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The primary NF-kB subunit that has been reported to transcriptionally activate JAG1 is RelA
(Bash, et al., 1999; Johnston, Dong, & Hughes, 2009). Furthermore, RelA was identified to
specifically increase the transcription of JAG1 and not the other four Notch ligands (i.e., JAG2,
DLL1, DLL3 and DLL4) (Yamamoto, et al., 2013). Prior reports have shown that the AHR
signaling pathway extensively crosstalks with the NF-kB pathway to influence target gene
expression (Tian, 2009; Beischlag, Luis Morales, Hollingshead, & Perdew, 2008; Kim, et al.,
2000; Salisbury & Sulentic, 2015) (Figure 13). Notably, TCDD-activated AHR signaling inhibits
the binding of RelA to NF-kB binding sites in target genes (Tian, 2009; Salisbury & Sulentic,
2015) (Figure 13). Based on the findings of these prior reports, we hypothesize that ITE or
TCDD-activated AHR signaling inhibits the binding of RelA to NF-kB binding sites on the
JAG1 promoter, and reduces the transcription and expression of JAG1 in TNBC cells (Figure
32). Proving that ligand-activated AHR signaling suppresses RelA binding to the promoter of
JAG1 can be addressed in future studies.
5.5.3. Potential Mechanisms by which ITE Inhibits the Migratory and Invasive
Activity of MDA-MB-231 Cells
Our findings show that ITE inhibits the migratory and cell invasive activity of MDAMB-231 cells (Figures 29A-29C). Prior reports have shown that JAG1 and cleaved-NICD
increase the movement and invasive activity of MDA-MB-231 cells (Leong, et al., 2007;
Shimizu, et al., 2011). Our data indicates that ITE reduced the levels of JAG1 (Figures 25-28)
and cleaved-NICD (Figures 26-27) in TNBC cells. We, therefore, propose that ITE inhibits the
migratory and invasive activity of MDA-MB-231 cells by decreasing the levels of JAG1 and
cleaved-NICD (Figure 29). Prior reports have provided insight into the mechanisms by which
JAG1 and cleaved-NICD promote the migratory and invasive activity of TNBC cells using the
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MDA-MB-231 cell model (Shimizu, et al., 2011). The secreted serine protease, µPA, converts
plasminogen to plasmin, and it has been shown to be a marker of breast cancer recurrence, high
metastatic risk, and poor breast cancer prognosis (Shimizu, et al., 2011). Shimizu et al.
demonstrated that siRNA-mediated knockdown of JAG1 or Notch1 caused reductions in the
expression of µPA in three TNBC cell lines, including MDA-MB-231 cells (Shimizu, et al.,
2011). The authors conducted further work and showed that reducing the expression of JAG1 or
µPA was sufficient to suppress the migratory and invasive activity of MDA-MB-231 cells
(Shimizu, et al., 2011). Collectively, Shimizu et al demonstrated that JAG1-mediated Notch
signaling induced the transcription of µPA upon the NICD binding to the promoter region of the
µPA gene, which in turn promoted the invasive and migratory activity of MDA-MB-231 cells
(Shimizu, et al., 2011). While our findings show that ITE reduces the levels of JAG1 and
cleaved-NICD in TNBC cells, a future study will be required to investigate whether ligandactivated AHR signaling also reduces the expression of µPA in MDA-MB-231 cells.
In addition to inducing the expression of µPA, JAG1 and cleaved-NICD have been
reported to increase the transcription and expression of a Snail Family of Transcriptional
Repressor (SNAI) member (Leong, et al., 2007). The SNAI2 (Slug) gene encodes a
transcriptional repressor that upon binding to E-box motifs suppresses the transcription and
expression of E-cadherin (Bolós, et al., 2003). The suppression of E-cadherin induces EMT and
promotes the mesenchymal phenotype, which is more migratory and invasive compared with the
properties of the epithelial phenotype (Bolós, et al., 2003). Thus, JAG1 and the NICD have been
proposed to increase the migratory and invasive activity of TNBC cells by increasing the
expression of Slug, which in turn downregulates E-cadherin and promotes EMT (Niessen, et al.,
2008). Considering the findings of these prior reports, it is possible that ITE by reducing the
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levels of JAG1 and the NICD also reduces the expression of Slug and suppresses EMT in TNBC
cells. Recent studies have also suggested that Notch signaling induces a specialized type of EMT
during normal heart development and that Notch up-regulates SNAI1 (Snail) in endothelial cells
to promote mesenchymal transformation (Timmerman, et al., 2004; Noseda, et al., 2004).
Whether ITE downregulates Slug or Snail in TNBC cells can be addressed in future studies.
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CHAPTER 6
SNAIL: AN ESSENTIAL REGULATOR FOR EMT
The SNAI family of zinc-finger transcription factors consist of Snail, Slug and SNAI3
(Smuc), which all share an evolutionarily conserved role in mesoderm formation in vertebrates
(Nieto, 2002). They possess a highly conserved carboxy-terminal region that contain 4-6
acetylene-type zinc fingers, which regulate sequence-specific interactions within DNA promoters
containing a CAGGTG E-box sequence (Wu & Zhou, 2010). Snail expression in both vertebrate
and Drosophila suppress gene expression through the interaction with the co-repressor Cterminal binding protein (CtBP) and also by directly promoting repressor complex formation
(Nieto, 2002). Peinado et al. was able to demonstrate that Snail interacted with co-repressor
complex Histone Deacetylase Complex Subunit Sin3a (SIN3A), histone deactylase 1 (HDAC1),
and histone deactylase 2 (HDAC2) in order to inhibit E-cadherin expression (Peinado, Ballestar,
Esteller, & Cano, 2004).
Snail employs global effects on the genome in epithelial cells and by altering the gene
expression profile. Therefore, it is involved in regulating EMT (Kalluri & Weinberg, 2009), cell
survival (Emadi Baygi, Soheili, Schmitz, Sameie, & Schulz, 2010), apoptosis (Kurrey, et al.,
2009), cell polarity (Moreno-Bueno, Portillo, & Cano, 2008) and stem cell-like properties
(Kurrey, et al., 2009). The regulatory and functional roles of Snail emerged as one of the hottest
topics in medicine these past few years in cancer biology. This chapter will focus on the
regulation of Snail and discuss its functions in EMT and stem cells, as well as how our lab shows
that TCDD and ITE regulate Snail in an AHR-dependent manner.
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6.1. Regulation of Snail
Snail has been identified as a highly unstable protein and is regulated by both protein
stability and cellular location. The expression of Snail is regulated by an integrated and complex
signaling network at the transcriptional and post-transcriptional level. This network includes
integrin-linked kinase (ILK), PI3K, MAPKs, GSK-3b, and NF-kB pathways (De Craene, van
Roy, & Berx, 2005; Wu, Y. et al., 2009). Fibroblast growth factor (FGF) and EGF signaling
induces Snail expression by suppressing the activity of GSK-3b (Wu & Zhou, 2010).
Many signaling pathways that are involved in embryonic development also regulate Snail
expression. One example is the TGFb signaling pathway, which induces Snail expression via
Smad binding directly to the Snail promoter in hepatocytes, epithelial and mesothelial cells (Xu,
Lamouille, & Derynck, 2009). Additionally, Notch signaling utilizes two distinct mechanisms
that regulate Snail expression synergistically by recruiting the NICD to the Snail promoter and
by NICD-HIF1a promoting expression of lysyl oxidase (LOX), a known stabilizer of Snail
(Sahlgren, Gustafsson, Jin, Poellinger, & Lendahl, 2008; Peinado, et al., 2005). The Wnt
signaling pathway also stabilizes Snail by suppressing GSK-3b activity (Yook, Li, Ota, Fearon,
& Weiss, 2005).
Snail expression can also be regulated by the NF-kB pathway via transcriptional and
post-transcriptional mechanisms. GSK-3b inhibition stimulates the transcription of Snail by
activating the NF-kB pathway (Bachelder, Yoon, Franci, de Herreros, & Mercurio, 2005). Posttranscriptionally, TNFa is the major signaling pathway that induces Snail stabilization. TNFaNF-kB-stabilized Snail is mediated by the transcriptional induction of casein kinase-b (CSN2),
which results in the inhibition of phosphorylation and ubiquitylation of Snail by GSK-3b (Wu,
Y., et al. 2009).
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6.2. Snail, EMT, and Stem Cells
EMT is a profound event for large-scale cell movement during morphogenesis at the time
of embryonic development (Wang, Shi, Chai, Ying, & Zhou, 2013). During this process,
epithelial cells detach from neighboring cells and gain mesenchymal properties, which enables
them to break through the basement membrane that separates different tissues within the embryo
(Kalluri & Weinberg, 2009). One of the hallmarks of EMT is the functional loss of E-cadherin,
which is thought to be metastatic suppressor during tumor growth and progression (Hanahan &
Weinberg, 2011). Snail is a prominent inducer of EMT by strongly repressing E-cadherin
expression (Barrallo-Gimeno & Nieto, 2005).
Because a similar process occurs at the invasive front of metastatic cancer, it has been
proposed that tumor cells exploit the developmental EMT program for their metastatic
dissemination. Metastasis is responsible for a majority of cancer patient deaths and is divided
into a series of steps, including detachment of tumor cells from the primary tumor, invasion,
intravasation, anoikis-resistance, extravasation, and secondary-site colonization (Pantel &
Brakenhoff, 2004). EMT is involved in the metastatic cascade of many solid tumors and entails
the molecular reprogramming and phenotypic changes that characterize the conversion of
immobile cancer epithelial cells to motile mesenchymal cells. Therefore, expression of Snail
positively correlates with tumor grade, recurrence, metastasis, and poor prognosis in various
cancer types (Peinado, Olmeda, & Cano, 2007; Hemavathy, Ashraf, & Ip, 2000; Moody, et al.,
2005; Chen, et al., 2010).
From a physiological stand-point, stem cells are the basis for tissue homeostasis in the
adult organism (Fuchs, Tumbar, & Guasch, 2004). Recent evidence has shown that Snail plays a
role in the preservation of stem cell function. de Frutos et al was able to demonstrate that Snail
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plays a fundamental role in controlling bone mass and bone homeostasis by acting as a repressor
of RUNX2 and Vitamin D Receptor (VDR) transcription (de Frutos, et al., 2009). The expression
of Snail is tightly regulated in bone development and its activity on osteoblasts regulates bone
cell differentiation in order to ensure proper bone remodeling (Wu & Zhou, 2010). Additionally,
Snail also regulates genes that are involved in neural stem cell self-renewal and multi-potency
(Southall & Brand, 2009). These observations identify that Snail is an important factor to the
preservation of stem cell function and maintenance.
6.3. TCDD and ITE Regulate Snail in an AHR-dependent Manner
Knowing that JAG1-dependent Notch signaling promotes expression of various target
genes that are required to promote cancer growth at various stages of tumor progression, we
questioned if whether the target genes downstream are also affected by ITE and TCDD
treatments in breast cancer cells. Therefore, we measured the changes of Snail, a down-stream
target of JAG1-Notch1 signaling that is critical for promoting EMT by suppressing the
expression of E-cadherin (Li, Masiero, Banham, & Harris, 2014).
When T47D and MDA-MB-231 cells were treated with 10nM TCDD, our data indicated
that TCDD was able to significantly decrease Snail expression after 24 hours (Figure 33). In the
case of ITE, we treated T47D, MDA-MB- 231, and MDA-MB-157 cells with 10µM ITE for 3
days to determine if there were any changes in Snail expression and observed decreases in Snail
in all three cell lines (Figure 33), signifying that the regulation of Snail via activation of the AHR
is independent of the ER.
In order to determine if regulation of Snail was AHR-dependent, MDA-MB-231 cells
transfected with non-targeting siRNA or AHR-targeting siRNA were treated with vehicle or 10
µM ITE for 3 days. We found a significant reduction in the levels of Snail protein in the
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Figure 33. Activation of AHR via TCDD and ITE Inhibits Snail Expression in Breast
Cancer Cells
A) T47D and MDA-MB-231 cells were treated with vehicle or 10 nM TCDD for 24 h. B) T47D,
MDA-MB-231, and MDA-MB-157 cells were treated with vehicle or 10µM ITE every 12 h for 3
days. Total cellular protein was isolated and subjected to western blot analysis. Blots were
probed with the indicated antibodies. Levels of Snail were normalized to GAPDH. Results
shown are the means ± SEM of three independent experiments. Significant reductions by ITE are
indicated by *P < 0.05 or **P<0.01.
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control cells treated with ITE compared with cells treated with vehicle (Figure 34). Finding that
ITE reduces the levels of Snail protein in control cells is consistent with our prediction that ITE
is functioning as an AHR ligand in MDA-MB-231 cells. We observed that AHR knockdown
cells were not responsive to ITE-stimulated reductions in Snail, indicating that the suppressive
effect of ITE on Snail expression is transmitted through the AHR (Figure 34). Collectively, our
data suggests that various AHR ligands that have been known to promote anti-cancer effects is
potentially achieved through a common mechanism of reducing JAG1 expression. This in turn
would expect to decrease the expression of genes that are targets of JAG1-dependent signaling,
which are required for cancer progression.
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Figure 34. AHR Knockdown Indicates ITE-stimulated Suppression of Snail Expression in
MDA-MB-231 Cells is AHR-dependent
Control cells were transfected with non-targeting siRNA and AHR knockdown cells were
transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells were treated
with vehicle or 10µM ITE every 12 hours for 3 days. Total cellular protein was isolated and
subjected to western blot analysis. Blots were probed with the indicated antibodies. Levels of
Snail and AHR were normalized to GAPDH. Data shown are the means ± SEM of three
independent experiments. Significant reductions by ITE or AHR-targeting siRNA are indicated
by ***P<0.001.
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CHAPTER 7
DISCUSSION AND FUTURE DIRECTIONS
7.1. Discussion
Towards the end of my research project, AHR signaling became even more fascinating
compared to when I first began studying it over three years ago. With AHR biology being so
diverse in its ability to bind various ligands, the endogenous roles seem to reveal themselves
slowly and branch out into a variety of cellular functions. In the realm of toxicology, the AHR is
one of the most commonly studied receptors, given the breadth of compounds which work
through AHR signaling to exert their effects. Even though the AHR has been studied extensively
in response to over 400 exogenous ligands, which include environmental pollutants/toxicants,
various drugs, and phytochemicals, there is still much to learn about endogenous AHR cellular
signaling. It is important to note that the AHR is an evolutionarily conserved protein, which has
played a vital role for allowing researchers to make great strides in understanding the
endogenous function of AHR. Moreover, researchers were also able to help characterize
endogenous AHR ligands that are produced by the microflora present in the body, based on diet
composition (Denison, Soshilov, He, DeGroot, & Zhao, 2011). While AHR research has shifted
from toxicology-based to a more cancer-based emphasis (Safe, Cheng, & Jin, 2017), it is clear
there is still much to learn regarding AHR functionality in both normal and cancer cell
physiology.
Our research objective was simple as well as diverse, which was to reveal a new tumor
suppressing role for the AHR in breast cancer by hypothesizing that non-toxic AHR ligands can
induce anti-cancer effects by regulating the expression of JAG1 and the Notch signaling
pathway. Since that has been accomplished, we can continue to approach this objective from
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alternate perspectives, as will be detailed later in this chapter. First, our findings show that
TCDD and ITE reduce JAG1 in both ER-positive (MCF7 and T47D) and ER-negative (MDAMB-231 and MDA-MB157) breast cancer cells as a novel discovery and provides a new insight
into the mechanism by which ligand-activated AHR signaling inhibits cancer hallmarks
including cell invasion and migration (Figures 19-29). However, our findings also show that the
AHR acts as a Notch signaling modulator, which is potentiated in a cell-type dependent manner.
This is due to the AHR activating the Notch signaling pathway in ER-positive cells (Figures 20
and 24) but inhibiting it in ER-negative cells (Figures 22, 26-27). Additionally, we were able to
characterize cell-cell communication and cell movement as new bio-functional roles for AHR
through RNA-seq analysis (Table 6). Therefore, future work involving the identification of
downstream target genes that are unique to JAG1-dependent Notch signaling and that are also
regulated by AHR activation would increase the evidence for the tumor-suppressing roles of the
AHR. The following sections will cover the therapeutic implications for targeting the AHR in
both ER-positive and ER-negative breast cancer cells.
7.1.1. Therapeutic Implications for Targeting ER-positive Breast Cancer via AHR
Activation
It is important for us to consider the potential therapeutic implications for targeting the
AHR through the use of non-toxic agonists for the treatment of ER-positive breast cancer. It has
been demonstrated that the protective effects of AHR ligands on tumor growth are related to the
ability of the receptor to antagonize ER signaling (Murray, Patterson, & Perdew, 2014). The
functional outcomes of the antagonistic AHR-ER crosstalk are apparent in both in vitro and in
vivo models in which TCDD was shown to completely reverse the proliferative effects of
estrogen mediated signaling (Weng, Tsai, Kulp, & Chen, 2008; McDougal, Wormke, Calvin, &
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Safe, 2001). In addition to the antagonistic effects on ER signaling, the AHR also regulates key
processes required for breast cancer cell growth (McDougal, Wilson, & Safe, 1997), cell cycle
control (Barhoover, Hall, Greenlee, & Thomas, 2010), chemokine signaling (Hsu, et al., 2007),
and cell migration (Hall, et al., 2010).
There are some cases that argue activation of the AHR promotes breast cancer
progression and that inhibiting AHR activity is the best route for the treatment of ER-positive
breast cancer. Dubrovska et al. demonstrated tamoxifen-resistant MCF7 cells maintain the CSC
population through the C-X-C motif chemokine receptor 4 (CXCR4), which resulted in the
activation of AHR-dependent gene transcription (Dubrovska, et al., 2012). This research
proposed that inhibition of CXCR4 or AHR (via antagonists) specifically targets the CSC
population and could be beneficial for the treatment of tamoxifen-resistant breast cancer.
However, it is uncertain if AHR activation occurs in a ligand-dependent manner in this particular
case, as the role of the AHR in facilitating cell cycle progression is primarily manifested in the
absence of an exogenous ligand because treatment with AHR agonists inhibits cell cycle
progression (Gomez-Duran, et al., 2009; Greenlee, Hushka, & Hushka, 2001; Elferink, Ge, &
Levine, 2001). It is therefore important to consider the possibility that there is a genuine ligandindependent AHR activation mechanism as it was demonstrated by Ikuta et al, who showed that
tumor cells with high levels of the AHR undergo dynamic nucleocytoplasmic shuttling (Ikuta, et
al., 2000). Dynamic nucleocytoplasmic shuttling could lead to AHR and ARNT
heterodimerization in the absence of ligand and present a different physiological outcome
compared to ligand-activated AHR signaling. This mechanism could also potentially occur in the
CSC population of ER-positive breast cancer cells, where the AHR promotes pro-tumorigenic
characteristics in a ligand independent manner (Oesch-Bartlomowicz, et al., 2005). However, our

145

lab measured gene expression with cancer profiling gene arrays that revealed TCDD-treated
MCF7 breast cancer cells decreased the mRNA expression of CXCR4, signifying another
addition to the tumor-suppressing role for ligand activated AHR signaling in MCF7 cells (Raw
reads and processed RNA-seq data were deposited in the Gene Expression Omnibus (GEO) at
the National Center for Biotechnology Information and are accessible via accession number
GSE98515). Hall et al. also demonstrated that TCDD inhibited expression of CXCR4 in both
ER-positive and ER-negative breast cancer cells (Hall, et al., 2010). Interestingly, Chiaramonte
et al. demonstrated that Notch activation was able to promote both multiple myeloma and
ovarian cancer growth and metastasis by promoting the expression of CXCR4, making the Notch
signaling pathway a viable target for treatment in these particular cancers (Chiaramonte, et al.,
2015). Based on our data and current literature, it is possible that AHR activation inhibits JAG1
expression, resulting in the decrease of CXCR4 mRNA expression as shown by our RNA-seq
analysis. Therefore, it is safe to postulate that even though both ITE and TCDD activated the
Notch pathway in ER-positive breast cancer by increasing cleaved-NICD and HES1 levels, the
decreased expression of JAG1 and CXCR4 indicates that JAG1-dependent Notch signaling may
be responsible for the regulation of CXCR4. However, further studies must be conducted to fully
elucidate this mechanism.
A study conducted by Al-Dhfyan et al. provides another example on how AHR activation
mediates the expansion of the BCSC population in MCF7 cells. This extensive study provided
the first strong evidence that activation of the AHR-CYP1A1 pathway via TCDD and 7,12dimethylbenz(a)anthracene (DMBA) promoted CSC development, maintenance, self-renewal,
and chemo-resistance through inhibition of phosphatase and tensin homolog (PTEN) and
activation of b-catenin and Akt-pathways (Al-Dhfyan, Alhoshani, & Korashy, 2017). Moreover,
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they showed that inhibition of the AHR via a-naphthoflavone sensitized CSCs to chemotherapy
by increasing the percentage of apoptotic CSCs in response to doxorubicin. However, even
though this study provides mechanistic insight into the relationship between AHR activation and
the CSC population from a toxicological stand-point, it does not establish appropriate clinical
relevance for antagonizing AHR for the treatment of ER-positive breast cancer. This study
utilized only highly stable carcinogenic compounds to determine functional relevance of AHR
activation on BCSCs as a means to promote AHR antagonism as a viable form of treatment.
Additionally, this study did not provide any evidence if this same outcome occurs with known
non-carcinogenic AHR agonists that have been demonstrated to promote inhibitory effects on the
CSC population and possess true clinical relevance. AHR agonists such as tranilast
(Prud’homme, et al., 2010), IC3 (Weng, Tsai, Kulp, & Chen, 2008), and DIM (Jin, 2011) were
shown to effectively inhibit the growth of both ER-positive and ER-negative breast cancer
similar to that of TCDD with none of the adverse effects. Moreover, their data regarding TCDD
treatments in MCF7 cells does not align with our data, as they showed that TCDD did not
increase the nuclear translocation of the NICD, hence why they claim the Wnt signaling pathway
is involved in CSC development, maintenance, and self-renewal. This can potentially be due to
the differences in our timed treatments as they treated MFC7 cells with TCDD for 3 days, which
may result in identifying down-stream effects of TCDD treatments rather than initial changes in
gene expression. Finally, and most importantly, this study looked at different functional
outcomes compared to our research as they studied AHR-regulated changes in mammosphere
formation and chemo-resistance while we observed changes in metastatic behavior involving
invasion and migration. Overall, what these discrepancies dictate is that the activation of the
AHR in the context of promoting the CSC phenotype in ER-positive breast cancer may require a
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process that balances the apparent advantage of modulating AHR activity for invasion, motility,
and colonization with the need for growth and proliferation. Unfortunately, the role of the AHR
in cellular physiology suffers from the toxicological origins of the receptor. In reality, the AHR
should be viewed in the same realm as other cellular receptors (i.e. ER, AR, and PR) with a
normal physiological role that can be disrupted by xenobiotic chemicals rather than a receptor
that evolved primarily as a xenobiotic sensor.
Despite the discrepancies present with AHR activation regarding the promotion of cell
proliferation and stem-cell maintenance, our lab was able to show AHR activation prevents
cancer promoting bio-functions, such as EMT and the metastatic process (i.e. invasion and
migration, see Figure 29). These anti-cancer functions are easily postulated due to our discovery
that both TCDD and ITE inhibit JAG1 expression in MCF7 cells, a vital component for the
promotion of metastasis, drug-resistance, and tumor recurrence (Li, Masiero, Banham, & Harris,
2014). Our hypothesis that TCDD inhibits these invasive and metastatic features in breast cancer
cells correlates with a study conducted by Hall et al., that demonstrated breast cancer cells
treated with exogenous AHR agonists (TCDD and DIM) significantly inhibited cell invasiveness
and motility by Boyden chamber assay and inhibited colony formation, in ER-positive cells
(Hall, et al., 2010). This is because they observed that AHR activation reduced the number of
invaded cells by 70% in MCF7, SKBR3, and ZR-75-1 breast cancer cell lines. In correlation with
this functional outcome, TCDD was able to significantly repress CXCR4 and matrix
metallopeptidase 9 (MMP9), two prominent genes heavily associated with metastasis (Hao, et
al., 2007). This observation not only correlates with our research, but also with a study
conducted by Dai et al, that demonstrated knockdown of JAG1 via siRNA resulted in decreased
expression of MMP9 in colorectal cancer cells, resulting in decreased invasion (Dai, et al.,
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2014). Additionally, knockdown of AHR via siRNA and the use of the AHR antagonist anaphthoflavone demonstrated that these anti-invasive outcomes were AHR-dependent (Hao, et
al., 2007). Together these studies suggest that the inhibition of motility and invasiveness by
exogenous AHR agonists are receptor-mediated and that endogenous AHR activity promotes an
anti-cancer role through inhibiting the metastatic process. Our discovery that the decreased
expression of JAG1 via TCDD and ITE in MCF7 cells could help elucidate the mechanism
behind the anti-metastatic effects of AHR activation.
Ultimately, the use of the non-toxic AHR agonists such as ITE in the presence of antiestrogenic treatments such as tamoxifen may provide a synergistic effect in the treatment of ERpositive breast cancer, especially drug-resistant breast cancer. The therapeutic strategy
combining AHR agonists and anti-estrogenic therapies is valid and logical, based on the study
conducted by Darakhshan & Ghanbar, where the combination of tranilast (a potent AHR agonist
which will be covered later in this chapter) and tamoxifen induced anti-tumorigenic effects in a
synergistic manner in MCF7 breast cancer cells (Darakhshan & Ghanbar, 2013).
7.1.2. Therapeutic Implications for Targeting ER-negative Breast Cancer via AHR
Activation
Some early stage and most later stage mammary tumors are ER-negative and patients
with ER-negative breast cancer do not respond well to endocrine therapy; successful adjuvant
chemotherapy requires the use of more highly cytotoxic agents commonly used to treat other
endocrine-independent tumors. These agents generally target some aspect of nuclear function
(i.e. DNA-chelation) or modulate microtubule formation/breakdown and include compounds
such as doxorubicin, cyclophosphamide, gemcitabine, taxanes, and capecitabine, a precursor of
5-flurouracil (5-FU) (Ismail-Khan & Bui, 2010). Evidence and observations from multiple
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studies on the use of AHR agonists for the treatment in ER-negative breast cancers possesses less
discrepancy and controversy compared to that of ER-positive breast cancer. These observations
may be due to the increasing evidence that the AHR plays a role in the inhibition of the
metastatic and invasive cellular processes, which are much more prominent in the ER-negative
breast cancer subtype (Hanieh, 2015; Hall, et al., 2010; Prud’homme, et al., 2010). These
observations stem from various extensive studies that show that treatment with exogenous AHR
agonists significantly inhibited cell invasiveness and motility in the Boyden chamber assay and
inhibited colony formation in soft agar regardless of ER, PR, or HER2 status (Hall, et al., 2010;
Meng, et al., 2000; Darakhshan & Ghanbar, 2013). This observation further signifies that the
anti-cancer mechanism behind AHR activation is not limited to the antagonistic action on ERdependent signaling. Zhang et al. demonstrated that both TCDD and the relatively non-toxic
AHR agonist 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) induced CYP1A1-dependent
ethoxyresorofin-O-deethylase (EROD) activity and inhibited proliferation of seven ER-negative
cell lines (BT474, HCC38, MDA-MB453, MDA-MB-435, MDA-MB-436, MDA-MB-157 and
MDA-MB-468) (Zhang, et al., 2009). In the case for MDA-MB-231 cells, Hall et al.
demonstrated decreased cell motility, invasiveness, and mammosphere formation in the presence
of TCDD and DIM (Hall, et al., 2010). Moreover, Prud’homme et al. clearly demonstrated that
tranilast is an AHR agonist with inhibitory effects on BCSCs and was especially effective against
CSCs in TNBC specifically selected for drug resistance (Prud’homme, et al., 2010). Therefore,
AHR activation presents a strong clinical application for the treatment for breast cancer,
especially for the TNBC subtype. However, there are a few studies that contribute AHR
activation to increased tumor progression and increased malignancy in ER-negative breast cancer
and are discussed below.
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One of those studies was conducted by Miret et al., which demonstrated that the
progression of TNBC occurs through AHR activation with the carcinogenic environmental
molecule hexachlorobenzene (HCB), and resulted in enhanced invasion and migration through
the promotion of the Smad, Jun amino-terminal kinase (JNK), and p38 pathway (Mireta, et al.,
2016). Enhanced invasion and migration indicates that HCB modulates crosstalk between AHR
and TGFb and consequently exacerbates a pro-migratory phenotype in MDA-MB-231 cells,
which contributes to a high degree of malignancy. Another case for AHR activation promoting
malignancy in MDA-MB-231 cells was demonstrated by D’Amato et al., as they showed that the
tryptophan metabolite kynurenine increased activation of AHR while cells were in suspension,
which in turn inhibits the cell death process anoikis during the metastatic process (D’Amato, et
al., 2015). Moreover, inhibition or knockdown of tryptophan 2,3-dioxygenase (TDO2) decreased
kynurenine production, increased anoikis sensitivity, while inhibiting proliferation, migration,
and invasion. Additionally, AHR inhibition or knockdown also decreased proliferation,
migration, and anchorage-independent growth. D’Amato et al. revealed that the TDO2-AHR
signaling axis activated in TNBC cells promoted anoikis resistance and metastasis, and that
pharmacological inhibition of TDO2 decreased lung colonization in a preclinical model of
TNBC.
These studies identify AHR as a tumor promoting factor in TNBC. However, there are
some therapeutic strategies to consider when incorporating AHR agonists in breast cancer
treatment regimens. Even though an endogenous AHR agonist such as kynurenine was able to
promote the metastatic process, we are unaware as to how these treatments regulate JAG1
expression. Moreover, kynurenine has been identified to be a weak AHR agonist (Mezrich, et al.,
2010), signifying that it has a low binding affinity to the AHR and can possibly be out-competed
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with non-toxic AHR ligands that are known to inhibit cancer as well as have a higher binding
affinity to the AHR, such as tranilast and ITE (Henry, Bemis, Henry, Kende, & Gasiewicz,
2006). This study allows us to postulate that perhaps these tumor-promoting AHR ligands may
not reduce JAG1 expression and may even increase its expression, which only adds to the
complexity of the endogenous regulatory roles of AHR and warrants further investigation.
However, as stated in the previous section, the role of the AHR in facilitating tumor progression
is only manifested in either the absence of a non-toxic exogenous AHR ligand (i.e. tranilast,
omeprazole, DIM, IC3) or through the knockdown and inhibition of the AHR (Ikuta, et al., 2000;
Al-Dhfyan, Alhoshani, & Korashy, 2017). Considering the fact that AHR signaling plays a
critical role in immunity, development, and hematopoiesis, targeting the AHR with antagonists
may promote unwarranted side effects during treatment.
Our studies reveal for the first time that TCDD and the endogenous AHR agonist ITE
plays a tumor suppressive role in two TNBC cell lines (MDA-MB-231 and MDA-MB-157)
(Figures 23, 25-30). We were able to determine that TCDD significantly decreased JAG1
expression after 24 hours in MDA-MB-231 cells, and that ITE was able to not only significantly
decrease JAG1 expression after 24 hours but was able to maintain JAG1 suppression over the
course of 5 days (Figure 25). Additionally, MDA-MB-231 cells treated with ITE for 3 days were
also able to inhibit the Notch signaling pathway because of the decrease in JAG1 (Figure 26).
This decrease of JAG1 expression was further indicted by observing decreases in the NICD
levels as well as the decrease of direct Notch target gene, HES1. Our AHR knockdown studies
were also able to demonstrate that inhibition of the Notch signaling pathway was AHRdependent, as removal of the AHR prevented ITE from suppressing JAG1 expression and
promoted the recovery of the Notch signaling pathway (Figure 27). In fact, in AHR knockdown
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cells not treated with ITE, there was significant increase in both JAG1 and NICD levels,
indicating that the AHR may act as a tonic JAG1 suppressor (Figure 27). MDA-MB-157 cells
were also treated with ITE for 3 days and mirrored the outcome of MDA-MB-231 cells, as the
decrease in JAG1 expression resulted in the inhibition of the Notch signaling pathway (Figure
26). From the functional perspective, we were able to demonstrate that the decrease in JAG1
expression from both ITE and JAG1-targeting siRNA inhibited both migration (scratch assay)
and invasion (Boyden chamber) of MDA-MB-231 cells (Figure 30).
Collectively, these results along with previously published data identify that activation of
the AHR inhibits invasion and migration, primarily through decreasing the expression of JAG1
and ultimately inhibiting the Notch signaling pathway in TNBC cells. Other than regulating
migration and invasion, JAG1-dependent Notch signaling also plays an important role in drugresistance and CSC maintenance (Li, Masiero, Banham, & Harris, 2014). This allows us to
hypothesize that ITE may promote inhibitory effects on BCSCs by decreasing JAG1 expression
and restore sensitivity to treatment regimens as it was demonstrated with the AHR agonist
tranilast. Tranilast was able to enhance treatment response and cytotoxicity in ER-negative breast
cancer in conjunction with tamoxifen and induced apoptosis in a synergistic manner (Darakhshan
& Ghanbar, 2013).
7.1.3. Preliminary Data
We expanded upon our first report showing that the decrease in JAG1 via TCDD and ITE
were AHR-dependent by studying other AHR ligands that have been identified to be non-toxic as
well as promote anti-cancer effects. One of the AHR ligands of interest was tranilast, an antiallergy medication that has gained attention for its anti-metastatic effects that were shown in both
in vivo and in vitro studies (Rogosnitzky, Danks, & Kardash, 2012). We applied tranilast
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(200µM) to MDA-MB-231 cells every 24 hours for 1, 3 and 5 days and discovered that tranilast
reduced JAG1 on day 3 and day 5 significantly, compared with vehicle-treated controls (Figure
29). Overall, we were able to show that small molecules which are structurally unrelated to each
other may be able to promote AHR-dependent anti-cancer effects with the same mechanism, by
decreasing JAG1 expression. From this data and our current knowledge, we can now pose a new
question: Our laboratory has identified three AHR ligands that induce anti-cancer effects, do
other non-toxic AHR ligands reduce JAG1 expression as a common mechanism behind their
anti-cancer effects?
Even though TCDD has been identified as a carcinogen, its ability to inhibit cancer
progression in vitro as well as in breast cancer patients who’ve been exposed to this chemical
after diagnosis has also been documented (Murray, Patterson, & Perdew, 2014). This presented a
unique paradox, where AHR activation was identified to possess both pro-cancer and anti-cancer
affects and developed a schism between researchers in terms of identifying the endogenous
function of the AHR as well as the strategy for targeting AHR signaling in cancer therapies.
Based on the findings from our research, we hypothesized that decreases in JAG1 would
decrease the expression of JAG1-dependent downstream target genes that have previously been
identified to promote cancer progression, such as Snail (Chen, Imanaka, Chen, & Griffin, 2010)
(Figures 33 and 34). Interestingly, we discovered that AHR knockdown breast cancer cells via
AHR-targeting siRNA are unable to suppress JAG1 levels in the presence of both TCDD and
ITE (Figure 27). In fact, MDA-MB-231 cells treated with AHR-targeting siRNA showed that
JAG1 expression was significantly increased in the untreated AHR-targeting siRNA treated
group compared to the untreated control siRNA group (Figure 27). Our findings in this study
complemented those found by Safe et al., leading to the discovery of a novel pathway by which
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the AHR functions to modulate the Notch signaling pathway as a method for suppressing cell
cycle progression and metastasis in response to various non-toxic small molecules from both
endogenous (produced via metabolism by the micro flora in the GI tract) and exogenous (present
due to diet, environment, and medication regimen) sources (Safe, Cheng, & Jin, 2017). This
research regarding the diet and microbiome composition could help propose another potential
therapy target for treating breast cancer as well as provide new insight on how small molecules
from our environment and diet can potentially regulate developmental signaling pathways and
the induction of corresponding changes in cellular physiology. With this information we can
pose two questions: 1) Does AHR activation also change the expression levels of JAG1 target
genes that are known to promote cancer progression? 2) How do AHR ligands that have been
identified as tumor-promoting, besides TCDD, effect JAG1 expression as well as target genes
downstream of JAG1-dependent signaling?
As promising and novel as this discovery is, what is critical to note is that even though
the decrease in JAG1 expression is AHR-dependent, it is not a direct AHR target gene (GEO
accession number GSE98515). Our research led to a discovery that uncovers an extremely
important connection between the small molecules present in our environment and cancer
progression through the modulation of developmental signaling pathways. However, the
mechanism behind AHR-dependent JAG1 suppression has yet to be completely understood. A
viable mechanism can potentially be determined by identifying if any of the 189 TCDD-treated
AHR-direct target genes (Table 7) can also act as a repressor of JAG1 or if AHR decreases
expression of a certain gene that is known to promote JAG1 expression. Elucidating the
complete mechanism can serve a critical importance in determining the differences between the
endogenous functionality of the AHR in the both cancerous and non-cancerous cell lines,
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considering that increased JAG1 protein levels in cancer cells correlate with increased
aggressiveness and metastatic potential while normal epithelial type or non-malignant cells have
little to no JAG1 expression (Cohen, et al., 2010). Therefore, it is important to ask the questions:
1) What are some AHR-direct target genes that can act as a suppressor of JAG1 expression? 2)
Does AHR inhibit expression of a gene that promotes JAG1 expression?
We studied the regulation of JAG1 via ITE in two ER-positive cell lines (MCF7 and
T47D) and two TBNC cell lines (MDA-MB-231 and MDA-MB-157) (Figures 19-29).
Surprisingly, when we treated HCC1134 TNBC cells with ITE every 12 hours for 5 days, JAG1
expression was increased significantly compared to the control group (Figure 35), which is
completely opposite of the results in MDA-MB-231 cells. However, the levels of the AHR in
HCC1143 cells were significantly lower compared to MDA-MB-231 cells (Figure 35). These
results tell us that the amount of AHR present within the cell can potentially determine the
direction JAG1 is regulated as well as may be used as a biomarker to determine the efficacy of
treatment with AHR agonists. This further suggests that suppressing expression of JAG1 is an
endogenous function of AHR, where low AHR levels resulted in the promotion of JAG1
expression in the presence of ITE. Moreover, this observation may also shed insight on how
AHR signaling can promote both pro-cancer and anti-cancer effects via activation of the AHR as
well as how the initial amount of JAG1 and or AHR in cancer cells may potentially give rise to
different cellular outcomes. Additionally, the increase in JAG1 levels may also occur because
HCC1143 cells fall under a different sub-category of TNBC cells compared to MDA-MB-231
cells, as HCC1143 are classified as basal-like, while MDA-MB-231 are classified as
mesenchymal-like. This observation can be justified based on an extensive study conducted by
Yamamoto et al. that demonstrated NF-kB-dependent induction of JAG1 and the Notch-
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Figure 35. Activation of AHR via ITE Promotes JAG1 Expression in HCC1143 Breast
Cancer Cells
HCC1143 and MDA-MB-231 cells were treated with vehicle or 200µM Tranilast every 24 hours
for 5 days. Total cellular protein was isolated and subjected to western blot analysis. Levels of
JAG1 and HES1 were normalized to GAPDH. Results shown are the means ± SEM of three
independent experiments. Significant differences in untreated HCC1143 cells compared with
untreated MDA-MB-231 cells are indicated by #P < 0.05, ## P<0.01, or ### P<0.001. Significant
changes in expression by ITE are indicated by *P < 0.05, **P<0.01, or ***P<0.001.
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dependent expansion of the CSC population occurs only in the basal-like subtype of TNBC
(Yamamoto, et al., 2013). Ultimately, this observation can lead us to ask the question: Could
direct JAG1 inhibition via monoclonal antibodies or small molecule inhibitors be a novel
chemotherapy tactic for the treatment of breast cancer as it may by-pass the controversy behind
the use of AHR agonists in the treatment for breast cancer?
In short, we have uncovered several novel roles for the AHR in breast cancer. The AHR
is required for the anti-cancer effects of non-toxic AHR ligands in breast cancer cells (Hall, et
al., 2010). TCDD, a prominent and well-studied AHR ligand, exposed the mechanism behind the
anti-cancer effects of AHR (Murray, Patterson, & Perdew, 2014). These anti-cancer effects
resulted in the discovery of non-toxic AHR ligands that are currently produced endogenously by
the diet and certain medications (Hubbard, Murray, & Perdew, 2015). Finally, ITE (Cheng, et al.,
2015) and tranilast (Rogosnitzky, Danks, & Kardash, 2012) treatment studies revealed that JAG1
(Li, Masiero, Banham, & Harris, 2014) is required for the proliferation, invasion and cellmovement of TNBC cells and that various targets downstream of JAG1-dependent signaling are
also regulated by activation of the AHR. The next section will discuss the preliminary data that
we currently have that can help answer some of the questions that were mentioned in this
section, as well as provide insight for future projects surrounding the relationship between JAG1
and the AHR.
7.2. Rationale for New Experiments
We hypothesize that other non-toxic AHR ligands induce their anti-cancer effects by
decreasing the expression of JAG1 and thereby reducing the expression levels of other
oncogenes that require JAG1-dependent Notch signaling. The rationale for this hypothesis stems
from prior reports showing that JAG1 is increased in more aggressive cancer types and is known
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as an indicator of poor prognosis (Cohen, et al., 2010). Upon activating the Notch signaling
pathway, JAG1 induces gene expression that promotes various functions in cancer biology
including but not limited to metastasis, EMT, proliferation, drug-resistance, and CSC
maintenance (Li, Masiero, Banham, & Harris, 2014). The activation of the AHR is highly
relevant to the suppression of breast cancer, considering that overexpression of JAG1 is
sufficient to induce growth of normal mammary cells and induce mesenchymal characteristics
(Duryagina, et al., 2013). The JAG1 gene is not only amplified in more aggressive subtypes of
breast cancer but also in ovarian cancer (Steg, et al., 2011), brain cancer (Purow, et al., 2005),
and various types of leukemia (Li, Masiero, Banham, & Harris, 2014). In this regard, one study
noted JAG1 was critical for MDA-MB-231 breast cancer growth in vitro and in vivo (Chen, et
al., 2016). Our preliminary data demonstrate that the amount of AHR protein present within the
cell may perhaps determine the regulatory outcome of JAG1 expression, as we showed that ITEtreated HCC1143 TNBC cells increased JAG1 expression and that the AHR levels are much
lower compared to the MDA-MB-231 cell line (Figure 35). Given the previous reports and
current data, we hypothesize that regulation of JAG1-dependent signaling via activation of the
AHR could be determined by the amount of AHR protein that is present within the cell.
High JAG1 expression is linked to promoting metastasis in various cancer types and
Snail expression has also been shown to be a necessity for the metastatic process. Snail is
required for promoting the transformation of epithelial cells into mesenchymal cells, in order to
induce cell-movement and invasion (Chen, Imanaka, Chen, & Griffin, 2010). This is because
Snail inhibits the expression of E-cadherin by binding directly to its promoter and blocking its
transcription, thereby suppressing the characterizations of the epithelial cell type. Our
preliminary data demonstrate that AHR signaling decreases the expression of JAG1 and Snail via
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TCDD and ITE (Figures 20-22, 24-26, 33) and we provide the first evidence that this could be
mediated in an AHR-dependent manner (Figures, 23, 27-28, 34). Given the previous reports and
our current data, we hypothesize that the decrease in JAG1 expression reduces the levels of
downstream target genes of JAG1-dependent Notch signaling such as Snail as the mechanism for
the anti-metastatic activity of AHR activation.
It is well established that the Notch pathway and, in particular, JAG1-dependent Notch
activation plays an important role in tumor biology because it affects both cancer cells and
multiple components of the vascular and immunological microenvironment. It has also been
shown that excess Notch activation transforms normal breast cells found in pre-invasive and
invasive human breast cancer and correlates with early recurrence (Li, Masiero, Banham, &
Harris, 2014). Moreover, inhibition of Notch signaling reduced BCSC activity (Simões, et al.,
2015). However, the major concern for targeting the Notch pathway by GSIs was the GI toxicity
that resulted in severe diarrhea; as the Notch signaling pathway is necessary to maintain the
goblet cell population to maintain consistent water absorption in the GI tract (Katoh & Katoh,
2007). Furthermore, GSIs may target proteases other than g-secretase, which could result in
unwarranted regulatory array of cellular functions. In order to overcome such limitations, recent
studies have shown natural products that are non-toxic to humans, such as DIM (Hall, et al.,
2010), IC3 (Weng, Tsai, Kulp, & Chen, 2008), and other indoles and isoflavones (Sarkar, Li,
Wang, & Kong, 2010) could potentially inhibit the metastatic and invasion process via reducing
the expression of Notch receptors and/or Notch receptor ligands. Interestingly, many of these
natural products act as AHR ligands. Given this known data, we hypothesize that the endogenous
AHR ligand ITE can increase sensitivity to current cancer therapy agents such as tamoxifen. The
following sections will detail future experiments that will be done to test our hypothesis.
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7.3. Characterizing the Role of AHR-dependent Regulation of JAG1 in Other Breast
Cancer Cell Lines Using ITE
An agonist of the AHR was isolated from porcine lung tissue and identified as ITE. Three
experiments support the conclusion that ITE is an AHR agonist: 1) ITE was shown to compete
with radioactive TCDD for binding to the AHR in human, murine, killifish, and zebrafish (Song,
et al., 2002), 2) Saturation-binding isotherms indicated a high affinity interaction between ITE
and the AHR (Henry, Bemis, Henry, Kende, & Gasiewicz, 2006) and 3) ITE treatments changed
the AHR to its DRE-binding conformation and promoted CYP1A1 expression in a
concentration- and time-dependent manner (Henry, Bemis, Henry, Kende, & Gasiewicz, 2006;
Song, et al., 2002). Furthermore, administration of ITE to pregnant mice led to AHR signaling in
fetal tissues without the toxicities related to TCDD exposure, indicating in vivo bioactivity
(Nugent, et al., 2013).
Given our current data and knowledge, AHR signaling promotes a suppressive effect on
JAG1 expression potentially by the given amount of AHR protein present in the cell (Figure 35).
These experiments would establish if the AHR levels, which vary between cell lines, is
responsible for the regulatory outcome of JAG1 expression. Two TNBC cell lines showed
differential regulation in JAG1 expression, which can potentially be linked to the amount of
AHR protein present in the cell (Figure 35). This is because the levels of the AHR in HCC1143
cells were significantly lower compared to MDA-MB-231 cells (Figure 35). This data also
mimicked the results from the AHR knockdown experiments conducted in MDA-MB-231 cells
when treated with ITE, where loss of the AHR removed the ability for ITE to reduce JAG1
expression (Figures 23 and 27). Therefore, it is imperative to conduct ITE treatments in various
breast cancer cell lines, as well as non-cancerous mammary cell lines, to help identify and
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establish the true nature of the AHR and its role in the regulation of JAG1 expression.
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143,
MDA-MB-468), ER-negative with the mesenchymal subtype (BT549, MDA-MB-231 and
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) would be
plated in 6-well plates at a density of 200,000 cells/mL and grown to full confluency before
being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle. Cells will be
rinsed with PBS, and total cellular extract will be collected in SDS sample buffer [40% glycerol,
8% SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat
denatured and then separated by SDS/PAGE followed by transfer to PVDF membrane. The blots
will be incubated overnight at 4 °C while rocking in primary antibody followed by an incubation
period of 90 minutes in secondary antibody at room temperature (37°C). Blots will then be
rinsed five times (5 minutes per rinse) with PBST before undergoing chemiluminescence to
identify JAG1, cleaved-NICD, HES1, and AHR protein concentrations before and after ITE
treatment; GAPDH will used as a loading control. ChemiDoc MP Imaging System will be
utilized to quantify band density and acquire western blot images.
A two-tailed unpaired t-test will be used to determine significant changes in AHR, JAG1,
HES1 and cleaved-NICD, due to the TCDD and ITE activating Notch signaling in ER-positive
breast cancer (MCF7 and T47D), while inhibiting it in ER-negative breast cancer (MDA-MB231 and MDA-MB-157) and that ITE increased JAG1 and HES1 protein expression in HCC1143
breast cancer cells.
Cell lines that experienced significant reductions or increases in JAG1 expression will
undergo AHR knockdown with AHR-targeting siRNA, to determine if these changes in JAG1
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expression are AHR-dependent. In brief, cell suspensions of 200,000 cells/mL concentrations
will be mixed with 100nM of AHR siRNA with 3µL of Lipofectamine RNAiMAX in
DMEM/FBS (10%) for ~20 minutes. Cells will then be immediately plated on 35mm tissue
culture plates in DMEM/FBS (10%) and cultured for 48 hours before being treated with 10µM
ITE every 12 hours for 3 days, followed by western blot analysis of GAPDH (loading control),
JAG1, cleaved-NICD, HES1 and AHR. For significance to be determined, a one-way ANOVA
will be used along with a Tukey’s Post-hoc test, to compare changes in protein levels among the
different groups.
To determine if ITE affects cell migration and invasion, scratch and Boyden Chamber
assays will be conducted on cell lines that regulated expression of JAG1. For the scratch assay,
cells will be plated in 12-well tissue culture plates at a concentration of 50,000 cells/well for 24
hours prior to treatment. The cells will be treated with vehicle or 10µM ITE in DMEM/FBS
(1%) every 12 hours for 5 days, then a scratch will be made in each well with a pipette tip. Media
will be aspirated to remove floating cells. Vehicle (DMSO) or 10µM ITE will be reapplied in
DMEM/FBS (1%). The scratches will be photographed at 0 hours and at 24 hours post scratch
using the Lycia Microscope and the exposed surface area of the plates will be measured using
ImageJ analysis software. For the Boyden chamber assays, cells will be plated on 35 mm tissue
culture plates in DMEM/FBS (10%) for 24 hours prior to treatment. After cells are treated with
vehicle or 10µM ITE in DMEM/FBS (10%) every 12 hours for 5 days, they will be detached
from tissue culture plates (using trypsin) and counted. 100,000 cells will be immediately
transferred to cell invasion chambers in 500µL of media. Chambers filled with cells will be
incubated in 24-well tissue culture plates containing DMEM/FBS (10%) as the chemoattractant
and incubated for 36 hours. Following the incubation in the presence of vehicle (DMSO) or
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10µM ITE, a cotton swab will be used to remove non-adherent cells that were not invasive.
Invasive cells will be stained with crystal violet for 10 minutes at room temperature, then rinsed
gently with water and then incubated in DMSO for 10 minutes with orbital shaking to extract
crystal violet. Cell lysates will be measured at 560nm for invasive activity. For the indicated
siRNA experiments, the cell invasion will be assayed 48 hours after transfection.
7.4. Characterizing the Regulation of JAG1 and the Anti-cancer Effects of ITE Using an in
vivo Model
To confirm the regulation of JAG1 and its corresponding anti-cancer effects in vivo,
female NOD scid gamma mice (8 weeks of age and weighed 18-22 grams) will be injected
unilaterally with MDA-MB-231 cells (2.5x10 cells/animal) in 200µL of 50:50
6

Matrigel/Collagen I into the fourth abdominal fat pad by subcutaneous injection at the base of
the nipple as described by Iorns et al (Iorns, et al., 2012). When the tumor volume reaches
approximately 110mm3, the mice will be divided into homogeneous blocks based on their tumor
volumes followed by randomly assigning each block into the vehicle control and ITE treatment
group (N = 5/group). The vehicle (DMSO) or ITE (80 milligrams (mg)/mL in DMSO) will be
administered by intraperitoneal injection once daily for 28 days at a volume of 1mL/kg body
weight.
A gross body weight and tumor volume will be determined twice weekly using a scale
and calipers expressed in mm , respectively. Tumor weights will be converted from tumor
3

volumes by assuming a tumor density of 1 mm3 = 1 mg. A net body weight will be obtained by
subtracting a tumor weight from a gross body weight. After the final injection, mice will be
given an additional day to document the tumor volume, body weight, and other clinical signs
before mice are euthanized by CO2 asphyxiation. At the time of sacrifice, a macroscopic
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examination of metastases will be noted in lung, liver, and kidney; any visible metastatic foci
will be counted.
For western blot analysis, primary tumor tissue samples will be collected and
homogenized in lysis buffer containing protease inhibitors. The protein will be collected via
centrifugation and concentrations will be determined by a bicinchoninic acid protein assay. 40µg
of total protein will be boiled in SDS sample buffer [40% glycerol, 8% SDS, 5% BME, 0.04%
bromophenol blue in Tris-HCl pH 6.8] for 10 minutes and then separated by SDS/PAGE
followed by transfer to a PVDF membrane. The blots will be incubated overnight at 4°C with
rocking in primary antibody followed by an incubation period of 90 minutes in secondary
antibody at room temperature (37°C). Blots will then be rinsed five times (5 minutes per rinse)
with PBST before undergoing chemiluminescence to identify JAG1, cleaved-NICD, HES1, and
AHR protein concentrations before and after ITE treatment; GAPDH will used as a loading
control. ChemiDoc MP Imaging System will be utilized to quantify band density and acquire
western blot images.
7.5. Determining the Effects of ITE in Combination with Tamoxifen in Breast Cancer Cells
Darakhshan & Ghanbar demonstrated that the combination between tranilast and
tamoxifen enhanced anti-tumor effects in both ER-positive (MCF-7) and ER-negative cells
(MDA-MB-231) as this particular combination resulted in synergistic effects on growth,
proliferation, TGFb signaling as well as vascular endothelial growth factor (VEGF) and MMP9
expression (Darakhshan & Ghanbar, 2013). These studies suggest that combining non-toxic
AHR agonists such as ITE with current breast cancer chemotherapies as a novel approach to
increase treatment efficacy for both ER-positive and ER-negative breast cancer. This
combination could be particularly effective in patients with aggressive cancer types such as ER165

negative breast cancer due to increased dependency of JAG1-Notch signaling (Li, Masiero,
Banham, & Harris, 2014). Regarding ER-positive breast cancer, ~50% of breast cancer patients
treated with tamoxifen experienced tumor reoccurrence combined with drug-resistance due to
increased JAG1 expression in the CSC population in breast tumors (Simões, et al., 2015).
Therefore, utilizing a non-toxic AHR agonist such as ITE may help target the CSC population in
drug-resistant breast cancer cells due to its ability to decrease JAG1 expression.
For cell culture and treatments, MCF-7 and MDA-MB-231 breast cancer cells would be
grown and maintained at 37 °C with 5% CO2 in DMEM/FBS (10%). The concentrations of
tamoxifen used will be 1, 2, 5, 10, and 20µM, concentrations of ITE will be 0.01, .1, 1, 10,
100µM, and the combination treatment will be conducted in 2µM tamoxifen with a range of
concentrations of ITE (0.01, 0.1, 1, 10, 100µM) every 12 hours for 3 days.
For western blot analysis, after 3 days of treatment, cells will be rinsed with PBS and
total cellular extract will be isolated in 250µL of SDS sample buffer [40% glycerol, 8% sodium
SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat denatured
and then separated by SDS/PAGE followed by transfer to PVDF membrane. The blots will be
incubated overnight at 4°C with rocking in primary antibody followed by an incubation period of
90 minutes in secondary antibody at room temperature (37°C). Blots will then be rinsed five
times (5 minutes per rinse) with PBST before undergoing chemiluminescence to identify JAG1,
cleaved-NICD, HES1, and AHR protein concentrations before and after ITE treatment; GAPDH
will be used as a loading control. ChemiDoc MP Imaging System will be utilized to quantify
band density and acquire western blot images. A two-tailed unpaired t-test will be conducted for
each concentration to determine significant changes in protein expression between treated and
untreated cells.
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For RT-qPCR, total RNA will be extracted using RNA purification columns (Qiagen).
Reverse transcription will be performed on 300ng of RNA using cDNA synthesis kits (Applied
Biosystems (Foster City, CA)) in accordance with the suppliers’ instructions. Real-time PCR will
be conducted with the StepOnePlus (Applied Biosystems) using SYBR green master mix
(Applied Biosystems) in accordance with the suppliers’ protocols. Samples will be analyzed in
triplicate and the average will be normalized to GAPDH loading control. Relative changes in
gene expression will be quantitated using the 2−ΔΔCT formula. A two-tailed unpaired t-test will be
conducted for each concentration to determine significant changes in mRNA expression between
treated and untreated cells.
One property of BCSCs is the ability to form colonies in soft agar, so a colony forming
assay will be conducted (Prud’homme, et al., 2010; Cheng, et al., 2015). Briefly, 20,000 cells in
0.5% agar will be layered on preformed 0.8% agar layer using a 35mm non-tissue culture dish.
The cells in agar will be treated with either vehicle, 2µM tamoxifen, 10µM ITE or a combination
of both in DMEM/FBS (10%) every 12 hours for 7 days. Colonies will be counted under a
microscope using low magnification (4x) and photographed after 7 days.
To identify any changes in cell population, a cell proliferation assay will be conducted.
1x104 cells/well of either MCF-7 or MDA-MB-231 will be transferred to 96-well plates and be
incubated overnight. When treatments begin, 300µL of fresh medium with the indicated drug
concentrations will be added to each well and incubated. Treatments will be replenished every 12
hours for 3 days and will also be tested in triplicate as well as replicated independently three
times. After 72 hours, 20µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) solution (5mg/mL in PBS) will be added to each well and incubated for 4 hours. The
media with MTT will be discarded and 100µL of DMSO will be added to dissolve formazan
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crystals at room temperature for 30 minutes. The optical density of each well will be determined
at 570nm and the percentage of cell viability will be calculated according to the following
equation: Cell viability (%) = [A570(sample)/A570(control)] x 100.
To determine changes in migration, a scratch assay will be conducted in 12-well tissue
culture plates at a concentration of 50,000 cells/well and grown to full confluency prior to
treatment. Cells will be treated with vehicle, 2µM tamoxifen, 10µM ITE or a combination of
both every 12 hours for 3 days before a scratch is made in each well with a pipette tip. Media
will be aspirated to remove floating cells and vehicle treatments will be reapplied in DMEM/FBS
(1%). The scratches will be photographed at 0 hour and at 24 hours post scratch using the Lycia
Microscope. The exposed surface area of the plates will be measured using ImageJ analysis
software.
To determine changes in invasion, a Boyden chamber assay will be conducted. Cells will
be plated on 35 mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior to treatment.
After cells are treated with vehicle, 2µM tamoxifen, 10µM ITE or a combination of both every
12 hours for 3 days, the cells will be detached from tissue culture plates (using trypsin) and
counted. 100,000 cells will be immediately transferred to cell invasion chambers in 500µL of
media. Chambers filled with cells will then be incubated in 24-well tissue culture plates
containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each experiment will include
a negative control in which chambers filled with cells will be incubated with DMEM lacking
FBS. Following the 36 hour incubation period in the presence of vehicle (DMSO) or 10µM ITE,
a cotton swab will be used to remove non-adherent cells that were not invasive. Invasive cells
will be stained with crystal violet for 10 minutes at room temperature and then rinsed gently with
deionized water. Stained cells will be incubated in DMSO for 10 minutes with orbital shaking to
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extract crystal violet. Cell lysates will be measured at 560nm for invasive activity.
7.6. Characterizing JAG1 Regulation with Other Non-toxic AHR Ligands
Given our current data and knowledge, AHR promotes a suppressive effect on JAG1
expression in breast cancer cells when treated with ITE (Figures 24-29). Currently, there are
known AHR agonists that have been documented to inhibit cancer growth and progression;
however, the mechanisms behind their anti-cancer effects have yet to be determined (Weng,
Tsai, Kulp, & Chen, 2008; Jin, 2011). A promising and productive approach for developing anticancer agents has been the repositioning of pharmaceuticals that were originally developed for
other purposes (Safe, Cheng, & Jin, 2017). Some AHR-active pharmaceuticals such as tranilast
and omeprazole may be effective AHR-dependent anti-cancer agents for single or
combination cancer chemotherapies for treatment of breast cancers. Other diet based AHR
agonists such as IC3 and DIM have also been identified as potential drug candidates (Hall, et al.,
2010; Weng, Tsai, Kulp, & Chen, 2008). Therefore, it is imperative to conduct experiments in
breast cancer cell lines that responded to ITE in order to help determine if the regulation of JAG1
expression possesses a common mechanistic outcome among other non-toxic AHR ligand
treatments. Table 12 depicts a summary of the known effects of non-toxic AHR in various breast
cancer cell lines along with the changes in functional outcomes.
7.6.1. JAG1 and Tranilast
Tranilast is an orally active non-toxic drug that is used for the treatment of allergies and
can be taken daily (Rogosnitzky, Danks, & Kardash, 2012). There is clear evidence for the anticancer effects of tranilast in both in vivo and in vitro models, through the inhibition of both cell
proliferation and cell cycle progression in several mammary carcinoma cell lines, including the
human lines MDA-MB-231, MCF-7, and BT- 474 (Chakrabarti, Subramaniam, Abdalla, Jothy,
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ITE

Tranilast

Omeprazole

IC3

DIM

Tested Breast
Cancer Cell Lines

MCF7
T47D
MDA-MB-231
MDA-MB-157

MCF7
MDA-MB-231
BCSCs
BT-474

MCF7
MDA-MB-231

MFC7
MDA-MB-231
MDA-MB-468

MCF7
T47D
MDA-MB-231
SKBR3

Targeted
Signaling
Pathways

TGF-β
Notch

TGF-β
MAPK

N/A

Targeted
Oncogenes

Bcl-2
Oct4
SNAIL
Cluster of
Differentiation 135

MMP9
CXCR4

(Decreased Expression)

JAG1
Snail
Oct4

Cyclin E
Cyclin D1
Bcl-2
VEGF
MMP9
Cyclin-dependent
Kinase 6

COX2
Survivin
SOX4
Bcl-2
Cyclin-dependent
Kinase 6

Functional
Outcome

Reduced migration
and invasion

Reduced
mammosphere
formation,
proliferation and
invasion

Reduced migration
and invasion

Induced cell cycle
arrest and
decreased proliferation,
migration, and invasion

Reduced invasion
and migration

Molecular
Structure

Estrogen
pAkt
NF-κB

Table 12. Currently Known Anti-cancer Effects Contributed by Non-toxic AHR Ligands
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& Prud’homme, 2009; Prud’homme, et al., 2010; Darakhshan & Ghanbar, 2013). Moreover,
tranilast was then identified as an AHR agonist with inhibitory effects against CSCs from TNBC
selected for anti-cancer drug resistance by inhibiting colony formation, mammosphere formation
and stem cell marker expression. Knowing that JAG1 promotes the BCSC phenotype, it is
important to determine if tranilast reduces JAG1 expression in breast cancer cells and to identify
if the regulation is AHR–dependent.
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 and
SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, MDAMB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and MDA-MB157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be treated,
processed, and analyzed in the same manner described in section 7.3., but instead of ITE, breast
cancer cells lines will be treated with either 200µM tranilast or vehicle (DMSO).
7.6.2. JAG1 and Omeprazole
Omeprazole is a well-known and commonly used proton pump inhibitor that has been
identified to clearly inhibit MDA-MB-231 cell migration and invasion in in vitro models (Jin,
Lee, Pfent, & Safe, 2014). This response was attenuated after knockdown of the AHR by siRNA
or after co-treatment with AHR antagonists. Moreover, these in vitro assays were complemented
by inhibition of lung metastasis of MDA-MB-231 cells in mice that had cells administered via
tail vein injection and treated with 200µM omeprazole and resulted in decreased expression of
pro-metastatic genes MMP9 and CXCR4 in a AHR-independent and –dependent manner,
respectively (Jin, Lee, Pfent, & Safe, 2014). Interestingly, Notch signaling increases expression
of CXCR4 in order to maintain the CSC phenotype in renal cell carcinoma and promotes
migration in ovarian cancer (Chillakuri, et al., 2013). Therefore, it is imperative to conduct
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omeprazole treatments in breast cancer cell lines, as well as in non-cancerous mammary cell
lines to help identify if the decrease in JAG1 expression acts as the mechanism responsible for
inducing anti-cancer effects.
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143,
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be
treated, processed, and analyzed in the same manner described in section 7.3., but instead of ITE,
breast cancer cells lines will be treated with either 200µM omeprazole or control vehicle.
7.6.3. JAG1, Indole-3-Carbinol (I3C) and 3,3’-Diindolylmethane (DIM)
Phytochemicals derived from precursor glucosinolates in cruciferous vegetables (i.e.
broccoli, cabbage, and cauliflower) such as the indoles have already been used therapeutically
and have been shown to possess potent anti-cancer activity (Murray, Patterson, & Perdew, 2014).
More importantly, phytochemicals have been the focus of clinical trials due to their reduced side
effects in normal cells and pronounced anti-cancer activities (Weng, Tsai, Kulp, & Chen, 2008).
Most of the attention has been given to IC3 and its stable condensation product DIM. IC3 was
identified to promote anti-cancer activity by increasing expression of microRNA-34a, a tumor
suppressive microRNA that is transcriptionally regulated by p53 (Hargraves, He, & Firestone,
2016). Interestingly, in vitro studies have determined that miRNA-34a decreases chemotherapy
resistance, cell proliferation and metastasis in human breast cancer cells through inhibition of the
Notch signaling pathway (Wang, Li, Kong, Ahmad, Banerjee, & Sarkar, 2010b). This is because
microRNA-34a targets both Notch1 and JAG1 mRNA and suppresses its translation to protein
(Hashimi, et al., 2009). More recently, DIM was also shown to increase the expression of
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miRNA-21 and the microRNA-212/132 cluster, which acted as a metastatic suppressor by
targeting JAG1 and SOX4, respectively (Hanieh, 2015). Therefore, it is imperative to conduct
IC3 and DIM treatments in breast cancer cell lines, as well as in non-cancerous mammary cell
lines in order to identify if there is a decrease in JAG1 expression.
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143,
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be
treated, processed and analyzed in the same manner described in section 7.3., but instead of ITE,
breast cancer cell lines will be treated with either 200µM I3C, DIM 25µM DIM, or control
vehicle.
7.7. Identifying Potential AHR-dependent Mechanisms that Regulate JAG1 Expression in
Breast Cancer Cells
Even though the decrease in JAG1 expression is AHR-dependent, it is important to note
that JAG1 is not a direct AHR target gene. As a result, the mechanism behind AHR-dependent
JAG1 suppression has yet to be completely understood. There are logical hypotheses that can
explain this outcome in various ways. It is important to note that the RNA-seq data from the
TCDD treated MCF7 breast cancer cells were analyzed 6 hours after a 100nM TCDD treatment,
signifying that the reduction of JAG1 mRNA as a rapid and early occurrence that may occur
without binding directly to the JAG1 promoter. Therefore, one of the mechanisms can involve
activation of a gene that suppresses JAG1 expression, which can potentially be identified from
any of the 41 TCDD/AHR-direct target genes that can also act as a repressor of JAG (Table 9).
This data set can also identify a second potential mechanism, which involves AHR activation
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increasing expression of certain microRNAs that are known to target JAG1 mRNA and lead to
the decrease of JAG1 protein levels. Lastly, another potential AHR-dependent mechanism that
decreases JAG1 levels can occur via crosstalk with other signaling pathways by squelching cofactors away from the NF-kB signaling pathway proteins. Each of these proposed potential
mechanisms will be reviewed in detail along with experimental designs in the following sections.
7.7.1. JAG1 and HES1
One potential mechanism that can potentially explain how the AHR decreases JAG1
expression is by increasing the expression of a gene that suppresses JAG1 expression, which can
potentially be one of the 189 TCDD-treated AHR direct target genes (Table 7). Several lines of
evidence suggest that activation of the AHR reduces the expression of JAG1 by increasing HES1
expression. Even though HES1 is a direct target gene of the Notch signaling pathway and has
been identified as an indicator for Notch signaling activation (Borggrefe & Liefke, 2012), HES1
also acts to suppress JAG1 expression as a negative-feedback mechanism for the Notch pathway
(Bray, 2006). Moreover, differential gene expression analysis shows that HES1 mRNA is
induced 1.8-fold after a 6 hour 100nM TCDD treatment and TCDD-stimulated AHR ChIP-seq
analysis has identified AHR binding sites in the HES1 gene (Table 9). Another prior report has
demonstrated that HES1 is a direct AHR gene target in T47D breast cancer cells (Kobayashi, et
al., 2009). More importantly, HES1 is a transcriptional repressor that binds to HES1 sites in the
JAG1 gene and inhibits the transcription of JAG1 in embryonic stem cells by binding directly to
the JAG1 promotor to suppress its transcription. Stable increases in HES1 would explain how
AHR activation via ITE induces long-term suppression (5 days) of JAG1 in MDA-MB-231 cells
(Figure 25), while the AHR is rapidly degraded by the proteasome soon after AHR activation
(Figure 15). Therefore, it is imperative that we conduct AHR knockdown experiments, in order
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to study if the increased expression of HES1 plays a role in the regulation of JAG1 in the
presence of ITE and to determine if any change in regulation is AHR-dependent.
Non-cancerous MCF-10A cells and ER-positive (MCF7, T47D, BT474 and SUM185)
breast cancer cells will undergo AHR knockdown transfections with HES1-targeting siRNA, in
order to determine if these reductions in JAG1 expression are AHR-dependent. In brief, cell
suspensions at 200,000 cells/mL will be mixed with 100nM of AHR-siRNA with 3µL of
Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 min. Cells will be immediately plated
on 35mm tissue culture plates in DMEM/FBS (10%) and cultured for 48 hours before being
treated with ITE (10µM) every 12 hours for 3 days, followed by western blot analysis of
GAPDH (loading control), JAG1, cleaved-NICD, HES1 (positive control) and AHR. For
significance to be determined for reduction in the levels of JAG1 and HES1 protein, a one-way
ANOVA will be used along with a Tukey’s Post-hoc test, to compare the changes in protein
among the four groups.
To determine if HES1 knockdown affects cell migration and invasion in the presence of
ITE, scratch and Boyden Chamber assays will be conducted on cell lines that inhibited
expression of JAG1. For the scratch assay, HES1-targeting siRNA transfected breast cancer cells
will be plated in 12-well tissue culture plates at a concentration of 50,000 cells/well for 24 hours
prior to treatment. The cells will be treated with vehicle or 10µM ITE in DMEM/FBS (1%)
every 12 hours for 5 days; a scratch will be made in each well with a pipette tip. Media will be
aspirated to remove floating cells, then vehicle (DMSO) or 10µM ITE will be reapplied in
DMEM/FBS (1%). The scratches will be photographed at 0 hours and at 24 hours post scratch
using a Lycia Microscope and the exposed surface area of the plates will be measured using
ImageJ analysis software.
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For the Boyden chamber assays, HES1-targeting siRNA transfected cells will be plated
on 35mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior to treatment. After cells
are treated with vehicle or 10µM ITE in DMEM/FBS (10%) every 12 hours for 5 days, they will
be detached from tissue culture plates (using trypsin) and counted. 100,000 cells will be
immediately transferred to cell invasion chambers in 500µL of DMEM. Chambers filled with
cells will be incubated in 24-well tissue culture plates containing DMEM/FBS (10%) as the
chemoattractant for 36 hours. Following an incubation period of 36 hours in the presence of
vehicle (DMSO) or 10µM ITE, a cotton swab will be used to remove non-adherent cells that
were not invasive. Invasive cells will be stained with crystal violet for 10 minutes and then
rinsed gently with tap water and then incubated in DMSO for 10 minutes with orbital shaking to
extract crystal violet. Cell lysates will be measured at 560nm for invasive activity.
7.7.2. JAG1 and microRNA-21
MicroRNAs are attractive candidates as upstream regulators of metastatic progression
because they can post-transcriptionally regulate entire sets of genes. There are a few examples of
AHR ligands that regulate microRNAs and in turn promote anti-tumor effects. DIM was
identified to induce microRNA-146a expression and inhibited cancer cell invasion by
suppressing EGFR, NF-kB and metastasis-associated protein 2 (MTA2) (Li, et al., 2010). DIM
also upregulated let-7b and miR-200c in gemcitabine-resistant pancreatic cancer cells, causing a
reversal of EMT via suppression of zinc finger E-box binding homeobox 1 (ZEB1), Slug, and
Vimentin, which in turn induced up-regulation of E-cadherin (Li, et al., 2009). TCDD and DIM
were also able to suppress breast cancer metastasis by increasing the expression of the
microRNA-212/132 cluster, which targeted SOX4 expression (Hanieh, 2015). Collectively,
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identifying microRNAs that are regulated by the AHR but also target JAG1 mRNA are viable
candidates for ITE- and TCDD-mediated JAG1 suppression.
Therefore, another possible mechanism for the decrease in JAG1 expression is that the
AHR may also indirectly promote the expression of miR-21, a microRNA that targets JAG1
mRNA and prevents its translation into protein (Selcuklu, Donoghue, Kerin, & Spillane, 2012).
Selcuklu et al. were able to demonstrate that MCF7 cells stimulated with estrogen showed
increased expression of JAG1. In contrast to JAG1, miR-21 is downregulated by estrogen
mediated signaling and is negatively correlated in breast cancer cells. When estrogen is applied
to MCF7 cells, miR-21 expression is down-regulated through a regulatory site in the miRNA-21
producing gene (MIRN21) promoter region. The ability for the AHR to potentially promote
expression of miR-21 was already demonstrated in a study showing that the AHR ligand DIM
increased miR-21 expression and targeted cell division cycle 25A (cdc25A) in MCF7 cells,
resulting in decreased cell proliferation (Jin, 2011). However, increases in miR-21 expression
have been demonstrated with other AHR ligands. Therefore, TCDD and ITE may promote the
expression of miR-21 by inhibiting its estrogen-mediated suppression and may potentially serve
as the mechanism behind decreased JAG1 expression in ER-positive breast cancer cells.
Non-cancerous MCF-10A cells and ER-positive (MCF7, T47D, BT474 and SUM185)
breast cancer cells will be cultured in DMEM/FBS (10%) at 37°C, then plated in 6-well plates at
a density of 200,000 cells/mL and grown to full confluency. To induce JAG1 expression, cells
will be treated with estrogen (50nM) overnight before being treated every 12 hours for 3 days
with either ITE (10µM) or control vehicle. Cells will be rinsed with PBS, and total cellular
extract will be isolated in SDS sample buffer [40% glycerol, 8% SDS, 5% BME, 0.04%
bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat denatured and then separated by
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SDS/PAGE followed by transfer to PVDF membrane. GAPDH loading control western blot will
be used to confirm equal protein loading (~15µL/sample). The blots will be incubated overnight
at 4°C with rocking in primary antibody followed by an incubation period of 90 minutes in
secondary antibody at room temperature. Blots will then be rinsed five times (5 minutes per
rinse) with PBST before undergoing chemiluminescence to identify JAG1 and AHR protein
concentrations before and after ITE treatment. ChemiDoc MP Imaging System will be utilized to
quantify band density and acquire western blot images. A one-tailed unpaired t-test will be
conducted to determine significant changes in protein expression between treated and untreated
cells.
In order to determine if AHR regulates miR-21 expression and if miR-21 regulates JAG1
expression, transient transfections with siRNA will be performed as described in Section 4.4. In
brief, cell suspensions (200,000 cells/1mL) will be mixed with 100nM of either miR-21-targeting
siRNA, AHR-targeting siRNA or control-siRNA with 3µL of Lipofectamine RNAiMAX in
DMEM/FBS (10%) for ~20 minutes before being treated every 12 hours for 3 days with either
ITE (10µM) or control vehicle.
RT-qPCR will be used to measure changes in JAG1 mRNA and miR-21 expression.
Total RNA will be extracted using RNA purification columns (Qiagen). Reverse transcription
will be performed on 300ng of RNA using cDNA synthesis kits (Applied Biosystems (Foster
City, CA)) in accordance with the suppliers’ instructions. StepOnePlus (Applied Biosystems)
will be used to take PCR measurements. Amplifications will be carried out using SYBR green
master mixes (Applied Biosystems) according to the manufactures protocols. Samples will be
done in triplicate and the average normalized to GAPDH will be quantified using the
2−ΔΔCT formula.
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In order to determine if the JAG1 3’-untranslated region (UTR) is targeted by miR-21 in
ER-positive breast cancer cells, reporter constructs and a luciferase assay will be conducted. The
JAG1 3’-UTR region (632 bp) harboring the miR-21 binding site will be PCR amplified from
human genomic DNA, cloned into endonuclease Spel/Hind III restriction sites in the pMIRREPORTS luciferase vector, designated as pMIR/JAG1 3’-UTR. A mutated sequence will be
generated using Quikchange Lightning SDM kit, designated as pMIR/JAG1-UTRdel. Cells will
be co-transfected with 300ng of each plasmid (pMIR/JAG1-UTR, pMIR/JAG1-UTRdel, or
pMIR) and 1ng of phRL renilla vector (for normalization) in 24-well plates. After 24 hours of
transfection, a dual luciferase assay will be performed according to the manufacturer’s protocol.
7.7.3. JAG1 and NF-kB Signaling
Even though increases in HES1 and miR-21 are prime candidates for the suppression of
JAG1 expression in the presence of TCDD and ITE, these mechanisms may not apply to the ERnegative breast cancer subtype because HES1 expression was suppressed in MDA-MB-231 and
MDA-MB-157 cells (Figures 26). Moreover, miR-21 expression was regulated in an ERdependent manner and was shown to be unaltered in MDA-MB-231 cells in the presence of
estrogen according to the study conducted by Selcuklu et al. (Selcuklu, Donoghue, Kerin, &
Spillane, 2012). It is therefore unlikely that TCDD or ITE reduces JAG1 expression in MDAMB-231 and MDA-MB-157 through increased expression of miR-21 and may occur through a
different mechanism.
It is possible that the decrease in JAG1 expression in ER-negative breast cancer cells can
potentially occur though a crosstalk mechanism that involves AHR activation and the NF-kB
signaling pathway (Figures 13 and 32). TNBC exhibits high levels of constitutively active NFkB signaling by inflammatory cytokines and induces JAG1 expression in order to promote
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Notch-dependent expansion of the CSC population (Yamamoto, et al., 2013). Yamamoto et al.
were able to clearly demonstrate that JAG1 expression is NF-kB-dependent in TNBC. Moreover,
this study was also able to determine that the NF-kB signaling pathway is highly activated in
basal-like (HCC1143) and mesenchymal-like (MDA-MB-231) subtype tumors and is
significantly positively-correlated with JAG1 expression. Interestingly, the expression levels of
other Notch ligands (i.e. JAG2 and DLL4) were not significantly affected by NF-kB signaling,
indicating that JAG1 is a unique gene that is specifically regulated by NF-kB in TNBC.
Specifically, in MDA-MB-231 cells, activation of the NF-kB signaling pathway via
TNFa did not induce expression of JAG1 mRNA or protein, although the induction of RelB, a
known NF-kB-inducible gene, was observed. On the contrary, JAG1 expression was
significantly decreased upon exposure to TNFa after 24 hours and signifies that JAG1
expression is not induced by the non-canonical NF-kB pathway via RelB in MDA-MB-231 cells
(Figure 13). Rather, JAG1 expression is most likely regulated by the canonical NF-kB pathway
through RelA in MDA-MB-231 cells, which was demonstrated by Bash et al. in HeLa-derived
HtTA-1 cells (Bash, et al., 1999) (Figures 13 and 31). However, it is important to note that
TNFa induces JAG1 expression via RelB in the basal-like (HCC1143) subtype. Therefore, JAG1
expression is likely regulated by the non-canonical pathway in addition to the canonical pathway,
signifying that the level of total NF-kB activation (the sum of canonical and non-canonical
activation) may determine the level of JAG1 expression (Yamamoto, et al., 2013). The ability for
the activation of the AHR to cross-talk with the NF-kB signaling pathway has been welldocumented and was reviewed in detail in the third chapter (Vogel, et al., 2007; Tian, 2009;
Sheppard, et al., 1998) (Figure 13). In short, activation of the AHR promoted direct protein
binding between the AHR and RelA, proposing that the mutual repressive effects were
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modulated by the formation of inactive AHR-RelA dimers, which in turn reduces the
concentration of available nuclear AHR protein and RelA needed for AHR-NF-kB-mediated
gene expression (Tian, 2009). This cross-talk interaction can potentially reduce expression of
JAG1 in MDA-MB-231 and MDA-MB-157 cells and therefore may promote the ability for the
AHR to induce anti-metastatic effects in the mesenchymal subtype of TNBC.
Non-cancerous MCF-10A cells, ER-negative breast cancer cells with the basal-subtype
(SUM190, HCC1143, MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549,
MDA-MB-231 and MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and
SKBR3) will be cultured in DMEM/FBS (10%) at 37°C, then plated in 6-well plates at a density
of 200,000 cells/mL and grown to full confluency before being treated every 12 hours for 3 days
with either ITE (10µM) or control vehicle. For western blot analysis, after 3 days of treatment
cells will be rinsed with PBS, and total cellular extract will be isolated in 250µL of SDS sample
buffer [40% glycerol, 8% SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8].
Proteins will be heat denatured and then separated by SDS/PAGE followed by transfer to PVDF
membrane. The blots will be incubated overnight at 4 °C with rocking in primary antibody
followed by an incubation period of 90 minutes in secondary antibody at room temperature.
Blots will then be rinsed five times (5 minutes per rinse) with PBST before undergoing
chemiluminescence to identify JAG1, cleaved-NICD, RelA, RelB, and AHR protein
concentrations before and after ITE treatment; GAPDH will used as a loading control.
ChemiDoc MP Imaging System will be utilized to quantify band density and acquire western
blot images. A two-tailed unpaired t-test will be conducted for each cell-line in order to
determine significant changes in protein expression between treated and untreated cells.
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In order to determine if RelA and RelB regulates JAG1 expression, transient transfection
with siRNA will be performed as described in Section 4.4. In brief, cell suspensions (200,000
cells/mL) will be mixed with 100nM of either RelA-targeting siRNA, RelB-targeting siRNA, or
control-siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes
before being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle.
In order to determine if heterodimers RelA-AHR or RelB-AHR are formed in the
presence of ITE, a co-immunoprecipitation (Co-IP) experiment will be conducted. After the 3
day ITE treatment, cells will be washed twice with cold PBS, harvested by scraping, and
collected by centrifugation at 1500 x g. Cells will then be lysed in lysis buffer (20 millimolar
(mM) 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), pH 7.4, 125mM
sodium chloride (NaCl), 1% Triton X-100, 10mM ethylenediaminetetraacetic acid (EDTA),
2mM ethyleneglycol-bis-(b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 2mM sodium
orthovanadate (NA3VO4), 50mM sodium fluoride (NaF), 20mM zinc chloride (ZnCl2), 10mM
sodium pyrophosphate (Na4P2O7), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 5µg/mL
leupeptin) and centrifuged for 15 minutes at 12,000 x g, and supernatant fraction will be
collected. Anti-AHR antibodies will be added to the lysate, and the binding reactions will be
performed at 4°C for 2 hours on a rotary shaker, then 30µL of GammaBind Plus Sepharose beads
will be added to precipitate the antibody-antigen complex. The beads will be washed 3 times in
lysis buffer and boiled in 2x SDS sample buffer and undergo western blot analysis with antiRelA and anti-RelB primary antibodies at a 1:1000 concentration and corresponding secondary
antibody.
To determine if ITE affects RelA-AHR and RelB-AHR heterodimers binding to the
JAG1 promoter, a ChIP assay will be conducted. Cells (500,000 per 60mm plate) will be plated
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and grown in DMEM/FBS (10%) before being treated with ITE or DMSO for 3 hours.
Formaldehyde (1%) will be added to the medium for 10 minutes, followed by glycine (.5 molar
(M)) for 5 minutes. Cells will then be rinsed with PBS, collected in PBS, pelleted by
centrifugation, and lysed in 300µL of lysis buffer (1% SDS, 5mM EDTA, 50mM Tris-HCl, pH
8) per 60mm plate plus protease inhibitors for 15 minutes on ice. Cell extracts will be sonicated
(5 times, 10 seconds each) and diluted 1:10 in dilution buffer (16.7mM Tris-HCl, pH 8, 167mM
NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100), rotated overnight at 4°C with 1µg of
non-specific IgG, Anti-RelA, or Anti-RelB antibody. Antibody-chromatin complexes will be
collected using 5 µL of magnetic protein A beads with rotation at 4°C for 90 minutes. Using
magnetic separation, beads will be washed sequentially with buffer 1 (20mM Tris-HCl, pH 8,
150 mM NaCl, 2 mM EDTA, 0.1% SDS), buffer 2 (20mM Tris-HCl, pH 8, 500 mM NaCl, 2
mM EDTA, 0.1% SDS), buffer 3 (10mM Tris-HCl (pH 8), 0.25 lithium chloride (LiCl), 1 mM
EDTA, 1% NP-40, 1% deoxycholate), and then 1X 10mM Tris-HCl with 0.1mM EDTA (TE)
buffer for 5 minutes each and incubated at 65°C for 4 hours in elution buffer (1% SDS, 0.1M
sodium bicarbonate (NaHCO3)) with proteinase K. DNA will be purified and analyzed using RTqPCR. Primers spanning RelA and RelB response elements in the JAG1 promoter and DREs in
the CYP1A1 promoter will be used.
7.8. Identifying Snail as a JAG1 Downstream Target Gene that Promotes Invasion and
Migration
It has been proposed that the initial steps in metastasis involve an EMT-like process,
which is the process that converts cells from an epithelial, non-motile morphology to become
migratory and prone to invade other tissues (Hanahan & Weinberg, 2000). EMT is accompanied
by specific changes in gene expression, such as down-regulation of E-cadherin, by which its
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promoter is repressed by several transcriptional repressors, including the zinc finger transcription
factor Snail (Wang, et al., 2009). Up-regulation of Snail correlates with metastasis and poor
prognosis, whereas silencing of Snail is critical for reducing tumor growth and invasiveness
(Wang, et al., 2009). Knowing that JAG1-dependent Notch signaling promotes expression of
various target genes that are required to promote cancer growth at various stages of tumor
progression, we questioned if whether the downstream target genes are also affected by ITE and
TCDD treatments in breast cancer cells. Furthermore, Notch can up-regulate Snail and induce
EMT in a normoxic environment during normal development in cardiac cell differentiation
(Timmerman, et al., 2004), although the detailed molecular mechanism for how Notch
controls Snail expression remains to be established. Sahlgren et al. were able to further
demonstrate that Notch signaling controls Snail expression by two distinct but synergistic
mechanisms, involving both direct transcriptional activation of Snail and an indirect mechanism
operating via LOX, leading to elevated Snail protein levels in cervical, colon, glioma, and
ovarian cancer (Sahlgren, Gustafsson, Jin, Poellinger, & Lendahl, 2008).
We found a significant reduction in the levels of Snail protein in both ER-positive and
ER-negative breast cancer cells treated with ITE and TCDD compared with control cells treated
with vehicle (Figures 33 and 34). Our preliminary data demonstrates that AHR decreases the
expression of JAG1 and Snail, and we provide the first evidence that this could be mediated
through an AHR-dependent manner (Figure 34). Given the previous reports and our current data,
we hypothesize that the decrease in JAG1 expression reduces the levels of downstream target
genes of JAG1-dependent Notch signaling such as Snail as the mechanism for the anti-metastatic
activity of AHR activation. We observed that cells with AHR knockdown were not responsive to
ITE-stimulated reductions in Snail, indicating that the suppressive effect of ITE on Snail
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expression is transmitted through the AHR (Figure 34). However, it has not been determined if
Snail expression is regulated in a JAG1-dependent manner in breast cancer cells.
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143,
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and
MDA-MB-157) will be treated, processed, and analyzed in the same manner described in section
7.4.
In order to determine if JAG1 regulates Snail expression in the presence of ITE, transient
transfection with short interfering RNA (siRNA) will be performed as described in section 4.4.
In brief, cell suspensions (200,000 cells/mL) will be mixed with 100nM of JAG1-siRNA or
control-siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes
before being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle.
7.9. Anticipated and Alternative Outcomes for Proposed Experiments
Given our preliminary data showing TCDD and ITE can stimulate a marked decrease in
JAG1 expression in ER-positive (MCF7 and T47D) and ER-negative (MDA-MB-231 and MDAMB-157) breast cancer cells, I expect that cell lines with high levels of AHR and JAG1
expression will inhibit the expression of JAG1. This decrease in JAG1 expression in turn will
reduce the migratory and invasive activity of breast cancer cells that rely on JAG1-dependent
signaling. Moreover, I expect to see the basal-like subtypes (SUM190, HCC1143, MDA-MB468) to either increase JAG1 expression or have no significant change when treated with ITE
compared to the control group.
Given our current data and previous literature showing that the combination of non-toxic
AHR agonists with current anti-estrogenic treatments proves to be an effective treatment for ER-
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positive breast cancer, I expect cell colony formation, proliferation, invasion, and metastasis to
be inhibited in a synergistic manner in the ITE and tamoxifen combination treatment
(Darakhshan & Ghanbar, 2013). Additionally, I expect the anti-proliferative effects to be more
prominent in MCF7 cells compared to that of MDA-MB-231 cells due to ITE not affecting cell
proliferation in ER-negative breast cancer cells (Figure 32). I also expect to see decreases in
JAG1 expression in both cell lines and for the Notch pathway to be inhibited in only MDA-MB231 cells. As for the MCF7 cells, I suspect the Notch signaling pathway to be affected in the
presence of both ITE and tamoxifen, as estrogen signaling promotes Notch-mediated tumor
growth and proliferation (Selcuklu, Donoghue, Kerin, & Spillane, 2012). Moreover, I suspect
that combinations that include an anti-estrogen treatment such as tamoxifen and a Notch
inhibitor may be effective in ER-positive breast cancer (Rizzo, et al., 2008).
Regarding other non-toxic, anti-cancer AHR ligands, I expect that tranilast will inhibit the
expression of JAG1, which in turn will also reduce the migratory and invasive activity of breast
cancer cells. I also believe the basal-subtype cell lines may exhibit decreases in JAG1 levels, due
to tranilast also being identified as a TGFb inhibitor, a known promoter of JAG1 expression
(Rogosnitzky, Danks, & Kardash, 2012). I expect that omeprazole will inhibit the expression of
JAG1 in an AHR-dependent manner, which in turn also reduces the migratory and invasive
activity of breast cancer cells. However, cell lines with low AHR levels such as HCC1143 may
exhibit increases or no change in JAG1 levels, which may not affect the overall physiology of
those particular cell lines. Given the data we produced and published literature, I also expect that
I3C and DIM will inhibit the expression of JAG1 in an AHR-dependent manner, which in turn
may also reduce the migratory and invasive activity of breast cancer cells. Similar to omeprazole,
I expect basal-like ER-negative cell lines such as HCC1143 to exhibit increases or no change in
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JAG1 levels, which may not affect the overall physiology of those particular cell lines.
In regard to the potential AHR-dependent mechanisms that suppress JAG1 expression in
ER-positive breast cancer, I expect that cell lines transfected with HES1-targeting siRNA will
inhibit the ability of ITE to decrease expression of JAG1 in an AHR-dependent manner, which in
turn would not affect the migratory and invasive activity of breast cancer cells. I also expect ITE
to increase miR-21 expression in the presence of ITE compared to the control group in ERpositive breast cancer cells and that knockdown of AHR prevents increased expression of miR21, which prevents the decrease in JAG1 expression to occur in the presence of ITE. Moreover, I
also expect to see that miR-21 knockdown cells prevent the suppression of JAG1 mRNA in the
presence of ITE. Finally, I predict that the JAG1 3’- UTR is targeted by miR-21 in ER-positive
breast cancer cells. It is also possible that these two mechanisms could occur simultaneously and
or in synchronicity, as they operate via independent pathways. However, more research needs to
be conducted to investigate this co-operative inhibition.
As for the regulation of JAG1 in the ER-negative basal-like breast cancer subtype, I
expect to see ITE induce AHR-RelB heterodimer formation and promote the expression of JAG1
by binding to the JAG1 promoter, that RelB knockdown prevents increases in JAG1 expression,
and that RelA knockdown does not alter changes in JAG1 expression. In the mesenchymalsubtype, I expect to see ITE induce AHR-RelA heterodimer formation and inhibit the expression
of JAG1 by decreasing the amount of RelA binding to the JAG1 promoter, that RelA knockdown
prevents the suppression of JAG1, and that RelB knockdown does not alter changes in JAG1
expression.
In regard to identifying potential downstream targets of JAG1-dependent signaling that
promotes the metastatic process, I expect to see the decrease in Snail expression in ITE-treated
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ER-positive breast cancer cells as well as mesenchymal-subtype ER-negative breast cancer cells
compared to the untreated group and that it occurs in a JAG1-dependent manner. In the basallike subtype of ER-negative breast cancer, there may be either no change or a promotion in Snail
expression due to the unaffected or increased expression in JAG1 upon ITE exposure.
7.10. Conclusion
Investigating the changes in JAG1 levels in the presence of both known anti- and procancer AHR ligands can provide important insight on how the expression of JAG1 in cancer
cells as well as changes in cell migration and invasion are altered in a ligand-dependent manner
(Hall, et al., 2010). These anti-cancer effects and changes in cell migration and invasion were
confirmed by treating MDA-MB-231 breast cancer cells with both TCDD and ITE in the absence
of AHR (siRNA) and an AHR antagonist, CH-223191 (Figures 23, 27-28). CH-223191 is
reported to selectively antagonize the binding of halogenated AHR ligands to the AHR binding
site and was able to prevent TCDD-stimulated reductions in JAG1 expression, but not ITEstimulated reductions. Not only does this finding indicate that ITE decreases JAG1 expression
through a different binding site used by TCDD, ITE binds AHR even in the presence of CH223191. This data allows researchers to come to an understanding that the basis of information
which supports both the use of AHR agonists and antagonists in the treatment of various cancers
is initially valid and logical. Because TCDD is a known carcinogen, the use of AHR antagonists
such as CH-223191 prevented TCDD from inducing toxicity, originally giving the AHR the role
as a tumor promoter. However, as researchers began to see the anti-cancer effects from nonhalogenated AHR ligands produced from either the natural products present in the diet or
medications being taken, a paradox started to take form and further increased the debate on the
role of the AHR in cancer biology.
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Therefore, considering all the evidence being presented in this dissertation promoting the
use of non-toxic and clinically relevant AHR agonists for the treatment of breast cancer, I can
safely oppose the use of AHR antagonists and inhibitors for the treatment of breast cancer. The
opposition to utilize AHR antagonists is due to two main factors, which include: 1) research
claiming that AHR promotes toxicity and cancer progression utilized highly stable known
carcinogenic compounds that possess no clinical relevance or weak endogenous AHR agonists
that could be out-competed by exogenous non-toxic AHR agonists with higher AHR-binding
affinity and 2) inhibition of AHR through the use of antagonists or inhibitors to treat breast
cancer can potentially cause unwarranted long-term side-effects in patients undergoing treatment
due to the endogenous roles the AHR regulates which include, but are not limited to immunity,
development, and hematopoiesis. Therefore, the use of AHR antagonists and inhibitors for the
purpose of cancer treatment could result in the inability to fight infections, reduce wound healing
efficiency, and induce anemia.
Moreover, the case where ITE increases JAG1 expression in the basal-like ER-negative
subtype (HCC1143) also allows us to propose that establishing a treatment strategy by targeting
JAG1 directly through the use of monoclonal antibodies, small molecule inhibitors, or JAG1
mRNA suppression as a method for the treatment of breast cancer. This proposal is due to a
number of factors, including: 1) research showing that JAG1-dependent Notch signaling
promotes various bio-functions that contribute to cancer progression and does not possess any
discrepancy in terms of JAG1 functioning as a tumor suppressor, unlike AHR. Even though there
are some cases where Notch signaling acts as a tumor suppressor, none of those studies were
linked through activation with JAG1. 2) Targeting JAG1 on the extracellular membrane directly
via monoclonal antibodies or small molecules that target JAG1 mRNA and/or its expression to
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avoid the use of GSIs, resulting in targeting the Notch pathway that promotes cancer progression
and not Notch pathway that is needed for normal cellular homeostasis. 3) Most importantly, this
approach may help bypass the controversy for the utilization of AHR agonists for the treatment
of breast cancer.
In conclusion, I succeeded in showing that activation of AHR through the use of a nontoxic AHR agonist (ITE) induced inhibition of JAG1 expression in both ER-positive and ERnegative breast cancer cells, which resulted in decreased cell migration and invasion. This
research could help propose another potential therapy target for treating breast cancer as well as
provide new insight on how small molecules from our environment and diet can potentially
regulate developmental signaling pathways and the induction of those corresponding changes in
the outcomes of cellular physiology.
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APPENDIX B: ABBREVIATIONS
3-MC….3-methylcholanthrene
4-HT….4-hydroxytamoxifen
5-FU….5-flurouracil
ABC….ATP binding cassette
ABCG2….ATP binding cassette, sub-family G member 2
ADAM….a-disintegrin and metalloproteinase
ADCs….antibody-drug conjugates
ADH1β….alcohol dehydrogenase 1β
ADP….adenosine diphosphate
AHH….aryl hydrocarbon hydroxylase
AHR….aryl hydrocarbon receptor
AHRR….aryl hydrocarbon receptor repressor
AIs….aromatase inhibitors
Akt…serine-threonine protein kinase
ALDH1….aldehyde dehydrogenase1
ALDH1A3….aldehyde dehydrogenase 1, family member A3
ANOVA….analysis of variance
AP-1….activator protein-1
APC….adenomatous polyposis coli
APEX1….apurinic/apyrimidinic endodeoxyribnuclease 1
AR….androgen receptor
ARNT….aryl hydrocarbon receptor nuclear translocator
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ATP….adenosine triphosphate
B[α]P….benzo[α]pyrene
Bcl-2….B-cell lymphoma-2
BCRP….breast cancer resistance protein
BCSCs….breast cancer stem cells
bHLH….basic helix-loop-helix
BLIA….basal-like immune activated
BLIS….basal-like immune suppressed
BME….β-mercaptoethanol
BRG1….brahma-related gene 1
c-myc….v-myc avian myelocytomatosis viral oncogene homolog
c-Rel….v-rel avian reticuloendotheliosis viral oncogene homolog
C2….calcium-binding
CAIX….carbonic anhydrase IX
cAMP….cyclic adenosine monophosphate
CAXII….carbonic anhydrase 12
CBP….CREB binding protein
CCND1….cyclin D1
CCND3….cyclin D3
CCNE….cyclin E
CD133….cluster of differentiation 133
CD24….cluster of differentiation 24
CD34….cluster of differentiation 34
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CD44….cluster of differentiation 44
CD46….cluster of differentiation 46
cdc25A….cell division cycle 25A
CDK2….cyclin-dependent kinase 2
CDK8….cyclin-dependent kinase 8
CDKN1A….cyclin-dependent kinase inhibitor 1A
ChIP….chromatin-immunoprecipitation
ChIP-seq….chromatin immunoprecipitation-sequencing
CK1α….casein kinase 1α
CMF…. cyclophosphamide, methotrexate, and fluorouracil
CMML….chronic myelomonocytic leukemia
Co-IP….co-immunoprecipitation
CO2….carbon dioxide
CoRs….co-repressors
COS2….kinesin motor protein costal-2
COX2….cyclooxygenase 2
CRD….cysteine-rich domain
CREB….cAMP response element binding protein
CSCs….cancer stem cells
CSL…. RBP-Jk/Su(H)/lag-1
CSN2….casein kinase-β
CtBP….c-terminal binding protein
CTLA4….cytotoxic T-lymphocyte-associated protein 4
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CUL4B….cullin 4B
CXCL10….C-X-C motif chemokine ligand 10
CXCR4….C-X-C motif chemokine receptor 4
CYP1A1….cytochrome P450, family 1 subfamily A member 1
CYP1B1….cytochrome P450, family 1 subfamily B member 1
CYP450….cytochrome P450
DCs….dendritic cells
DDB1….damaged DNA binding protein 1
Dhh….desert hedgehog
DICD….DLL intracellular domain
DIM….3,3-diindolylmethane
Dlg….discus large homolog
DLL….delta-like ligand
DLL1….delta-like ligand 1
DLL3….delta-like ligand 3
DLL4….delta-like ligand 4
DM1….emtansine
DMBA….dimethylbenz(a)anthracene
DMEM….Dulbecco’s Modified Eagle Medium
DMEM/FBS (1%)….DMEM containing 1% FBS
DMEM/FBS (10%)….DMEM containing 10% FBS
DMSO….dimethyl sulfoxide
DNA ….deoxyribonucleic acid
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DRE….dioxin response element
DSL…delta-serrate-lag1
DVL….dishevelled
ECD….extracellular domain
EDTA….ethylenediaminetetraacetic acid
EGF….epidermal growth factor
EGFR….epidermal growth factor receptor
EGTA….ethyleneglycol-bis-(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
EMT….epithelial-mesenchymal transition
ER….estrogen receptor
ERE….estrogen response element
EROD….ethoxyresorofin-O-deethylase
FBS….fetal bovine serum
FBXW7….F-box and WD repeat domain containing 7
FDA….Food and Drug Administration
FDR….false discovery rate
FGF….fibroblast growth factor
FGFR2….fibroblast growth factor receptor 2
FICZ….6-formylindolo [3,2-b]-carbazole
Foxp3….forkhead box P3
FSH….follicle stimulating hormone
G-CSF….granulocyte colony-stimulating factor
GAPDH….glyceraldehyde-3-phosphate dehydrogenase
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GEO….Gene Expression Omnibus
GHR….growth hormone receptor
GI….gastrointestinal
Gli….glioma associated oncogene
Gli-1….glioma associated oncogene-1
Gli-2….glioma associated oncogene-2
Gli-3….glioma associated oncogene-3
Gli-A….activated Gli
Gli-R….restricted Gli
GM-CSF….granulocyte macrophage colony-stimulating factor
GSCs….glioma stem cells
GSH….glutathione
GSIs….𝛾-secretase inhibitors
GSK-3β….glycogen synthase kinase-3β
GSK2….glycogen synthase kinase 2
GSTs….glutathione-S-tranferases
HCB….hexachlorobenzene
HDAC1….histone deactylase 1
HDAC2….histone deactylase 2
HEPES….2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
HER1….human epidermal growth factor receptor 1
HER2….human epidermal growth factor receptor 2
HER3….human epidermal growth factor receptor 3
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HER4….human epidermal growth factor receptor 4
HES….hairy enhancer of split
HES1….hairy enhancer of split 1
HES5….hairy enhancer of split 5
HEY….HES related family bHLH transcription factor with YRPW motif
HEY1….HES related family bHLH transcription factor with YRPW motif 1
HGF….human growth factor
Hh….hedgehog
HIF-1α….hypoxia inducible factor 1α
HNSCC….head and neck squamous cell carcinoma
HRE….hypoxic response element
HSCs….hematopoietic stem cells
HSP90….heat shock protein 90
I3C….indole-3-carbinol
ICD….intracellular domain
ICZ.…indolo [3,2-b] carbazole
IDeA….Institutional Development Award
iDRE….inhibitory dioxin response element
IFN𝛾….interferon-g
IGF-1R….insulin-like growth factor-1 receptor
Ihh….indian hedgehog
IKKα….inhibitor of NF-κB subunit α
IL-1β….interleukin-1β
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IL-10….interleukin-10
IL-17….interleukin-17
IL-2….interleukin-2
IL-22….interleukin-22
IL-6….interleukin-6
IL-8….interleukin-8
IL1R1….interleukin 1 receptor, type 1
ILK….integrin-linked kinase
IPA….Ingenuity Pathway Analysis
ITE….2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methylester
IκB….inhibitor of NF-κB
IκBK….inhibitor of NF-κB kinase
JAG1….Jagged1
JAG2….Jagged2
JICD….JAG1 intracellular domain
JNK…. Jun amino-terminal kinase
Kb….kilobases
KIF7….kinesin family member 7
KIT….KIT proto-oncogene receptor tyrosine kinase
LAR….luminal/androgen receptor
LCK….lymphocyte-specific protein tyrosine kinase
LEF1….lymphoid enhancing factor 1
Lfng….lunatic fringe
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LH….luteinizing hormone
LiCl….lithium chloride
LOX….lysyl oxidase
LPS….lipopolysaccharide
LRP….low-density lipoprotein receptor
LRP5….low-density lipoprotein 5
LRP6….low-density lipoprotein 6
M….molarity
mAbs….monoclonal antibodies
MAML….mastermind-like
MAP3K1….mitogen-activated protein kinase kinase kinase 1
MAPK….mitogen-activated protein kinase
MCDF….6-methyl-1,3,8-trichlorodibenzofuran
MES….mesenchymal
MIRN21….miRNA-21 producing gene
miRNA-21….microRNA-21
mg….milligrams
mL….milliliter
mm….millimeter
mM….millimolar
MMP2….matrix metallopeptidase 2
MMP7….matrix metallopeptidase 7
MMP9….matrix metallopeptidase 9
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mRNA….messenger RNA
MRP1….multidrug resistance-associated protein 1
MT….metallothionein
MTA2….metastasis-associated protein 2
mTOR….mechanistic target of rapamycin
MTT….3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
myc….MYC proto-oncogene
NA3VO4….sodium orthovanadate
Na4P2O7….sodium pyrophosphate
NaCl….sodium chloride
NAD+….nicotinamide adenine dinucleotide
NaF….sodium flouride
NaHCO3….sodium bicarbonate
NCOA-1….nuclear receptor co-activator-1
NF-κB….nuclear factor-κB
NICD….Notch intracellular domain
NICD1….Notch1 intracellular domain
NICD2….Notch2 intracellular domain
NIK….NF-κB inducing kinase
NLS….nuclear localization sequence
ng….nanograms
nm….nanometer
nM….nanomolar
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O2….oxygen
OCT4….octamer-binding protein 4
OH….hydroxyl group
OX40L….tumor necrosis factor receptor, superfamily member 4
P-gp….P-glycoprotein
p….phosphate group
PAGE….polyacrylamide gel electrophoresis
PAHs….polycyclic aromatic hydrocarbons
PARP….poly-(ADP-ribose) polymerase
PBS….phosphate buffer saline
PBST….PBS with 0.05% Tween-20
pCR….pathologic complete response
PDGF….platelet-derived growth factor
PDGF-b….platelet-derived growth factor-b
PDGFR-β….platelet-derived growth factor receptor-β
PDZ….PSD-95/Dlg/ZO-1
PHAHs….polycyclic halogenated aromatic hydrocarbons
PHD….prolyl hydroxylase domain
PI3K….phosphoinositide-3-kinase
PIK3CA….phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α
Pin1….prolyl-cis/trans-isomerase 1
PKA….protein kinase A
PMSF….phenylmethylsulfonyl flouride
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PPAR𝛾….peroxisome profilerator-activated receptor 𝛾
PR….progesterone receptor
PSD-95….postsynaptic density protein-95
PTCH1….patched1
PTEN….phosphatase and tensin homolog
PVDF….polyvinylidene difluoride
pVHL….von Hippel-Lindau tumor suppressor gene product
qPCR….quantitative polymerase chain reaction
RA….rheumatoid arthritis
RAS….rat sarcoma viral proto-oncogene
RBP-Jk….recombination signal binding protein for immunoglobulin κJ region
RBX1….ring box1
RelA….v-Rel avian reticuloendotheliosis viral oncogene homolog A
RelB….v-Rel avian reticuloendotheliosis viral oncogene homolog B
RET….ret proto-oncogene
RIN….RNA integrity number
RIP140….receptor interacting protein 140
RNA….ribonucleic acid
RNA-seq….RNA-sequencing
ROS….reactive oxygen species
RT-qPCR….real-time quantitative PCR
RUNX2….runt related transcription factor 2
RUNX3….runt related transcription factor 3
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SDS….sodium dodecyl sulfate
SEM….standard error margin
SERDs….selective estrogen receptor down regulators
SERMs….selective estrogen receptor modulators
Shh….sonic hedgehog
SIN3A….histone deactylase complex subunit Sin3a
siRNA….short-interfering RNA
SMO….smoothened
SNAI….snail family of transcriptional repressor
Snail….SNAI1
Slug….SNAI2
Smuc….SNAI3
SOX2….SRY-box 2
SOX4….SRY-box 4
SPEN….sharp and mint
SRY….sex-determining region Y
Su(H)….suppressor of hairless
SUFU….suppressor of fused
T-ALL….T-cell acute lymphoblastic leukemia
T-DM1….Ado-trastuzumab emtansine
TACE….TNFα converting enzyme
TBL3….transducin beta like 3
TCDD….2,3,7,8-tetrachlorodibenzo-p-dioxin
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TCF/LEF….T-cell factor/lymphoid enhancing factor
TDO2….tryptophan 2,3-dioxygenase
TE….10mM Tris-HCl with 0.1mM EDTA
TGFα….tumor growth factor α
TGFβ….tumor growth factor β
Th17….T-helper 17
TILs….tumor infiltrating lymphocytes
TKIs….tyrosine kinase inhibitors
TLRs….toll-like receptors
TNBC….triple negative breast cancer
TNF….tumor necrosis factor
TNFα….tumor necrosis factor α
TOP2α….topoisomerase 2α
TP53….tumor protein 53
TP63….tumor protein 63
Treg….T-regulatory
TRGs….TCDD-regulated genes
Tris-HCl….tris-hydrochloride
TSS….transcription start site
TUBB2B….tubulin b, class IIB
Ub….ubiquitin
µg….microgram
µL….microliter
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µM….micromolar
µPA….urokinase-type plasminogen activator
UTRs….untranslated regions
VDR….vitamin D receptor
VEGF…. vascular endothelial growth factor
VTCN1….v-set domain containing T-cell activation inhibitor
VWF….von Willebrand Factor
Wnt….wingless-type MMTV integration site family
WV-INBRE….West Virginia-IDeA Networks of Biomedical Research Excellence
XAP2….Hepatitis B virus X-associated protein 2
ZEB1….zinc-finger E-box binding homeobox 1
ZO-1….zona occludens 1
ZnCl2….zinc chloride
avb3-integrin….integrin av and integrin b3
α….alpha
β….beta
𝛾….gamma
κ….kappa
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